netFormulary
 Report : A-Z of formulary items 25/02/2020 11:47:27
[Back]
 
Section Name Details
06.01.02.03 Exenatide (Immediate-release) Byetta®

Green Bath

Amber Salisbury and Swindon

  • Existing patients only.
  • 5 microgram, 10 microgram - 60 dose pre-filled pen (250 microgram/ml)
  • Dose: 5mg BD for one month, increase to 10 micrograms BD if response insufficient and patient tolerating medication.
14.04 23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II
  • Primary Care:  at NHS expense for patients in accordance with the national immunisation programme. Adults over 65 years and at risk groups, as listed in the Green Book, chapter 25.
  • Use practice stock and claim on FP34 appendix form. 
05.03.01 Abacavir 
  • Tablets 300mg
  • Oral solution 20mg/ml
05.03.01 Abacavir and Lamivudine Tablet
  •  600 mg of abacavir (as sulfate) and 300 mg lamivudine
10.01.03 Abatacept Orencia®
  • 250mg vial, powder for reconstitution. Injection 125mg pre-filled syringe
  • Commissioned by CCG for:
    • The treatment of rheumatoid arthritis in line with NICE TA195, TA375.
  •  Commissioned by NHS England From Specialist Centres Only for:
    • Juvenile idiopathic arthritis in line with NICE TA373.
    • Paediatric indications where an adult NICE TA is available.
  • Check individual Trust contracting arrangements.

 

02.09 Abciximab 
  • GWH and SFT only
  • Non formulary at RUH
  • 10mg in 5ml
  • Adjunct in percutaneous coronary intervention
08.03.04.02 Abiraterone 
  • 500mg tablets
04.10.01 Acamprosate 
  • Tablets e/c 333mg
  • Use only in the context of supervised withdrawal regime with psychosocial recovery programme. For maintenance of abstinence in alcohol dependent patients.
  • See shared care guidelines below for maintenance of abstinence.
  • Acamprosate is supported by NICE (CG115) following assisted withdrawal or for harmful drinkers and people with mild alcohol dependence who have requested a pharmacological intervention in combination with an individual psychological intervention.
06.01.02.03 Acarbose 
  • 50mg, 100mg
  • Acarbose should be taken or chewed with the first mouthful of food or swallowed whole with liquid immediately before food.
  • No new patients - no longer recommended in any national guidance.

 Not on formulary in Swindon

11.06 Acetazolamide 
  • Green Bath and Salisbury for glaucoma
  • Amber Swindon for glaucoma
  • 250mg tablets and 250mg MR capsules (NB capsules more costly)
  • Note: at RUH and GWH, acetazolamide is included on the formulary for idiopathic intracranial hypertension as Amber Unlicensed indication
  • Note - Private prescription only for prophylaxis of mountain sickness. Not licensed and NOT for prescribing on NHS. For further information see link below 
11.06 Acetazolamide Injection 
  • 500mg injection
12.01.01 Acetic Acid 2% 
  • Please note: Patients should self-care in the first instance

 

11.08.02 Acetylcholine 
  • 20mg powder and solvent for solution for intraocular irrigation
03.11 Acetylcysteine 
  • 600mg Tablets (unlicensed)
  • 200mg/1ml 10ml ampoules Infusion (Also used for treatment of poisoning)
  • Interstitial pneumonia (unlicensed)/ Idiopathic Pulmonary Fibrosis (unlicensed)
  • Renal protection before CT scan with contrast agent
  • NHS England Specialised Commissioning - Respiratory Interstital Lung Disease Adults
11.08.01 Acetylcysteine 
  • Acetylcysteine eye drops 5%, hypromellose 0.35% 10ml (includes benzalkonium chloride, disodium edetate)
  • Specialist initiation - Only if filamentary keratitis present.
05.03.02.01 Aciclovir  
  • Green 
  • 200mg
  • 400mg
  • 800mg
  • During Varicella Zoster Immunoglobulin Shortage (Aug 2018):
    • Amber "off label" use during the shortage of Varicella Zoster Immunoglobulin (VZIG)in patients who are 20+ weeks pregnant.Only to be used as AMBER on specialist advice.
    •  Dose 800mg four times a day from day 7 to 14 after exposure
05.03.02.01 Aciclovir  
  • 250mg/10ml IV infusion
  • 500mg/20ml IV infusion
  • 1g/40ml IV infusion
11.03.03 Aciclovir 
  • 3% eye ointment
13.10.03 Aciclovir 5%  
  • Cream 5% 2g, 10g
  • Apply to lesions every 4 hours (5 times a day) for 5-10 days
13.05.02 Acitretin 
  • Capsules 10mg, 25mg
  • Consultant Dermatologist Only
  • For severe resistant or complicated psoriasis,- not recommended in women of child bearing age.
  • Pregnancy Prevention Scheme applies if prescribed in women of child bearing age. Acitretin is highly teratogenic and must not be used by women who are pregnant. The same applies to women of childbearing potential unless strict contraception is practiced 4 weeks before, during and for 3 years after treatment 
03.01.02 Aclidinium Eklira Genuair®
  • For patients with manual dexterity problems or an eGFR<30ml/min. 
  • Inhalation powder 322 microgram/dose aclidinium

 

 

 

03.01.04 Aclidinium and formoterol inhaler Duaklir Genuair ®
  • Combination of Formoterol fumarate / Aclidinium (as bromide)
  • Breath actuated dry powder MDI 12/340 Genuair device

 

01.05.03 Adalimumab Imraldi®Amgevita®Humira®
  • 40mg pre-filled pens or pre-filled syringes.
  • Prescribe BY BRAND. Biosimilar first-line option. Imraldi® first-line biosimilar.
  • Please note: Adalimumab should be prescribed in accordance with either the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway or the BSW STP Crohn's Disease Biologic / Biosimilar Commissioning Pathway.
10.01.03 Adalimumab Imraldi®Amgevita®Humira®
  • Injection 40mg prefilled syringe, prefilled pen
  • Prescribe by brand. Biosimilar first-line option.  Imraldi® first line biosimilar across BSW
  • For rheumatoid arthritis in accordance with NICE TA375.
  • Commissioned by NHS England From Specialist Centres Only for:
    • Juvenile idiopathic arthritis in line with NICE TA373.
    • Paediatric indications where an adult NICE TA is available
  • Check Trust contracting arrangements.

 

13.05.03 Adalimumab Imraldi® Amgevita® Humira®
  • Prescribe by brand. Biosimilar first-line option.  Imraldi® first line biosimilar across BSW
  • Injection 40mg pre-filled syringe
  • Commissioned by CCG for psoriasis in accordance with NICE TA146.
  • Restricted Item Commissioned by NHS England via specialist centres only for treating moderate to severe hidradenitis suppurativa in accordance with NICE TA392.
13.06.01 Adapalene 
  • Cream 0.1% 45g
  • Gel 0.1% 45g
  • For the prevention of relapse.

 

13.06.01 Adapalene + Benzoyl peroxide 
  • Gel Adapalene 0.1% and Benzoyl Peroxide 2.5% 45g
09.05.01.01 Adcal ® 

Swindon only

Bath and Salisbury - not on formulary 

  • Caplets containing 300mg / 7.5mmol calcium and 200 units/5micrograms of vitamin D (as vitamin D3 /colecalciferol). 
  • Chewable tablets containing 600mg/15mmol calcium and 400 units /10micrograms of vitamin D (as vitamin D3 /colecaciferol). 
  • Dissolve, effervescent tablets containing 600mg calcium and 400 units of vitamin D (as vitamin D3) 
05.03.03.01 Adefovir Dipivoxil Hepsera®
  •  Tablets 10mg
02.03.02 Adenosine 
  • 6mg in 2ml
03.04.03 Adrenaline / epinephrine EpiPen® Emerade®

Dosing as per Resuscitation Council guidance:

Adrenaline  IM doses of 1:1000 adrenaline (repeat after 5 min if no better)

  • Adult and child over 12 years 500 micrograms IM (0.5 mL)
  • Child 6 -12 years: 300 micrograms IM (0.3 mL)
  • Child less than 6 years: 150 micrograms IM (0.15 mL

The recommended dose for adults and children over 12 years is only available in the EMERADE® brand.

Note: patients will have been trained to use a particular product. Please check with patient when dispensing if the brand is not clear.

Emerade 150 µg, 300 µg, and 500 µg sol. for injection in pre-filled pen 
Patient information leaflet , patient brochure and instruction video.

EpiPen 0.3 mg and EpiPen Jr. 0.15 mg adrenaline auto-injector
Patient information leaflet EpiPen and EpiPenJr, user guide and instruction video.

 

 

03.04.03 Adrenaline / Epinephrine Adrenaline 1 in 1000
02.07.03 Adrenaline / Epinephrine 1 in 10,000 
  • Injection 100 micrograms/ml, 1ml amp, 10ml amp,
  • Injection 100 micrograms/ml 3ml, 10ml prefilled syringes
03.04.03 Adrenaline / epinephrine 1 in 10,000 
  • Slow IV inj reserved for severely ill patients where there is doubt about adequacy of the circulation and absorption from the IM site with ECG monitoring.
  • Ensure that the correct strength of adrenaline injection is used. 
03.01.05 AeroChamber Plus ® 
  • Aerochamber Plus standard with mask cannot be used without the mask. Please prescribe standard device with mouthpiece if the mask is not required.
08.01.05 Afatinib 
  • 20mg, 30mg, 40mg and 50mg tablets
11.08.02 Aflibercept Eylea®
05.05.08 Albendazole 
  • Eskazole 400mg tablets (Imported (France)
  • Zentel 200mg chewable tablets (Imported (Australia)
  • Zentel 400mg chewable tablets (Imported (United States)
  • Dermatology use for cutaneous larva migrans
09.02.02.02 Albumin Solution 

GWH and SFT

RUH - Non formulary

  • 4.5% & 20% infusions
08.02.03 Alemtuzumab 
  • 12mg/1.2ml infusion
06.06.02 Alendronic Acid 
  • Tablets 70mg weekly
  • Oral Solution 70mg/100ml (for patients with NG or PEG tubes)
09.06.04 Alfacalcidol One-Alpha®

 Green Salisbury 

 Amber SCA Swindon and Bath

  • Capsules 250 nanograms, 500 nanograms, 1 microgram
  • Oral drops- 2 micrograms/mL, one drop contains approximately 100 nanograms
  • Bath: Recommended brand - One- Alpha
  • Note: Patients receiving alfacalcidol or calcitriol should have their plasma calcium levels checked regularly (at intervals recommended by specialist, usually every 3-6 months)
15.01.04.03 Alfentanil 
  • 1mg in 2ml amp
  • 5mg in 10ml amp
  • 5mg in 1ml amp intensive care injection

 

 

 

07.04.01 Alfuzosin 
  • Tablets 2.5mg
  • Modified-release tablets 10mg
02.12 Alirocumab Praluent®
  • 75mg/ml, 150mg/ml solution for injection in a pre filled pen
  • Consultant Lipid specialist only.
  • As an adjunct to diet in primary hypercholesterolaemia or mixed dyslipidaemia: with a statin when LDL-C response to a statin alone is insufficient, and alone or with other lipid-lowering treatments if statins are contraindicated or not tolerated.

 

 

13.05.01 Alitretinoin 
  • Oral alitretinoin is licensed for the treatment of severe chronic hand eczema unresponsive to potent topical corticosteroids, in adults.
  • Alitretinoin should ONLY be prescribed by dermatologists.
  • Prescriptions of alitretinoin for women of childbearing potential should be limited to 30 days of treatment and continuation of treatment requires a new prescription. Ideally, pregnancy testing, issuing a prescription and dispensing of alitretinoin should occur on the same day. Dispensing of alitretinoin should occur within a maximum of 7 days of the prescription.
  • Pregnancy is an absolute contraindication to treatment with alitretinoin.
  • A treatment course of alitretinoin may be given for 12 to 24 weeks depending on response.
  • Discontinuation of therapy should be considered for patients who still have severe disease after the initial 12 weeks of treatment. In the event of relapse, patients may benefit from further treatment courses of alitretinoin. Patients should still be advised to use daily emollients during therapy and once the eczema has cleared.
  • Capsules 10mg; 30mg
  • Please see links below to risk materials on generic and branded alitretinoin forms
  • Use for other indications is via IFR application only to CCG
10.01.04 Allopurinol 
  • 100mg and 300mg tablets
  • The dose of allopurinol should be reduced in patients with renal failure.
04.07.04.01 Almotriptan 
  • 3Ts formulary only
  • 12.5mg tablets
  • The maximum recommended dose is two doses in 24 hours.
06.01.02.03 Alogliptin 
  • 6.25mg, 12.5mg, 25mg
  • Not licensed for monotherapy and no data to support the use of alogliptin with metformin & a sulphonylurea in triple oral therapy
  • First line DPP-4 for all new patients who fulfil criteria in accordance with NICE guidance NG28 December 2015
  • Most cost-effective gliptin
09.06.05 Alpha Tocopheryl Acetate 

Green Salisbury

Amber Swindon

Red Bath

 

  • unlicensed unlicensed tablets 100mg - Available on a names patient basis only and therefore are considerably more expensive than the suspension.  
  • Suspension 500mg in 5ml
07.01.01.01 Alprostadil Prostin VR®
  • RUH only
  • Non formulary at GWH and SFT
  • 500 micrograms/ml solution for infusion
07.04.05 Alprostadil  Vitaros®
  • 3mg/g cream for application to tip of penis.
  • GWH and SFT only
  • Non formulary at RUH
07.04.05 Alprostadil Caverject®
  • 10 microgram, 20 microgram, 40 microgram intracavernosal injection. 
  • Please note patients will be taught, in clinic, how to administer the dual chamber system. If this form of Caverject is unavailable, patients should not be switched to other Caverject preparations, unless advised by a specialist, as they will need to be re-trained in how to use the new device.
07.04.05 Alprostadil Viridal® Duo
  • 10 microgram, 20 microgram, 40 microgram intracavernosal injection.

 

07.04.05 Alprostadil MUSE®
  • 125 microgram, 250 microgram, 500 microgram, 1000 microgram transurethral delivery system.   
02.10.02 Alteplase 
  • Vial 20mg, 50mg

 

16.02 Alteplase Actilyse Cathflo 
  • 1 vial with powder contains: 2 mg alteplase (corresponding to 1,160,000 IU)
  • Paediatric central venous catheter management
09.04.02 Altraplen Compact 
  • Ready to drink COMPACT MILKSHAKE style ONS.
  • For those who require smaller volumes or with fluid restrictions
  • 125ml bottle
  • Flavours: Hazel-chocolate, strawberry, vanilla, banana
  • 300 kcals 12 g protein 125ml fluid
  • Contains lactose 
  • IDDSI level  2
A2.02.02.03 Altraplen Compact ®  

125 ml fluid

28 day supply = 56 bottles, 7000 ml

300 kcals, 12 g protein, 125 ml fluid

IDDSI Level 1 - Slightly thick fluids

A2.04.01.02 Altrashot®  

120 ml bottle

28 day supply = 28 bottles, 3360 ml

420 kcal, 6 g protein

Recommended dose = 4 x 30 ml / day

IDDSI level 2  - Mildly thick

09.05.02.02 Aluminium Hydroxide Alu-Cap®
  • Bath and Salisbury
  • Alucap capsule aluminium hydroxide 475mg
  • Swindon - not on formulary
13.12 Aluminium Salts 
  • 20% aluminium chloride hexahydrate in an alcoholic basis
  • Anhydrol Forte®, 60ml         
  • Driclor® 60ml, 75ml
  • Notes: Aluminium chloride is a potent antiperspirant used in the treatment of severe hyperhidrosis.
04.09.01 Amantadine 
  • Capsules 100mg
  • Syrup 50mg in 5ml
  • For Parkinsons Disease
  • 'Off label' for the treatment of fatigue in Multiple Sclerosis according to NICE CG186 Oct14 
11.03.01 Amikacin 
  • GWH only. For treatment of Acanthamoeba keratitis.
  • Non formulary at RUH and Salisbury
16.15 Amikacin 
  • 500mg/2ml

Swindon only

  • Paediatric consultant/microbiology advice only
  • Monitoring of drug levels required - NOT ROUTINELY STOCKED AT GWH

Non-formulary at BaNES and Salisbury

02.02.03 Amiloride Hydrochloride Tablet
  • Tablets 5mg
  • Note: Amiloride is a weak diuretic, but is useful for potassium conservation and is the most appropriate alternative to potassium supplements
03.01.03 Aminophylline Phyllocontin Continus®
  • Modified release tablets 225mg (Phyllocontin®) m/r
  • In asthma - use only at Step 4, after long acting β2 agonists, leukotriene antagonist and high dose steroids.  Referral may be preferable. 
  • In COPD - Not recommended for routine use. Referral may be preferable.
03.01.03 Aminophylline IV 
  • Aminophylline Injection 250 mg/10ml
  • For selected patients with acute severe asthma or severe exacerbations of COPD.
02.03.02 Amiodarone 
  • Injection 150mg in 3ml
  • Pre-filled syringe 300mg in 10ml
  • Note: Should only be used where facilities for cardiac monitoring, defibrillation and cardiac pacing exist.

 

02.03.02 Amiodarone Hydrochloride Oral
  • Tablets 100mg, 200mg
  • A Shared Care Document is in the process of being written for BSW in line with NHSE guidance (June 2019) that prescribers should not initiate amiodarone in primary care for any new patient and that if, in exceptional circumstances, there is a clinical need for amiodarone to be prescribed, this should be undertaken in a cooperation arrangement with a multi-disciplinary team and/or other healthcare professional. 
04.02.01 Amisulpride 
  • Tablets 50mg, 100mg, 200mg, 400mg
  • Oral Solution
04.03.01 Amitriptyline 
  • Tablets 10mg, 25mg, 50mg
  • Oral solution 25mg in 5ml
  • Not recommended for the treatment of depression – see BNF. A sedating TCA with a high incidence of side-effects and can be fatal in overdose.  Low dose useful for neuropathic pain.
04.07.03 Amitriptyline 
  •  Tablet 10mg, 25mg, 50mg
  • 'Off label' use for pain

 

 

04.07.04.02 Amitriptyline 
  • Tablet 10mg, 25mg, 50mg
  • Notes: Initial dose 10mg nocte gradually increasing up to 75mg nocte if necessary (max 150mg nocte).
  • N.B. Not included in NICE CG150, but local neurologists recommend this option first-line.
  • Useful if migraine co-exists with depression, disturbed sleep, chronic pain condition or troublesome tension-type headache.
  • Trial at maximum tolerated dose for 6-8 weeks.
02.06.02 Amlodipine 
  • Tablets 5mg, 10mg
  • Amlodipine is for angina and hypertension, has a longer duration of action and can be given once a day. The besilate salt should NOT be prescribed as is more costly.
13.10.02 Amorolfine 
  • Nail lacquer 5%  5ml ,  3ml
  • Apply once or twice a week to affected nail for 6 months for fingernails and 12 months for toenails.

 

05.01.01.03 Amoxicillin 
  • Capsules 250mg, 500mg.
  • Oral suspension (SF) 125mg/1.25ml, 125mg/5ml, 250mg/5ml
05.01.01.03 Amoxicillin  
  • 250mg
  • 500mg
  • 1g
16.09 Amoxycillin 
  • Capsules 250mg, 500mg 
  • Suspension 125mg/5ml and 250mg/5ml
05.02 Amphotericin 
  •  Infusion 50mg
  • The National Patient Safety Agency has advised all healthcare staff involved in the use of intravenous amphotericin of the potentially lethal results if non-lipid and lipid formulations of the drug are confused. Caution: double check.
11.03.02 Amphotericin 
  • GWH only - Requires consultant /senior ophthalmologist approval. Treatment of fungal endophthalmitis see information sheet for dilution instructions
  • Non formulary at RUH and Salisbury
05.02 Amphotericin liposomal Ambisome ®
  •  Infusion 50mg.
  • The National Patient Safety Agency has advised all healthcare staff involved in the use of intravenous amphotericin of the potentially lethal results if non-lipid and lipid formulations of the drug are confused. Caution: double check.

 

08.01.05 Amsacrine 
  • 75mg/1.5ml solution for infusion ampoules and diluent
09.01.04 Anagrelide 
  • 500 microgram
  • For the treatment of essential thrombocythaemia
08.03.04.01 Anastrozole 
  • 1mg tablets
05.02.04 Anidulafungin 
  • 100mg powder for concentrate for solution for IV infusion
  • Treatment of invasive candidiasis in adult non-neutropaenic patients who are unable to tolerate fluconazole or have invasive candidiasis that is resistant to fluconazole as per acute trust guidance.
21 Antacid and Oxetacaine  
  • Oxetacaine 10mg/5ml with aluminium and magnesium hydroxides Suspension
  • For palliative care use
12.03.01 Antacid with Oxetacaine 
  • Oral suspension: Each 5ml contains 10mg Oxetacaine, Aluminium hydroxide equivalent to 200mg aluminium oxide + 100mg magnesium hydroxide 150ml bottle.
  • Not on formulary in Swindon and Salisbury.
  • BaNES only - Antacid and anaesthetic relief of oesophageal pain in palliative care patients (unlicensed)

 

11.04.02 Antazoline 0.5% with Xylometazoline 0.05% 
  • Bath only
  • Non formulary in Swindon and Salisbury
  • Xylometazoline hydrochloride 500 microgram, antazoline sulfate 5mg per 1ml
14.05.03 Anti-D (Rh0) Immunoglobulin 

Red GWH and SFT

Amber Bath

01.07.01 Anusol® 
  • Cream, ointment & suppositories.
01.07.02 Anusol-HC® Rectal
  • Ointment & suppositories.
02.08.02 Apixaban Eliquis®
  • Tablets 2.5mg, 5mg
  • For stroke prevention in people with non-valvular AF
  • For the treatment and secondary prevention of DVT and/or PE

 

02.08.02 Apixaban Eliquis®
  • Tablets 2.5mg, 5mg
  • For prevention of VTE after total hip or knee replacement in adults.
  • Following total hip replacement 2.5mg twice daily for 28 days post op, then stop.
  • Following knee replacement 2.5mg twice daily for 14 days post op then stop.

 

04.09.01 Apomorphine 
  • Injection 20mg/2ml, 50mg/5ml
  • APO-go® pen 10mg/ml 3ml pen injector
  • APO-go® PFS 5mg/ml 10ml prefilled syringe
  • Supply of Neria lines and ancillaries available via homecare (contact RUH pharmacy homecare team) for BaNES patients.  Neria lines via FP10 from GP for all other CCGs.
  • Note: Apomorphine is sometimes helpful in stabilising patients experiencing unpredictable "off" periods with levodopa treatment. It is essential to stabilise patients on domperidone for at least 2 days before starting treatment with apomorphine.
11.08.02 Apraclonidine 
  • 0.1% solution
10.01.03 Apremilast Otezla®
  • Titration pack, tablets, f/c, 14-day starter pack of apremilast 4 x 10 mg (pink) with 4 x 20 mg (brown) and 19 x 30 mg (beige).  
  • Tablet, f/c, apremilast 30 mg (beige) for maintenance treatment.

 

 

13.05.03 Apremilast 
  • Titration pack, tablets, f/c, 14-day starter pack of apremilast 4 x 10 mg (pink) with 4 x 20 mg (brown) and 19 x 30 mg (beige).  Otelza
  • Tablet, f/c, apremilast 30 mg (beige) x 56 Otelza
04.06 Aprepitant 
  • Capsules 80mg, 125mg
  • As an adjunct to dexamethasone and a 5HT3 antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy
13.02.01 Aproderm colloidal ® oat cream

VERY LIGHT MOISTURISER FOR VERY SENSITIVE MILD DRY SKIN, IF ISOMOL GEL HAS BEEN TRIED AND FAILED.

  • Branded generic version of Aveeno (cheaper than Aveeno) 
  • Patients requiring an emollient who are using medical oxygen therapy should use Aproderm Colloidal as this is a non-paraffin based emollient.

 

13.02.02 Aproderm® Barrier cream
  • Cream 30g, 100g
  • Dimethicone and Trimethylsiloxysilicate (4%)
A2.03.01 Aptamil Pepti 1 

'1' from birth, '2' from 6 months

13.02.01 Aquamax ® 
  • SFT only for in-patients
  • NOT for use in primary care
01.06.03 Arachis Oil  
  • 130ml enema.
  • Avoid the use of arachis oil in patients with a known nut allergy.
02.08.01 Argatroban 
  • 1mg/ml soultion for infusion vials
  • Restricted for use on the advice of a Haematologist for the treatment/prophylaxis of thromboembolic disease in patients with a history of heparin-induced thrombocytopenia
  • Used in preference to danaparoid in patients with moderate renal impairment
09.08.01 Arginine  

Red GWH and RUH only unlicensed unlicensed

  • Tablets: 500 mg
  • Oral solution: 50mg/ml
  • Powder:100g
  • Injection: 500mg/ml
  • For paediatric prescribing only. 
  • SFT - non formulary
  • Restricted - to initiation by Consultant Paediatricians for the treatment of metabolic disorders on the advice of tertiary centres in accordance with NHS England commissioning of highly specialised metabolic disorder services. 
04.02.01 Aripiprazole 
  • Tablets 5mg, 10mg, 15mg, 30mg
  • Orodispersible tablet 10mg, 15mg
  • Oral solution 1mg/ml
08.01.05 Arsenic Trioxide 
  • 10mg/10ml infusion
15.02 Articaine Hydrochloride with Adrenaline injection
  • Articaine hydrochloride 40mg/ml, adrenaline 1 in 100,000 (10 micrograms/ml), 2.2ml cartridge for dental use
09.06.03 Ascorbic Acid Vitamin C

Salisbury not on formulary

BaNES not on formulary and not stocked at RUH. Only ordered in for medically diagnosed deficiency (i.e. treatment and prevention of scurvy) 

  • Tablets 50mg, 100mg, 500mg. Effervescent 1g (Not prescribable on NHS)
  • Notes: Deficiency is rare and ascorbic acid is not recommended
  • Vitamins should not be routinely prescribed in primary care due to limited evidence of clinical effectiveness.
  • The only exception is medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery that results in malabsorption. Continuing need should however be reviewed on a regular basis
02.09 Aspirin (antiplatelet) 
  • Dispersible tablets 75mg
  • Dispersible tablets 300mg
  • Suppositories 300mg 

 

 

05.03.01 Atazanavir Reyataz®
  • 150mg
  • 200mg
  • 300mg
05.03.01 Atazanavir + Cobicistat Evotaz®
  •   Atazanavir sulphate corresponding to 300 mg atazanavir and 150 mg of cobicistat
02.04 Atenolol Oral
  • Tablets 25mg, 50mg, 100mg
  • SyrupSF 25mg/5ml
02.04 Atenolol Injection
  • 500micrograms per 1mL injection
04.07.04.02 Atenolol 
  • Tablets 25mg, 50mg, 100mg
  • SyrupSF 25mg/5ml
  • Note: Atenolol 25mg once daily increasing to 50mg once daily (unlicensed for this indication, atenolol may be better tolerated than propranolol. Not included in NICE CG150)
08.01.05 Atezolizumab 
04.04 Atomoxetine 
  • Capsules 10mg, 18mg, 25mg, 40mg, 60mg 

 Note: SCA for Adults link below. SCA for Paeds see Chapter 16

16.05 Atomoxetine 
  • 10mg, 18mg, 25mg, 40mg, 60mg
  • See relevant locality SCA (link below) 
02.12 Atorvastatin 
  • 10mg, 20mg, 40mg, 80mg
  • Primary Prevention: New patients offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10% or greater 10 year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool as per NICE CG below.
  • Secondary Prevention: New patients start statin treatment in people with CVD with atorvastatin 80 mg. Use a lower dose of atorvastatin if any of the following apply: potential drug interactions, high risk of adverse effects, patient preference as per NICE CG below.
  • Primary prevention for people with type 1 diabetes as per NICE CG below, start treatment for adults with type 1 diabetes with atorvastatin 20 mg.
  • Primary prevention for people with type 2 diabetes as per NICE CG below, Offer atorvastatin 20 mg to people who have a 10% or greater 10?year risk of developing CVD using the QRISK2 assessment tool
07.01.03 Atosiban 
  • Injection 7.5mg/mL (6.75mg/0.9mL vial)
  • Concentrate for IV infusion 7.5mg/mL (37.5mg/5mL vial)
05.04.08 Atovaquone 
  • GWH use for the treatment of PJP (Pneumocystis jirovecii pneumonia)
05.04.01 Atovaquone with proguanil hydrochloride Malarone®
  • Proguanil 100mg/ atovaquone 250mg tablets
  • Treatment for Malaria is available on the NHS.
  • Patients requiring Malaria prevention must acquire this on a private prescription
15.01.05 Atracurium Besilate injection
  • 25mg in 2.5ml amp
  • 50mg in 5ml amp
  • 250mg in 25ml vial

 

 

11.05 Atropine 
  • 1% ophthalmic drops

 

11.05 Atropine Sulphate 
  • 1% single use minims

 

15.01.03 Atropine Sulphate 
  • Red for use within secondary care
  • Green very rarely some GPs need to use this for emergencies in primary care.
  • 600 micrograms in 1ml amp
  • 1mg in 1ml amp
  • 1mg in 10ml PFS
07.04.05 Aviptadil + phentolamine Invicorp®
  • Solution for intracavernosal injection.
  • GWH and SFT only
  • Non formulary at RUH
08.01.05 Axitinib 
  • 1mg, 3mg, 5mg and 7mg tablets
09.04.02 Aymes Shake Compact Powdered MILKSHAKE style ONS
  • Powdered MILKSHAKE style ONS (to be mixed with 200ml full fat milk) Consider whether patient has access to milk and ability to make up the drink with milk. Consider cost to patient. Not suitable for those with lactose intolerance.
  • Flavours: Banana, chocolate, neutral, strawberry, vanilla
  • 57g sachets
  • 316 kcal 12.6 g protein 125 ml fluid
  • Contains lactoset
  • IDDSI level  1
A2.02.01.02 AYMES Shake Compact 

Made with 100 ml whole milk.

316 Calories, 12.6g Protein, 12.5g fat and 27 vitamins and minerals.

IDDSI level 1 - Slightly Thick

09.04.02 Aymes Shake Smoothie Juice style ONS
  • Not suitable for people with diabetes, COPD and wounds - due to carbohydrate:protein ratio
  • Flavours: Pineapple, mango, peach, strawberry, cranberry 
  • 66g sachet
  • 297 kcals 10.7g protein 150 ml fluid
  • Residual lactose
  • IDDSI level  2
08.01.03 Azacitidine 
  • 100mg injection
01.05.03 Azathioprine 
  • Amber with Shared Care - Bath, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH).
  • Red - GWH - Swindon DAWN patients.
  • 25mg & 50mg tablets.
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information.
08.02.01 Azathioprine 
  • 25mg and 50mg tablets
  • Chemotherapy/post transplant
10.01.03 Azathioprine 
  •  Amber with Shared Care - Bath, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH)
  •  Red - Swindon DAWN patients
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information
  • 25mg and 50mg tablets
13.05.03 Azathioprine 
  • Severe refractory eczema or as a steroid sparing agent (unlicensed use)
  • Tablets 25mg; 50mg
  • Shared care agreement for SFT and GWH patients in development (Nov 19)
13.06 Azelaic Acid 
  • Non-antibiotic treatment option for rosacea (adults only) and mild to moderate papular-pustular acne of the facial area (age 12 upwards).
  • Gel 15% 30g
  • Apply twice daily discontinue if no improvement  after 1 month (acne) or 2 months (rosacea) 

 

12.02.01 Azelastine 
  • 140micrograms/dose nasal spray 22ml
  • Useful option for patients who do not want to try a corticosteroid or have contra-indications to them

 

05.01.05 Azithromycin 
  • Tablets 250mg
  • Oral suspension 200mg/5ml
  • Included for primary care use only as an option for the treatment of chlamydia, travellers diarrhoea (private prescription) and certain types of Lyme diease.
  • See primary care antibiotic guidance for further advice.
  • Amber For COPD prophylaxis (off-label use), the decision to start azithromycin for several months at a time should be initiated by secondary care once the diagnosis of COPD has been confirmed and all the necessary preliminary investigations (eg CT and sputum cultures) has been done. NOT to be initiated by GPs without specialist input.

 

16.09 Azithromycin 
  • 250mg and 500mg
  • 200mg/5ml 
05.01.02.03 Aztreonam 
  • 500mg
  • 1g
  • 2g
10.02.02 Baclofen 
  • Tablets 10mg
  • Liquid 5mg in 5ml 
  • Serious side-effects can follow abrupt withdrawal of baclofen; therapy should be discontinued by gradual dose reduction over at least 1-2 weeks (longer if symptoms occur)
  • Bath only - Intrathecal Baclofen - Refer to the NHS Commissioning Board Clinical Policy D04/P/c: Intrathecal baclofen (ITB) 
01.05.01 Balsalazide 
  • 750mg capsules.
  • Please note: Balsalazide is indicated for the treatment of mild to moderate ulcerative colitis and maintenace of remission, but should ONLY be prescribed for patients not responding to other aminosalicylates. 
10.01.03 Baricitinib Olumiant®
  • 2mg and 4mg tablets
  • CCG commissioned as per NICE TA466
13.02.02 Barrier preparation Cavilon®Film
  • Use within GWH ONLY, not for use by primary care
14.04 BCG vaccine diagnostic agent 
  • Tuberculline purified protein derivative (PPD) (Mantoux test) - named patient. 
14.04 BCG vaccine Intradermal 
  • Bacillus calmette-guerin vaccine
  • The BCG vaccine (which stands for Bacillus Calmette-Guérin vaccine) is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB
06.01.01.03 BD Microfine ® Pen needles 
  • Swindon only - To be used second line to GlucoRx 
06.01.01.03 BD Safe-Clip ® Needle clipping device
06.01.01.03 BD Viva ® Pen needles 
  • BaNES and Wltshire - Second line to GlucoRx 
  • 4mm/32G, 5mm/31G and 8mm/31G sizes only  
03.02 Beclometasone Qvar®, Kelhale®
  • Prescribe by brand name
  • MDI 50mcg and 100mcg
  • Clenil® and Kelhale® /Qvar® are first line pMDI low dose ICS for asthma.

 

 

03.02.02 Beclometasone and formoterol Fostair NEXThaler®
  • First choice ICS/LABA DPI for asthma and COPD. 
  • Combination of beclometasone and formoterol
  • For asthma: dry powder inhaler; beclometasone 100 micrograms, formoterol 6 micrograms dose and beclometasone 200 micrograms, formoterol 6 micrograms dose 
  • For COPD with FEV1<50%: dry powder inhaler; beclometasone 100 micrograms, formoterol 6 micrograms dose only in line with the product guidance
03.02.02 Beclometasone and formoterol Fostair®
  • First choice ICS/LABA pMDI for asthma and COPD and the only licensed pMDI for COPD
  • Aerosol inhalation MDI 120 dose unit beclometasone 100 micrograms, formoterol 6 micrograms dose and beclometasone 200 micrograms, formoterol 6 micrograms dose 
  • Adults over 18 years only. (dose = 1-2 puffs twice daily, max 4 puffs twice daily) 
03.02 Beclometasone Dipropionate Clenil Modulite®
  • Prescribe by brand name
  • Clenil® Modulite aerosol inhalation MDI 50, 100, 200, 250 micrograms/dose
  • Clenil® and Kelhale®/Qvar® are first line pMDI low dose ICS for asthma.

 

 

12.02.01 Beclometasone Dipropionate 
  • 200 dose nasal spray, 50 micrograms per spray     
  • Beclomethasone is licensed for the prophylaxis and treatment of allergic and vasomotor rhinitis.    
  • First line for treatment of allergic rhinits  . OTC for over 18 years.

 

 

 

10.01.03 Belimumab Benlysta®
  • Intravenous infusion, powder for reconstitution 120mg vial; 400mg vial
  • Commissioned by NHSE at specialist centres e.g RUH
  • Non Formulary at GWH and SFT 
08.01.01 Bendamustine 

 

02.02.01 Bendroflumethiazide Tablet
  • Tablets 2.5mg
  • Note: 2.5mg produces a maximal blood pressure lowering effect, with very little biochemical disturbance.
13.06.01 Benzoyl Peroxide 
  • Aqueous gel 2.5%, 5%, 10% 40g    
  • Cream: 5%, 10% 40g      
13.06.01 Benzoyl Peroxide 5% with Clindamycin 1% 
  • Gel benzoyl peroxide 5%, clindamycin 1% 25g, 50g
  • Apply once daily in the evening.

 

12.03.01 Benzydamine 
  • oral rinse 0.15% 300ml
  • oromucosal spray 0.15% 30ml
05.01.01.01 Benzylpenicillin 
  •   Green  for emergency treatment of meningitis
  •   Red  for all other indications
  • 600mg vials
  • 1.2g vials
05.01.01.01 Benzylpenicillin Benzathine 
  • GWH use to treat syphilis in HIV patients by the sexual health team.
  • RUH sexual health specialists use this as well for syphilis
  • A long acting form of benzylpenicillin administered by deep intramuscular injection. It is usually given as a single dose or weekly for the treatment of syphilis depending on the disease stage and guidelines used.
  • 600,000 units or 1.2 MU Injection
04.06 Betahistine Dihydrochloride Tablet
  • Tablet 8mg, 16mg
06.03.02 Betamethasone 
  • Green Salisbury (tablets only)
  • Red RUH (tablets/injection)
  • Red SFT - injection for prophylactic treatment of neonatal respiratory distress syndrome
  • Red GWH (tablets only) used as a mouthwash. Dissolve a 500mg tablet in 10ml of water and used as a mouthbath up to five times a day.
  • Injection 4mg in 1ml
  • Soluble tablets (as sodium phosphate) 500 microgram   

 

11.04.01 Betamethasone 
  • 0.1% ophthalmic drops

 

13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic®
  • Potent steroid for scalps with salicylic acid
  • Scalp Application Betamethasone valerate 0.05% & Salicylic Acid 3% 100ml
  • For very scaly scalps.
13.04 Betamethasone (as Valerate) 0.025% Betnovate-RD®
  • Moderate potency steroid
  • Cream, Ointment 0.025% 100g
  • Apply sparingly once or twice daily
13.04 Betamethasone (as Valerate) 0.1% Betnovate®
  • Potent steroid
  • Cream, Ointment 0.1%  30g, 100g
13.04 Betamethasone (as Valerate) 0.1% with Clioquinol 
  • Potent steroid
  • Cream, Ointment Betamethasone (as valerate) 0.1% clioquinol 3% 30g
  • Was Betnovate C (discontinued)
13.04 Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet®
  • Potent steroid
  • Cream, Betamethasone 0.1%, fusidic acid 2% 30g, 60g
11.04.01 Betamethasone 0.1% with Neomycin 0.5% 
  • Ophthalmic drops with antibacterial

 

12.01.01 Betamethasone 0.1% with Neomycin 0.5%  Betnesol N®
13.04 Betamethasone Dipropionate 0.05% w/w plus Salicylic Acid 3.00% w/w Diprosalic®
  • Potent steroid
  • 30g, 100g
  • For palmoplantar hyperkeratotic inflammatory disease
13.04 Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm®
  • Potent steroid
  • Cream Betamethasone diproprionate 0.05%, clotrimazole 1% 30g
13.04 Betamethasone Esters Betacap®
  • Potent steroid
  • Scalp application 0.1% 100ml water miscible in basis containing coconut oil derivative. 
  • Well-tolerated if scalp stings easily.
13.04 Betamethasone Esters Bettamousse®
  • Potent steroid
  • 100g
12.02.01 Betamethasone Sodium Phosphate 0.1% 
  •  5ml nasal drops

 

12.01.01 Betamethasone sodium phosphate drops 0.1% Ear drops
  • Ear drops 0.1%  
  • Prolonged use of topical corticosteroids should be avoided.
  • Betamethasone products for use in nasal allergy please refer to 12.2.1
11.06 Betaxolol 
  • 0.5% ophthalmic drops and 0.25% ophthalmic solution

 

11.08.02 Bevacizumab  Avastin®
  • Updated commissioning policies to be added once agreed across BSW
02.12 Bezafibrate 
  • Only to be prescribed after having had a telephone consultation with a specialist
  • 200mg, modified release tablets 400mg (Bezalip mono®)
  • NICE. Do not do recomendationDo not routinely offer fibrates for the prevention of CVD to any of the following: -people who are being treated for primary prevention -people who are being treated for secondary prevention -people with CKD -people with type 1 diabetes -people with type 2 diabetes.
08.03.04.02 Bicalutamide 
  • 50mg and 150mg tablets
05.03.01 Bictegravir, Emtricitabine, Tenofovir alafenamide Biktarvy®
  • Tablets containing bictegravir sodium equivalent to 50 mg of bictegravir, 200 mg of emtricitabine, and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide
  • For treatment of HIV-1 in adults in line with NHSE CCP
11.06 Bimatoprost 
  • 100microgram/ml ophthalmic drops
  • 300microgram/ml preservative free single use eyedrops available where indicated as per BSW glaucoma guidance
11.06 Bimatoprost with Timolol 
  • 300micrograms and 5mg/ml combination ophthalmic drops

 

12.03.05 Biotene Oralbalance ® 
  • Saliva replacement oral gel
  • 50g
  • ACBS
09.08.01 Biotin  

unlicensed unlicensed GWH only

  • Tablets: 5mg
  • Injection: 5mg/ml
  • Non formulary SFT and RUH
  • Restricted - to prescribing by Consultant Paediatricians on the recommendation of tertiary Paediatric Specialists only. 
06.01.01.02 Biphasic Insulin Aspart NovoMix® 30

Green Salisbury

Amber Bath and Swindon

  • Type 2 diabetes only
06.01.01.02 Biphasic Insulin Lispro Humalog® Mix

Green Salisbury

Amber Bath and Swindon

  • Type 2 only
06.01.01.02 Biphasic Isophane Insulin Insuman® Comb
  • Type 2 diabetes only
  • NOTE - Insuman Comb 15 cartridge is being discontinued.
  • NOTE - Insuman Comb 25 vial is being discontinued.
06.01.01.02 Biphasic Isophane Insulin Humulin® M3
  • Type 2 diabetes only
01.06.02 Bisacodyl 
  • 5mg tablets.
  • 5mg & 10mg suppositories.
  • Please note: Bisacodyl tablets are much more cost-effective than senna tablets in primary care, where all new patients should be commenced on bisacodyl tablets or, if necessary, senna liquid.
12.02.03 Bismuth + iodoform impregnated gauze (BIPP)  
  • A paste of composition Iodoform 40% w/w, Bismuth Subnitrate 20% w/w and Paraffin Liquid 40% w/w. presented in a labelled aluminium laminated pouch.
01.03.03 Bismuth subsalicylate Pepto-Bismol®
  • Green - Salisbury & Swindon.
  • Non-formulary - Bath.
  • 262.5mg chewable tablets.
  • Please note: This is ONLY included for use as part of H.pylori eradication therapy, as described above in Section 01.03 Helicobacter pylori infection.
  • When used as the bismuth element of H. pylori eradication therapy, the dose of bismuth subsalicylate is 525mg four times daily (prescribe generically).
02.04 Bisoprolol 
  • Tablets 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg, 10mg
  • Note: For heart failure, use should be initiated cautiously, titrated slowly and adequately monitored.
02.08.01 Bivalirudin 
  • Injection, powder for reconstitution 250mg vial
  • Anticoagulation during PCI

 

08.01.02 Bleomycin 
  • 15,000 unit powder for injection
08.02 Blinatumomab 
14.04 Boostrix IPV ® 
  • Boostrix-IPV suspension for injection in pre-filled syringe
  • Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) (schedule between 3yrs & 4/12 to 5 years)
08.01.05 Bortezomib 
02.05.01 Bosentan 
  • Formulary at RUH and SFT (under shared care with Southampton)
  • Tablets 62.5mg, 125mg
  • For digitial ischaemia and ulceration in Raynaud's Disease and scleroderma as per NHSE policy below within Specialist Centres
08.01.05 Bosutinib 
04.07.04.02 Botulinum A toxin botox®
04.09.03 Botulinum A toxin 
  • Dysport® injection 300 or 500 unit vial
  • Botox® Injection powder for reconstitution 50 unit vial, 100 unit vial, 200 unit vial
  • Xeomin® Injection powder for reconstitution 50 unit vial, 100 unit vial, 200 unit vial.
  • See BSW CCG Botulinum commissioning policy for approved indications on the link below.
  • Botox can also be used for migraine in accordance with recommendations of NICE TA 260.
  • Xeomin® may be used for chronic sialorrhoea associated with chronic neurological conditions in line with licences and with NICE TA605
  • Preparations are not interchangeable and should be used under specialist supervision.
  • Commissioned by NHS England for use in focal spasticity in children according to set criteria.

 

13.12 Botulinum A toxin 
  • GWH.
  • A specific commissioning policy for the use of this for hyperhydrosis is under development (August 19). Current botulinum policy is found below.
  • Botulinum toxin units are not interchangeable from one product to another.  Prescribe by brand as advised by hospital pharmacy department.
07.04.03 Botulinum toxin 
  • See BSW CCG Botulinum commissioning policy for approved indications:
  • Management of bladder dysfunction in adults not adequately managed with anticholinergics for: Overactive bladder with symptoms of urinary incontinence, urgency and frequency.
  • Neurogenic detrusor over-activity with urinary incontinence due to sub-cervical spinal cord injury or MS.
08.01.05 Brentuximab 
08.01.05 Brigatinib 
  • 30mg, 90mg and 180mg
11.06 Brimonidine Tartrate 
  • 0.2% ophthalmic eye drops
  • Note - higher risk of side-effects and sensitivity.

 

11.06 Brinzolamide 
  • 1% eye drops

 

11.06 Brinzolamide 1% with Timolol 0.5%  
  • Brinzolamide 1% with Timolol 0.5% 
11.06 Brinzolamide 10mg/ml & brimonidine 2mg/ml 
  • ophthalmic drops containing 10 mg/mL of brinzolamide and 2 mg/mL of brimonidine tartrate equivalent to 1.3 mg of brimonidine.

BaNES/Wilts - For use as per Glaucoma guidance 
Swindon - Not on formulary

04.08.01 Brivaracetam 
  • Tablets 10mg, 25mg, 50mg, 75mg, 100mg
  • Liquid 10mg/1ml
  • IV 10mg/1ml 5ml ampoule
  • Brivaracetam recommended as an adjunctive AED treatment for adult patients (≥16 years) with focal-onset seizures.
  • Only to be used when first or second line treatments have failed. 
13.05.03 Brodalumab 
  • 210 mg solution for injection in pre-filled syringe
  • Use as per NICE TA
06.07.01 Bromocriptine 

Not on formulary Swindon

  •  1mg, 2.5mg   
01.05.02 Budesonide Jorveza®
  • Red - RUH & Salisbury - For treatment of eosinophlic oesophagitis.
  • Non- formulary - Swindon - Awaiting NICE TA publication.
  • 1mg oro-dispersible tablets.
  • Please prescribe BY BRAND.
01.05.02 Budesonide  Budenofalk®
  • 2mg per actuation white foam, 1 canister (14 days treatment).
  • Please note: Budesonide foam enema is ONLY indicated for use second line in patients unable to use / tolerate Colifoam® enema.
01.05.02 Budesonide Budenofalk®
  • 3mg gastro-resistant capsules.
  • Please note: Budenofalk capsules are available for use for their licensed indications of:
    • induction of remission in patients with mild to moderate Crohn's disease affecting the ileum and/or ascending colon,
    • induction of remmission in patients with active collagenous colitis,
    • autoimmune hepatitis (Swindon ONLY).
  • Please prescribe BY BRAND. 
01.05.02 Budesonide Cortiment®
  • Red - RUH - For induction of remission in patients with mild to moderate ulcreative colitis, where 5-ASA treatment is not sufficient.
  • Non-formulary - Salisbury & Swindon.
  • 9mg prolonged-release tablets.
  • Please prescribe BY BRAND.
03.02 Budesonide Pulmicort®, Easyhaler®
  • Prescribe by brand name
  • Easyhaler dry powder for inhalation MDI 100 micrograms/dose, 200 micrograms/dose, 400 micrograms/dose
  • Turbohaler dry powder inhaler MDI 100 microgram/dose, 200 micrograms/dose, 400 micrograms/dose
  • Easyhaler Budesonide® and Pulmicort® are the first line DPI low dose ICS for asthma

 

12.02.01 Budesonide Nasal spray
  • Budesonide nasal spray 64micrograms / spray 120 dose
  • Second line for the treatment of allergic rhinitis
  • Licensed for nasal polyps.

 

03.02.02 Budesonide and formoterol Symbicort®
  • No new prescribing. Existing patients only.
  • Can be used in a MART regime. 
  • Prescribe by brand.
  • Combination of budesonide and formoterol
  • Turbohaler dry powder inhaler DPI 100/6; 200/6; 400/12
  • Notes: Symbicort Turbohaler is licensed for both asthma and COPD;

 

03.02.02 Budesonide and formoterol DuoResp Spiromax®
  • No new prescribing. Existing patients only.
  • Can be used in a MART regime.
  • Prescribe by brand.
  • Combination of budesonide and formoterol fumarate dihydrate
  • Dry Powder Inhaler 320micrograms/9 micrograms (equivalent to 400/12) and 160micrograms/4.5 micrograms (equivalent to 200/6)
  • For the treatment of asthma and COPD within product licence

 

03.02.02 Budesonide and formoterol Fobumix Easyhaler®
  • First choice ICS/LABA DPI for asthma.
  • Can be used in a MART regime.
  • Prescribe by brand
  • Combination of budesonide and formoterol fumarate dihydrate
  • Breath-actuated dry powder inhaler 80 micrograms/4.5 micrograms, 160 micrograms/ 4.5 micrograms and 320 micrograms/9 micrograms
  • For the treatment of asthma and COPD within product licence
  • Most cost effective option July 2018

 

03.02 Budesonide Nebuliser Suspension 
  • Green  Bath
  • Green  Salisbury
  • Amber  Swindon (Occasional paediatric use.)
  • Respiratory solution 500 micrograms per 2ml, 1mg per 2ml
02.02.02 Bumetanide 
  • Tablets 1mg, 5mg
  • Bumetanide is significantly more expensive than Furosemide in primary care.
15.02 Bupivacaine and Adrenaline injection
  • 0.25% w/v
  • 0.5% w/v
  • 1 in 200,000 
15.02 Bupivacaine Hydrochloride injection
  • 25mg in 10ml (0.25%) amp
  • 50mg in 10ml (0.5%) amp
  • 75mg in 10ml (0.75%) amp
  • GWH only: 0.1% and 0.125% epidural infusion bags used.

 

 

15.02 Bupivacaine Hydrochloride with Glucose injection
  • 0.5% solution for injection, 4ml ampoule
  • Not routinely stocked at RUH
04.07.02 Buprenorphine 
  • 7 day patch of choice for consistency and safety
  • Patch 5 microgram/hour for 7 days 
  • Patch 10 microgram/hour for 7 days
  • Patch 15 micrograms/hour for 7 days
  • Patch 20 microgram/hour for 7 days
  • Only to be used in patients with cognitive deficit or swallowing difficulties, after a trial of soluble/liquid medication. Zomorph capsules can be opened up for ease of swallowing.
  • Buprenorphine patches are NOT suitable, or licensed, for management of acute / intermittent pain.
  • Patients and/or their carers neeed to be aware that these patches need to be applied at appropriate seven-day intervals. Remember to remove the old patch before application of new patch. Avoid use of multiple patches.
04.07.02 Buprenorphine 
  • Patch 35 microgram/ hour, for 4 days
  • Patch 52.5 microgram/ hour, for 4 days
  • Patch 70 microgram/ hour, for 4 days
  • Only to be used in patients with cognitive deficit or swallowing difficulties, after a trial of soluble/liquid medication. Zomorph capsules can be opened for ease of swallowing.
  • Buprenorphine patches are not suitable for management of acute / intermittent pain.
  • Patients and/or their carers need to be aware that these patches need to be applied at appropriate 96 hour intervals (or 4 days). Remember to remove the old patch before application of new patch. Avoid use of multiple patches.
04.10.03 Buprenorphine  
  • Amber with Shared Care For BaNES CCG 
  • Amber Swindon/North Wilts: Under review
  • Sublingual Tablets 400micrograms, 2mg, 8mg
  • For treatment of substance misuse 
  • See BaNES CCG shared care for substance misuse on link above
  • The recommended criteria for generalist prescribers to prescribe in the field of opioid dependence is that they have completed the RCGP Certificate in the Management of Drug Misuse (part one) and be part of the Local Enhanced Service (LES) for substance misuse
  • GPs with Specialist Interest (GPwSI) in substance misuse and specialist prescribers in the field of substance misuse (not LES prescribers) are "secondary care prescribers" for the purpose of these guidelines.
  • Supervised Consumption through an accredited pharmacy should be undertaken for a minimum of twelve weeks at the start of methadone and buprenorphine treatment in line with DOH and NICE

 

04.10.02 Bupropion Hydrochloride 
  • Tablets m/r, f/c 150mg
  • CSM advice: Bupropion is contra-indicated in patients with a history of seizures or of eating disorders, a CNS tumour, or who are experiencing acute symptoms of alcohol or benzodiazepine withdrawal.
06.07.02 Buserelin 
  • For fertility treatment
  • 150 micrograms / metered spray
08.03.04.02 Buserelin 
  • 100microgram and 150microgram nasal spray
04.01.02 Buspirone Hydrochloride Tablets
  • Tablets 5mg
  • No withdrawal effects but response to treatment may take up to 2 weeks
08.01.01 Busulfan 
  • 2mg tablets
08.01.01 Busulfan 
  • 60mg/10ml infusion
03.04.03 C1 esterase inhibitor Cinryze® /Berinert®
  • Injection podwer for reconstitution, 500 unit vial
      Acute Treatment or Short-term prophylaxis prior to planned procedures for Hereditary Angioedema and Acquired Angioedema
    • In accordance with NHS England commissioning policy
    • May only be initiated by (or on advice of) Specialist Centres
    • Drug costs for emergency use in other hospitals will be reimbursed through the Specialist Centre


    • Prophylactic treatment of hereditary angioedema (HAE) types I and II
    • In accordance with NHS England commissioning policy in patients who fail, are intolerant or have contra-indications to oral prophylactic therapies.
    • May only be initiated by Specialist Centres
    • Prior approval must be given via Blueteq system
08.01.05 Cabazitaxel 
  • 60mg/1.5ml infusion
06.07.01 Cabergoline 
  • 500 micrograms    
  • Shared care agreement in development
08.01.05 Cabozantinib 
08.01.05 Cabozantinib 
  • 20mg, 40mg and 60mg tablets
09.05.01.01 Calcichew ® 

Bath and Salisbury only

Swindon - not on formulary

  • Chewable tablets containing 500mg / 12.5mmol calcium and 400 units /10micrograms of vitamin D (as vitamin D3) 
13.05.02 Calcipotriol 50mcg/g 
  • Scalp solution, calcipotriol 50 micrograms/ml
  • Ointment 50micrograms/g: Note this is not licensed in under 18 years
  • First Line Calcipotriol Ointment 50mcg/g 30g Dovonex®
  • Apply Calcipotriol thickly twice a day maximum of 100g per week
  • Second Line - If very itchy or inflamed consider adding in a steroid as a separate product e.g Eumovate or Betnovate RD:
  • Calcipotriol Ointment 50mcg/g 30g Dovonex® PLUS Eumovate Cream OR
  • Calcipotriol Ointment 50mcg/g 30g Dovonex® PLUS Betnovate RD Cream
  • Apply calcipotriol in the mornings thickly and steroid in the evenings thinly.
  • Gradually reduce the steroid and increase the calcipotriol to twice daily

 Note: When preparations used together, maximum total calcipotriol 5mg in any one week (eg. scalp solution 60ml with cream/ointment 30g OR cream/ointment 60g with scalp solution 30ml)

13.05.02 Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet
  • Ointment Calcipotriol 50mcg/g betamethasone diproprionate 500mcg/g 120g  
  • Contains a potent steroid which may destabilise psoriasis and increase its severity due to rebound pustulation and inflammation.
  • Usual max duration of treatment is 4 weeks. 
  • Max 15g daily to no more than 30% of body surface area; max 100g weekly; 75g weekly (child >12 yrs)
13.05.02 Calcipotriol and betamethasone 50 microgram/g + 0.5 mg/g  Dovobet
  • Indications: Topical treatment of scalp psoriasis in adults. Topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults.
  • Contains a potent steroid which may destabilise psoriasis and increase its severity due to rebound pustulation and inflammation.
  • The recommended treatment period is 4 weeks for scalp areas and 8 weeks for “non-scalp” areas. If it is necessary to continue or restart treatment after this period, treatment should be continued after medical review and under regular medical supervision.
  • The maximum daily dose should not exceed 15 g. The body surface area treated with calcipotriol containing medicinal products should not exceed 30 %
13.05.02 Calcipotriol and Betamethasone cutaneous foam Enstilar®
  • One gram of cutaneous foam contains 50 micrograms of calcipotriol (as monohydrate) and 0.5 mg of betamethasone (as dipropionate).
  • Contains a potent steroid which may destabilise psoriasis and increase its severity due to rebound pustulation and inflammation.
  • Usual max duration of treatment is 4 weeks. 
  • Max 15g daily to no more than 30% of body surface area; max 100g weekly; 75g weekly (child >12 yrs)
06.06.01 Calcitonin 

NOTE - Not on formulary Bath or Salisbury 

  • 50units/1ml,100units/1ml ,400units/2ml

Swindon only For the short-term treatment of:

  • Paget's disease - now restricted to patients who do not respond to, or cannot tolerate, alternative treatments (i.e. patients with renal impairment). Duration of calcitonin should be limited to up to 3 months, but may be extended to 6 months under exceptional circumstances (e.g. patients with impending pathologic fractures)
  • Acute bone loss due to sudden immobilisation, for up to 4 weeks only
  • Hypercalcaemia of malignancy

At minimum effective dose

09.06.04 Calcitriol 

 

  • 250 nanograms, 500 nanograms
  • For renal indication only. 
  • Note: Patients receiving alfacalcidol or calcitriol should have their plasma calcium levels checked regularly (at intervals recommended by specialist, usually every 3-6 months)
13.05.02 Calcitriol 3micrograms/g Silkis®
  • Can be used on the face (with caution) and flexures unlike Dovonex.
  • It is recommended that not more than 35% of the body surface be exposed to daily treatment. Not more than 30 g of ointment should be used per day. There is limited clinical experience available for the use of this dosage regimen of more than 6 weeks.
09.05.01.01 Calcium 5.1mmol/10ml Syrup Alliance Calcium Syrup®
  • Salisbury only
  • Bath and Swindon not on formulary
  • Replaces Calcium Sandoz syrup (discontinued)
09.05.02.02 Calcium Acetate 

Amber Swindon

Green Bath 

  • Phosex Tablets calcium acetate 1g
  • As a phosphate binder according to NICE CG 157
  • Each 1g tablet contains 250mg calcium or 6.2mmol Ca2+. Usual dose 4-6 tablets daily according to phosphate levels. 
09.05.02.02 Calcium Carbonate Calcichew®

Green Salisbury and Bath

  • Calcichew chewable tablet containing 500mg calcium/12.5mmol Ca2+
09.05.01.01 Calcium Chloride 
  • Parental preparation - Calcium Chloride Injection
  •  Min-I-jet 10ml           
08.01 Calcium Folinate 
  • Folinic acid (as Calcium folinate) 7.5mg per 1ml
  • Chemotherapy induced mucositis and myelosuppression
09.05.01.01 CALCIUM GLUCONATE 10%  
  • 10ml ampoule
  • Infusion 50ml         

 

06.01.02.03 Canagliflozin 
  • Green 
  • Amber IN COMBINATION WITH INSULIN IN TYPE 2 DIABETES FOLLOWING NICE GUIDANCE ONLY
  • 100mg,300mg
  • Renal Impairment: See SPC for patients with eGFR <60mL/minute/1.73m2
02.05.05.02 Candesartan 
  • Tablets 2mg, 4mg, 8mg, 16mg, 32mg
13.05.02 Capasal ® Shampoo
  • Coal tar distilled 10 mg per 1 gram
  • Coconut oil 10 mg per 1 gram
  • Salicylic acid 5 mg per 1 gram
  • 250ml

 

08.01.03 Capecitabine 
  • 150mg and 500mg tablets
12.03.01 Caphosol ®  Medical Device
  • GWH only: Restricted for use in patients undergoing autologous stem cell transplant only. Consultant haematologist prescription only.
04.07.03 Capsaicin 
  • Cream containing 0.075% capsaicin (Axsain®)   
  • For the treatment of post herpetic neuralgia (after lesions have healed) & painful diabetic peripheral neuropathy sparingly up to 3-4 times a day.
  • The recommended duration of use in the first instance is 8 weeks, since there is no clinical trial evidence of efficacy for treatment of more than 8 weeks duration. After this time, it is recommended that the patient's condition should be fully clinically assessed prior to continuation of treatment, and regularly re-evaluated thereafter, by the supervising consultant.

 

10.03.02 Capsaicin Zacin®
  • Amber Swindon only - for painful diabetic peripheral polyneuropathy (off-label)
  • Cream containing 0.025% capsaicin (Zacin®)
  • For symptomatic relief in osteoarthritis. It may need to be used for 1-2 weeks before pain is relieved
10.03.02 Capsaicin Qutenza®
  • Pain clinic use only as per local policy below.  
10.03.02 Capsaicin Axsain®
  • Amber Swindon only - for painful diabetic peripheral polyneuropathy.
  • Cream containing 0.075% capsaicin (Axsain®)
  • For treatment of post herpetic neuralgia (after lesions have healed) & painful diabetic peripheral neuropathy
16.01 Captopril 
  • 12.5mg, 25mg and 50mg
  • 5mg/5ml and 25mg/5ml SF solution

Swindon only

Non-formulary in BaNES and Salisbury

04.02.03 Carbamazepine 
  • Tablet 100mg, 200mg, 400mg
  • Tegretol® m/r tablet 200mg, 400mg.  Prescribe M/R tablet by brand
  • Chewable tablet 100mg, 200mg
  • LiquidSF 100mg/ml
  • Suppository 125mg, 250mg
  • Prescribe generically for non epilepsy indications.
  • Carbamazepine may be used for the prophylaxis of bipolar disorder in patients unresponsive to lithium; it seems to be particularly more effective in patients with rapid cycling manic-depressive illness (4 or more episodes per year).
04.07.03 Carbamazepine 
  • Tablets 100mg, 200mg, 400mg
04.08.01 Carbamazepine 
  • Tablet 100mg, 200mg, 400mg
  • Tegretol® m/r tablet 200mg, 400mg.  Prescribe M/R tablet by brand (Category 1 MHRA)
  • Chewable tablet 100mg, 200mg
  • LiquidSF 100mg/ml
  • Suppository 125mg, 250mg
  • Prescribe generically for non epilepsy indications.
06.02.02 Carbimazole 
  • 5mg, 20mg
  • CSM warning: Neutropenia and agranulocytosis. Doctors are reminded of the importance of recognising bone marrow suppression induced by carbimazole and the need to stop treatment promptly.
  • Initiate following discussion with/at the point of referral to a specialist.
  • Monitor for signs of infection and warn patients to report sore throat or other signs of infection. Counsel patient of possible risk of skin rash or agranulocytosis.  
  • Discuss any course of treatment over 3 years with a specialist.  
  • 5mg carbimazole is equivalent to 50mg propylthiouracil
03.07 Carbocisteine 
  • Capsules 375mg
  • Oral liquid 250mg/5ml
  • Sachets 750mg/10ml Sugar free oral solution
  • Note: liquid must still be used in patients with feeding tubes
11.08.01 Carbomer 
  • 0.2% gel 10g
11.08.01 Carbomer 980 eye drops 
  • 0.2% gel 10g
  • Suitable for contact lense wearers
08.01.05 Carboplatin 
  • 150mg/15ml, 450mg/45ml, 50mg/5ml and 600mg/60ml infusion
07.01.01 Carboprost Hemabate®
  • 250micrograms/1ml solution for injection ampoules 
  • Indicated for postpartum haemorrhage due to uterine atony in patients unresponsive to ergometrine and oxytocin.
11.08.01 Carboxymethylcellulose, glycerine & castor oil eye drops 
  • Carmellose 0.5ml, glycerol 1%, castor oil 0.25% 10ml
08.01.05 Carfilzomib 
  • 10mg, 30mg and 60mg infusion
11.08.01 Carmellose 
  • 1% drop 10ml
  • Cellusan is the most cost-effective preservative-free carmellose preparation in primary care
  • Swindon only - Use Celluvisc SDUs in secondary care.
12.03.01 Carmellose Sodium Orabase®
  • Please note: Patients should self-care in the first instance
09.08.01 Carnitine 
  • GWH only
  • 100mg / ml (10 x 10ml single dose)
  • Non formulary - RUH and SFT
  • Commissioned by NHS England for carnitine deficiency when supplied in secondary care, as per NHS England service specification. For initiation by specialist centres only.
02.04 Carvedilol 
  • Tablets 3.125mg,6.25mg,12.5mg,25mg

Amber SFT and RUH

Green Swindon

05.02.04 Caspofungin 
  • 50mg Powder for conc for soln for infusion
  • 70mg Powder for conc for soln for infusion
  • Indicated for the treatment of invasive candidiasis. Treatment of invasive aspergillosis in patients refractory to or intolerant of amphotericin and/or itraconazole. Empirical therapy for presumed fungal infections in febrile neutropenic patients. Used as per microbiology advice only.
07.04.04 Catheter Patency Solutions 
07.04.04 Catheter Patency Solutions 
07.04.04 Catheter Patency Solutions 
07.04.04 Catheter Patency Solutions 
13.09 Ceanel Concentrate® Liquid
  • Cetrimide 100 mg per 1 ml
  • Phenylethyl alcohol 75 mg per 1 ml
  • Undecenoic acid 10 mg per 1ml
  • 150ml,500ml

 

05.01.02 Cefalexin 
  •  Capsules 250mg, 500mg
  • Tablets 250mg, 500mg.
  • Oral suspension 125mg/5ml, 250mg/5ml, 500mg/5ml.
  • For use in UTIs please see local Primary Care Antibiotic Guidance
05.01.02 Cefotaxime  
  • Green  for meningococcal disease for Penicillin allergic patients
  • Red for all other indications 
  • 500mg
  • 1g
  • 2g

 

05.01.02 Ceftazidime 
  • 250mg
  • 500mg
  • 1g
  • 2g
  • 2000mg surefuser device over 24hrs via local Outpatient Parenteral Antibiotic Treatment (OPAT) services (acute trusts).
05.01.02 Ceftriaxone 
  • Red for use in acute trusts
  • Green for use in primary care as follows:
    • for treatment of cellulitis in the community in BaNES via Virgin Care primary care services 
    • 1g IM STAT used for treatment of pelvic inflammatory disease with high risk of gonococcal infection in conjunction with oral antibiotics as per local primary care antibiotic guidance.
  • 250mg, 1g and 2g
05.01.02 Cefuroxime  
  • 250mg
  • 750mg
  • 1.5g.
11.03.01 Cefuroxime  
  • 5% eye drops
11.08.02 Cefuroxime intracameral injection Aprokam®
  • Red - GWH ONLY.
  •  Non-formulary - Bath & Salisbury.
  •  3mg in 0.3ml pre-prepared injection.
  •  50mg vial.
10.01.01 Celecoxib Celebrex®
  • Salisbury only
  • Non formulary in Bath and Swindon
  • 100mg and 200mg capsules
08.01.05 Ceritinib 
  • 150mg capsules
13.05.03 Certolizumab 200mg 
  • 200mg pre-filled pen or syringe
  • For people whose psoriasis has partially responded to the lowest licensed maintenance dose, increasing to the highest licensed dose (400 mg) is not cost effective compared with switching to an alternative biological treatment. Hence only the 200mg maintenance dose has been approved by NICE.
10.01.03 Certolizumab Pegol Cimzia®
  • Prefilled syringe 200mg.
  • Use in accordance with NICE guidance and local pathways for RA, AS or PSA.
  • Not routinely commissioned by NHS England for paediatric indications - see NHS England drugs list. 

 

 

03.04.01 Cetirizine 
  • Self Self Care Medicine for primary care.
  • Tablets 10mg
  • Oral solutionSF 5mg in 5ml
08.01.05 Cetuximab 
04.01.01 Chloral Hydrate 
  • 143mg/5ml oral solution
  • GWH: Paediatric use only
  • SFT: used for pre-procedure sedation only.
  • Short-term use only. License is for severe insomnia which is interfering with normal daily life and where other therapies have failed. 
  • Not to be initiated in primary care.
05.01.07 Chloramphenicol 
  •  1g injection
11.03.01 Chloramphenicol 
  • 0.5% ophthalmic drops
  • 0.5% minims available for patients allergic to preservatives, administering more than 6 times a day, undergoing eye surgery
  • Eye drops available OTC for adults and children over 2 years
11.03.01 Chloramphenicol 
  • 1% ophthalmic ointment
  • Eye ointment available OTC for adults and children over 2 years
04.10.01 Chlordiazepoxide 
  • Capsule 5mg, 10mg
  • Use only in the context of supervised withdrawal regime over a period of 5-10 days, with psychosocial recovery programme.
13.11.02 Chlorhexidine 0.05% 
  • Surgical scrub 4% w/v in surfactant solution (pink)
  • Obstetric Cream , chlorhexidine gluconate solution 5%
  • Hard surface wipes
  • Sterile topical solution sachets for irrigation
  • 0.5% w/v in 70% industrial methylated spirits for preop skin use.
  • Hand Rub 
  • Sterile 0.015% w/v with cetrimide 0.15% (yellow) 25ml sachets
  • Chlorhexidine gluconate 4% surgical scrub is used for pre-operative hand and skin preparation and for general hand disinfection.
  • A 5-7 day course of mupirocin 2% ointment or cream and chlorhexidine wash is used to decolonise patients with MRSA.
12.03.04 Chlorhexidine gluconate 1% 
  • GWH ICU only
12.02.03 Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin®
  • Contains arachis oil: Should be avoided in peanut or soya allergy
  • To avoid the development of resistance, the treatment course should not exceed 7 days and the course not repeated on more than one occasion  
12.03.04 Chlorhexidine mouthwash 0.2% 
  •  300ml or 600ml bottles
08.01.01 Chlormethine Hydrochloride (Mustine) 
  • 10mg powder for reconstitution
05.04.01 Chloroquine phosphate 
  • Treatment of non-falciparum malaria is available on the NHS.
  • Patients requiring Malaria prevention must acquire this on a private prescription or can buy it OTC
  • Tablets 250mg (equivalent to 155mg chloroquine base)
  • Syrup 68mg/5ml (equivalent to 50mg chloroquine base per 5ml)
16.01 Chlorothiazide 
  • Only available as an unlicensed preparation for specialist initiation only.

Swindon only

Non-formulary in BaNES and Salisbury

03.04.01 Chlorphenamine 
  • Self Self Care Medicine for primary care.
  • Tablets 4mg
  • Injection 10mg/ml
04.02.01 Chlorpromazine 
  • 25mg,50mg,100mg tablets
  • 25mg/5ml solution SF
  • 25mg/5ml syrup
  • 100mg/5ml solution

 

11.03.01 Chlortetracycline 
  • RUH only
  • Non formulary at GWH and Salisbury
  • 1% eye ointment
14.04 Cholera vaccine Dukoral®
  • This vaccine is not indicated for most travellers
12.03.01 Choline Salicylate 
  • Please note: Patients should self-care in the first instance
  • 8.7% dental gel 15g
06.05.01 Choriogonadotropin Alfa Ovitrelle®
  • Not on formulary GWH
  • prefilled syringe 6500 unit/0.5ml (250 micrograms/0.5ml) 
  • Female infertility       

 

06.05.01 Chorionic Gonadotrophin Pregnyl ®
  • Not on formulary RUH
  • 5000 I.U. powder for solution for injection.
03.02 Ciclesonide Alvesco®
  • Amber Salisbury ONLY 
  • Non-formulary Bath
  • Non-formulary Swindon

For persistent asthma in exceptional cases e.g in patients with poor compliance or patients having side effects on standard inhaled corticosteroids. For initiation by Respiratory consultant and ongoing prescription by GP

 

 

01.05.03 Ciclosporin 
  • Amber - Salisbury.
  • Amber with Shared Care - Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH).
  • Red - GWH - Swindon DAWN patients.
  • Red - RUH.
  • 10mg, 25mg, 50mg & 100mg capsules.
  • 250mg in 5ml ampoules for intravenous infusion.
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information.
08.02.02 Ciclosporin Sandimmun®
  • Infusion 50mg/ml
08.02.02 Ciclosporin Capimune ®Deximune®Neoral®
  • 25mg, 50mg and 100mg capsules
  • For SOLID organ transplant patients continue on brand specifed by the specialist.
  • Preparations are not interchangeable.
  • NHSE commissioner when ciclosporin used for solid organ transplants. Available from Specialist Centres ONLY.

 

08.02.02 Ciclosporin 
  • 25mg, 50mg and 100mg capsules
  • Indicated for bone marrow stem cell transplant.
  • The brand to be dispensed should be specified by the prescriber due to differences in bioavailability.
  • Preparations are not interchangeable.
  • RUH and SFT - Neoral

 

10.01.03 Ciclosporin 
  • Red in BaNES and for Swindon DAWN patients
  • Amber with Shared Care in Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH)
  • Amber in Salisbury for rheumatology indications
  • 10mg, 25mg, 50mg and 100mg capsules

 

 

 

11.08.01 Ciclosporin 
  • 0.2% eye ointment - Unlicensed preparation
  • GWH only - ONLY for patients who respond to ciclosporin but fail to tolerate Ikervis presentation. Only to be prescribed on yellow GWH hospital outpatient prescription and NOT FP10
  • Non formulary in RUH and SFT

 

11.08.01 Ciclosporin Ikervis®
  • 0.1% drops (1 mg/mL eye drops, emulsion)
  • Note - Ensure correct product is prescribed; available products have different licensing information and TLS. 
  • Ikervis ® is licensed for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.
  • Verkazia®  is licensed for the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents. See here
13.05.03 Ciclosporin 
  • Amber GWH ONLY: for licensed indications:  Treatment of severe psoriasis in patients in whom conventional therapy is inappropriate or ineffective and for patients with severe atopic dermatitis when systemic therapy is required
  • Red for SFT/RUH and for use in all unlicensed indications
  • Capsules 10mg; 25mg; 50mg;

 

16.15 Ciclosporin Verkazia®
  • 0.1% drops (1 mg/mL eye drops, emulsion)
  • SFT only. 
  • Not on formulary at RUH or GWH
  • Note - Ensure correct product is prescribed; available products have different licensing information and TLS. 
  • Verkazia®  is licensed for the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents. 
  • Ikervis® is not licensed in paediatrics.
05.03.02.02 Cidofovir 
  •  IV infusion 75mg/ml, 5ml vial
09.05.01.02 Cinacalcet 

For initiation and follow-on prescribing by an Endocrinology Specialist for the treatment of complex primary hyperparathyroidism

  • 30mg, 60mg, 90mg
09.05.01.02 Cinacalcet 
  • Non formulary at RUH for this indication
  • Amber shared care at QAH Portsmouth for SFT patients.

 

  •  30mg, 60mg, 90mg
  • Renal Specialist for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on dialysis, in line with NICE TA 117
04.06 Cinnarizine 
  • Tablet 15mg 
05.01.12 Ciprofloxacin 
  • Only to be used in line with local primary care antibiotic guidance indications.
  • The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information. 
  • Tablets 250mg, 500mg
  • Oral suspension 250mg/5ml
05.01.12 Ciprofloxacin  
  • The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information. 
  • IV infusion 100mg/50ml, 200mg/100ml, 400mg/200ml
11.03.01 Ciprofloxacin 
  • Green Salisbury
  • Red GWH - For treatment of corneal crystallisation and                                                            endophthalmitis
  • Non formulary in Bath
  • 0.3% ophthalmic drops
12.01.01 Ciprofloxacin 
  • 2 mg/ml ear drops solution in single-dose container
  • Licensed for the treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane
  • The ampoule contents should be used immediately after opening the single dose ampoule.
  • Each pack contains 15 ampoules
  • Used at SFT only
12.01.01 Ciprofloxacin 0.3% 
  • GWH ENT use eye drops in the ear (off-label)
15.01.05 Cisatracurium 
  • SFT only
  • 2mg/ml or 5mg/ml
08.01.05 Cisplatin 
  • 10mg/10ml, 50mg/50ml and 100mg/100ml infusion
04.03.03 Citalopram 
  • Tablets 10mg, 20mg, 40mg
  • Oral dropsSF 40mg in 1ml–8mg (4 drops may be considered equivalent to 10mg tablet)
  • Note: Fewer drug interactions than fluoxetine or paroxetine. 
  • For citalopram, new restrictions on the maximum daily doses now apply:
    • 40 mg for adults;
    • 20 mg for patients older than 65 years;
    • 20 mg for those with hepatic impairment.
01.06.05 Citramag ® Sachet
  • Sachet containing citric acid anhydrous 17.79 gram & magnesium carbonate heavy 11.57 gram.
08.01.03 Cladribine 
  • 10mg/10ml infusion
  • For the treatment of hairy cell leukaemia in accordance with cancer network guidelines
05.01.05 Clarithromycin 
  • Tablets 250mg, 500mg
  • Oral suspension (SF) 125mg/5ml, 250mg/5ml

 

05.01.05 Clarithromycin 
  •  IV infusion -used by BaNES community IV service
08.02.04 Clarithromycin 
  • RUH only
  • Used in combination with lenalidomide and pomalidomide as per DTC899
  • 250mg and 500mg tablets
05.01.06 Clindamycin  
  •  600mg/4ml
  • GWH use as part of treatment protocol for PCP (Pneumocystis jirovecii pneumonia)
05.01.06 Clindamycin  
  •  75mg
  • 150mg
  • For use in primary care as per local antibiotic guidance for unresolving cellulitis.
  • GWH use as part of treatment protocol for PCP (Pneumocystis jirovecii pneumonia)
  • High risk for clostridium difficile disease. Clindamycin is associated with Clostridium difficile diarrhoea, which limits its use. Patients should discontinue treatment immediately if diarrhoea develops.
07.02.02 Clindamycin Dalacin®
  • 2% vaginal cream  
13.06.01 Clindamycin 1% 
  • 10% aqueous Solution
  • Topical antibiotics should not be used in isolation; use in combination with retinoids or benzoyl peroxide topically if possible.
  • Resistance is more likely with topical antibiotics and topical clindamycin can cause resistance to oral erythromycin. Only use topical clindamycin if retinoids/BPO aren't tolerated and the patient does not want to take an oral antibiotic (or has contra-indications).
13.06.01 Clindamycin/ tretinoin  
  • Gel Tretinoin 0.025% and Clindamycin 1% 30g
04.08.01 Clobazam 
  • 10mg (Category 2 MHRA)
  • Endorse SLS when used for epilepsy.
  • Clobazam oral suspension 5mg or 10mg/5ml is available but is expensive. Use only if no other option is suitable and there are significant swallowing problems.

     

13.04 Clobetasol propionate Etrivex®
  • Very potent steroid
  • 125ml shampoo 500mcg/g
13.04 Clobetasol Propionate 0.05% Dermovate®
  • Very potent steroid
  • Cream 0.0525%, Ointment 0.05375% 30g, 100g
  • Scalp Application 0.05% 30ml, 100ml
13.04 Clobetasol Propionate with neomycin and nystatin 0.5mg/5mg/100,000 IU/g 
  • Very potent steroid
  • SFT and GWH only
  • NOT for primary care use.
  • £87 a pack in primary care (Feb 2020)
  • Only available generically. Dermovate NN has been discontinued.
13.04 Clobetasone Butyrate 0.05% Eumovate®
  • Moderate potency steroid
  • Cream, Ointment 0.05% 30g, 100g
  • Apply sparingly up to twice a day
  • Note: Clobetasone butyrate (Eumovate®) cream can be sold over the counter for short-term symptomatic treatment & control of patches of eczema & dermatitis (but not seborrhoeic dermatitis) in adults and children over 12 years.   
08.01.03 Clofarabine 
  • 20mg/20ml infusion
  • ONLY Approved for use in acute myeloblastic leukaemia in accordance with the criteria set out by the NHS England Cancer Drugs Fund

 

 

06.05.01 Clomifene Citrate 

 

  • 50mg       
  • Note: Clomifene is only indicated for patients in whom ovulatory dysfunction has been demonstrated and other causes of infertility have been excluded or adequately treated.

Prescribing should fall within NICE CG156:
• Do not offer oral ovarian stimulation agents(such as clomifene citrate, anastrozole or letrozole) to women  with unexplained infertility, and
• For women who are taking clomifene citrate, do not continue treatment for longer than 6 months.
In accordance with the product SPC, 3 courses should constitute an adequate trial.
Due to the limited length of time it is used and that patients are likely to be receiving ongoing care in a specialist setting the number of requests to pick up this prescribing in primary care should be minimal.

04.03.01 Clomipramine 
  • Capsule 10mg, 25mg, 50mg
  • Note: Also used in phobic and obsessional states
04.08.01 Clonazepam 
  • Tablet 500 microgram, 2mg (Category 2 MHRA)
  • For injection see 4.8.2 
04.08.02 Clonazepam  
  • 1mg/ml or infusion of 1mg 
  • Discontinued in the UK however an unlicensed import is used by acute trusts. 
02.09 Clopidogrel 
  • 75mg
07.02.02 Clotrimazole 
  • 1% cream 20g
  • 10% vaginal cream 5g 
  • 500mg pessary 
  • Patients should be advised that clotrimazole products might damage latex condoms and diaphragms.
12.01.01 Clotrimazole 1% 
  • 1% solution is licensed to be used as ear drops
13.10.02 Clotrimazole 1%  
  • Cream 1% 20g  
04.02.01 Clozapine Zaponex®
  • Tablets 25mg, 100mg
  • Note:  Patients must be registered with the Zaponex® Treatment Access System (ZTAS). Licensed for treatment resistant schizophrenia.
  • The patient, the supervising consultant and the dispensing pharmacy must all be registered with ZTAS. In this formulary area the AWP internal pharmacy is the primary supplier for clozapine for almost all patients.
  • Regular (minimum monthly) full blood counts are required prior to and during clozapine treatment, if these are not up-to-date then medication cannot be dispensed.
13.05.02 Coal Tar 10% Carbo-Dome®
  • Coal Tar solution 10% in a water-miscible basis 100g
13.05.02 Coal Tar Extract 5% (Alcoholic) 
  • Alphosyl 2 in 1®
  • 250ml
13.05.02 Coal tar lotion 5% Exorex®
  • Coal Tar solution 5% emulsion 100ml, 250ml
  • Useful for guttate psoriasis. Dilute with water to form an emulsion. Apply a thin layer twice or three times a day. Also useful applied to scaly scalps overnight.

 

02.02.04 Co-amilofruse (furosemide and amiloride) 
  • 2.5mg/20mg, 5mg/40mg, (amiloride/furosemide)
  • Note: Combination diuretics are not generally recommended, as the individual components cannot be adjusted independently. Restrict use to patients at risk of hypokalaemia, or if compliance problems. 
02.02.04 Co-amilozide 
  • 2.5mg /25mg (amiloride /hydroclorothiazide)
  • Note: Combination diuretics are not generally recommended, as the individual components cannot be adjusted independently. Restrict use to patients at risk of hypokalaemia, or if compliance problems.  
  • Note: BaNES only - Co-amilozide included for ENT indications relating to balance e.g Menieres
05.01.01.03 Co-Amoxiclav  
  • 500/100
  • 1000/200
  • Do not prescribe with metronidazole, unless very significant faecal contamination of abdominal cavity identified during surgery.
  • Cholestatic jaundice can occur either during or shortly after
    the use of co-amoxiclav. The risk of acute liver toxicity is about
    6 times greater with co-amoxiclav than with amoxicillin.
    Cholestatic jaundice is more common in patients above the
    age of 65 years and in men.
  • The duration of treatment should not usually
    exceed 14 days.
05.01.01.03 Co-Amoxiclav  
  • Tablets 250/125, 500/125.
  • Oral suspension (SF) 125/31 in 5ml, 250/62 in 5ml.
  • Do not prescribe with metronidazole, unless very significant faecal contamination of abdominal cavity identified during surgery.
  • Cholestatic jaundice can occur either during or shortly after use of
    co-amoxiclav. The risk of acute liver toxicity was about 6 times greater
    with co-amoxiclav than wth amoxicillin. Cholestatic jaundice is more
    common in patients above the age of 65 years and in men.
  • The duration of treatment should not usually exceed 14 days.
04.09.01 Co-Beneldopa 
  • Capsule 62.5mg, 125mg, 250mg
  • Dispersible tablet 62.5mg, 125mg
  • M/R capsule 125mg.
15.02 Cocaine 5% with adrenaline 1:2000 
  • GWH A&E only 
15.02 Cocaine HCl 
  • GWH only
  • Sterile oromucosal solution 10% 
  • For topical use only. Not for injection or to be taken.
  • Cocaine Hydrochloride Solution is indicated to provide local anaesthesia and vasoconstriction of accessible mucous membranes prior to surgery especially in the oral, laryngeal, and nasal cavities.
04.09.01 Co-Careldopa 
  • Sinemet-62.5,  Sinemet 110 (10/100) Sinemet Plus (25/100), Sinemet-275 tablet
  • Half Sinemet CR m/r tablet 25/100
  • Sinemet CR m/r tablet 50/200.
04.09.01 Co-Careldopa and Entacapone Sastravi®
  • Prescribe as Sastravi® brand (Bioequivalent and more cost effective). Sastravi exactly the same strengths as Stalevo - see below:
    • Tablets 50mg levodopa, 12.5mg carbidopa, 200mg entacapone
    • Tablets 75mg levodopa, 18.75mg carbidopa, 200mg entacapone
    • Tablets 100mg levodopa, 25mg carbidopa, 200mg entacapone
    • Tablets 125mg levodopa, 31.25mg carbidopa, 200mg entacapone
    • Tablets 150mg levodopa, 37.5mg carbidopa, 200mg entacapone
    • Tablets 175mg levodopa, 43.75mg carbidopa, 200mg entacapone
    • Tablets 200mg levodopa, 50mg carbidopa, 200mg entacapone
13.05.02 Cocois® 
  • Coal tar solution 120 mg per 1 gram
  • Salicylic acid 20 mg per 1 gram
  • Sulfur precipitated 40 mg per 1 gram
  • 40g,100g

 

13.06.02 Co-Cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 
  • Tablets cyproterone 2000mcg ethinyl estradiol 35mcg per tablet (prescribe generically, previous brand name Dianette)
01.04.02 Codeine phosphate 
  • 15mg & 30mg tablets.
  • 60mg tablets (Salisbury & Swindon ONLY).
  • Please note: Codeine can cause sedation and constipation, and there is a risk of dependence with long term use. It should be reserved for short courses, and is best avoided in stoma patients.
04.07.02 Codeine Phosphate 
  • Tablet 15mg, 30mg, 60mg
  • Oral solution 25mg in 5ml
  • Useful for the relief of mild to moderate pain but is too constipating for long-term use
10.01.04 Colchicine 
  • 500 microgram tablets
  • The dose of colchicine in acute gout is 1mg initially followed by 500 micrograms every 2-3 hours until relief of pain is obtained or vomiting or diarrhoea occurs or until a total dose of 6mg (12 tablets) has been reached. The course should not be repeated within 3 days.
09.06.04 Colecalciferol Stexerol D3®
  • 25,000 unit or 1,000 unit.
  • Tablets containing 25,000 units vitamin D3 (625 micrograms) colecalciferol
  • Loading Dose: TWO tablets (50,000 units) per week for 6 weeks
  • Maintenance dose: ONE tablet (25,000 units) monthly (packs of 12) 
  • Tablets containing 1,000 units Vitamin D3 ( 25 micrograms) colecalciferol
  • Maintenance dose: ONE tablet (1,000 units) daily
  • Stexerol film-coated tablets are suitable for vegetarians, certified halal & kosher, peanut oil free, soya oil free, gelatine free, & gluten free. The tablets can be crushed or swallowed whole and can be taken with food. The vitamin D is derived from sheep’s wool so they may not be suitable for vegans but they are suitable for vegetarians.
  • Use as per local vitamin D guidance above.
09.06.04 Colecalciferol  Fultium D3®

 

  • Non formulary Bath.
  • 20,000 unit, 3200 unit, 800 unit available 
  • Licensed for use in children 12-18 years old and adults.
  • Please note capsules contain gelatin

 

09.06.04 Colecalciferol 25,000 unit Invita D3
  • Licensed for use in children 0-18 years old and adults with swallowing difficulties.
  • May be mixed with a small amount of cold or lukewarm food immediately before administration. 
  • Use as per local vitamin D guidance above.
09.06.04 Colecalciferol and calcium carbonate Accrete D3®
  • Bath and Swindon - first line for primary care
  • Salisbury - non formulary
  • Tablet 1.5g (equiv to calcium 600mg)/400iu Dose: 1 tablet twice daily
  • Tablet chewable 2.5g (equiv to calcium 1g)/880iu Dose: 1 tablet once daily
  • Cost effective alternative to Calceos
09.06.04 Colecalciferol and calcium carbonate Adcal-D3®
  • Caplets containing 300mg/ 7.5mmol calcium and 200 units/5micrograms of vitamin D (as vitamin D3/coleclciferol. Dose: 2 caplets twice daily
  • Chewable tablets containing 600mg/15 mmol calcium and 400 units/ 10micrograms of Vitamin D (as vitamin D3/colecaciferol). Dose: 1 tablet twice daily.
  • Dissolve, effervescent tablets containing 600mg calcium and 400 units of vitamin D (as vitamin D3). Dose: 1 tablet twice daily. 

 Swindon: FIRST LINE IN SECONDARY CARE

09.06.04 Colecalciferol and Calcium carbonate Calcichew-D3® Forte

Not on Swindon formulary

  • Chewable tablets containing 500mg / 12.5mmol calcium and 400 units /10micrograms of vitamin D (as vitamin D3) Dose: 1 tablet twice a day
01.09.02 Colesevelam  
  • 625mg tablets.
  • Please note: Colesevelam is included for the treatment of diarrhoea associated with bile salt malabsorption (off label) only in patients unable to tolerate colestyramine. Please refer to our Colesevelam Shared Care Agreement for further information.
  • Please note: Colesevelam has not been approved for the treatment of hypercholesterolaemia.

SUPPLY ISSUES WITH COLESTYRAMINE 

Jan 2020 - BaNES, West Wilts and Swindon patients - Temporary change in TLS from AMBER with SCA to GREEN While Colestyramine is unavailable, RUH gastroenterologists have provided interim advice and guidance for local GPs to prescribe suitable alternatives in primary care for patients with bile acid malabsorption disorders.  Gastroenterology recommends GPs consider prescribing one of the two following options:

- Colesevelam 625mg tablets - One capsule OD or

- Colestipol 5g sachet - 1 sachet OD

as per BNF instructions, particularly around timings of other medications. Then increase the dose incrementally at weekly intervals to control symptoms up to the maximum dose as recommended in the BNF. If the alternatives aren’t effective, then GP should consider prescribing Loperamide and consider alternative diagnoses +/- secondary care referral where appropriate.

01.09.02 Colestipol Hydrochloride Sachet
  • 5g sachet.

SUPPLY ISSUES WITH COLESTYRAMINE 

Jan 2020 - BaNES, West Wilts and Swindon patients - Temporary change in TLS from AMBER to GREEN While Colestyramine is unavailable, RUH gastroenterologists have provided interim advice and guidance for local GPs to prescribe suitable alternatives in primary care for patients with bile acid malabsorption disorders.  Gastroenterology recommends GPs consider prescribing one of the two following options:

- Colesevelam 625mg tablets - One tablet OD or

- Colestipol 5g sachet - 1 sachet OD

as per BNF instructions, particularly around timings of other medications. Then increase the dose incrementally at weekly intervals to control symptoms up to the maximum dose as recommended in the BNF. If the alternatives aren’t effective, then GP should consider prescribing Loperamide and consider alternative diagnoses +/- secondary care referral where appropriate.

01.09.02 Colestyramine Sachet
  • 4g sachet.
  • Please note: Sugar- fee sachets are more expensive.

SUPPLY ISSUES WITH COLESTYRAMINE 

Jan 2020 - BaNES, West Wilts and Swindon patients - While Colestyramine is unavailable, RUH gastroenterologists have provided interim advice and guidance for local GPs to prescribe suitable alternatives in primary care for patients with bile acid malabsorption disorders.  Gastroenterology recommends GPs consider prescribing one of the two following options:

- Colesevelam 625mg tablets - One capsule OD or

- Colestipol 5g sachet - 1 sachet OD

as per BNF instructions, particularly around timings of other medications. Then increase the dose incrementally at weekly intervals to control symptoms up to the maximum dose as recommended in the BNF. If the alternatives aren’t effective, then GP should consider prescribing Loperamide and consider alternative diagnoses +/- secondary care referral where appropriate.

02.12 Colestyramine 
  • Powder 4g sachet (Note: The sugar free sachet is less cost effective)
  • Should only be used for lipid-lowering in exceptional circumstances and be initiated by a consultant. It remains useful in the small number of patients for whom statins cannot be used.

 

05.01.07 Colistimethate 
  • Red BaNES CF patients (seen at BRI hospital) TLS Red for management of acute and chronic CF infections 
     
  • Amber with Shared Care Bath only: Nebulised- NON-CF patients chronically colonised with P.aeruginosa Prescribe as Colomycin® brand along with sodium chloride ampoules for reconstitution as detailed in SCA (below)

  • Amber GWH for use in bronchiectasis and existing CF patients (usually nebulised).
  • Red GWH for use in new CF patients (usually nebulised).
  • Red GWH use IV for treatment of carbapenemase-producing Enterobacteriaceae

  • 500,000 units
  • 1 million units
  • 2 million units

 

05.01.07 Colistimethate  Colobreathe®
  •  Dry powder for inhaler and hard capsule 1.66 million units/capsule
16.08 Colistimethate Sodium Promixin®
  • 1million-units
  • For use in paediatrics only following initiation by specialist
10.03.01 Collagenase Xiapex®
  • 900microgram injection

FEB 2020 - PLEASE NOTE - NICE HAVE WITHDRAWN TA459 - collagenase clostridium histolyticum (Xiapex) is no longer available in the UK.

01.01.01 Co-magaldrox 
  • SuspensionSF 195/220 (low sodium, bowel neutral). 
06.04.01.01 Combined continuous HRT  Kliofem
  • 2mg estradiol and 1mg norethisterone
  • 1 prescription charge. 
06.04.01.01 Combined continuous HRT Premique low dose
  •  300 micrograms conj. oestrogens and 1.5mg medroxyprogesterone acetate
06.04.01.01 Combined continuous HRT Femoston Conti
  • 1mg estradiol + 5mg dydrogesterone
  • 0.5mg estradiol + 2.5mg dydrogesterone (low dose)

 

06.04.01.01 Combined continuous HRT Kliovance
  • estradiol 1mg and norethisterone acetate 500micrograms
06.04.01.01 Combined continuous HRT  Evorel® Conti
  • Patches 50 micrograms estradiol 170 micrograms norethisterone
  • Change Twice a week
06.04.01.01 Combined cyclical HRT  Evorel® Sequi
  • Patches 50 micrograms estradiol and 170 micrograms norethisterone acetate
  • Change patch Twice a week
06.04.01.01 Combined cyclical HRT  Elleste-Duet®
  • Tablets estradiol (1mg, 2mg) with 1mg norethisterone acetate
  • 2 prescription charges
06.04.01.01 Combined cyclical HRT  Femoston®
  • Tablets (1mg or 2mg) estradiol with 10mg dydrogesterone 
07.03.01 Combined Hormonal Contraceptives Evra
  • Transdermal patch containing 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).
  • Restricted for use in women who are likely to comply poorly with combined oral contraceptives.
07.03.01 Combined Hormonal Contraceptives Logynon ED®
  • Multiphasic pills containing ethinylestradiol 30 micrograms, levonorgestrel 50 micrograms;  ethinylestradiol 40 micrograms, levonorgestrel 75 micrograms; ethinylestradiol 30 micrograms, levonorgestrel 125 micrograms; 7 inactive lactose tablets. 3 x 28 tablets.
07.03.01 Combined Hormonal Contraceptives Microgynon 30 ED®
  • Tablets containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms (21 beige tabs); lactose (7 white tabs) 3 x 28 £2.99 December 2018.
07.03.01 Combined Hormonal Contraceptives NuvaRing®
  • Ethinylestradiol 15 micrograms/24 hours with Etonogestrel 120micrograms/24 hours. 3 ring pack. 1 ring to be inserted into the vagina, removed on day 22; subsequent courses after 7 day ring-free interval.
  • May be considered in women:
    • with GI disturbance /malabsorption.
    • getting persistent breakthrough bleeding with COCP (good cycle control).
    • who have difficulties swallowing pills, and are not keen on other methods of contraception.
    • getting hormonal side effects with COCP (relatively low oestrogen exposure).
13.02.02 Conotrane® Barrier cream
  • 100g, 500g
  • Benzalkonium chloride, cetrimide
  • Nappy rash or for use in elderly in nursing homes
06.05.01 Corticorelin 

Not on formulary Salisbury or Swindon 

  • For Corticotrophin releasing Hormone (CRH) test which is a dynamic endocrine test
  • Powder and solvent
  • 100microgram used as an intravenous injection as a single dose
05.01.08 Co-trimoxazole  
  • 480mg/5ml
  • 960mg/10ml
05.01.08 Co-trimoxazole 
  • Tablets 480mg, 960mg
  • Suspension 240mg/5ml, 480mg/5ml
  • Included in primary care antibiotic guidance as an alternative option for the treatment of acute exacerbations of COPD
  • Otherwise used as recommended by a microbiologist.
05.04.08 Co-trimoxazole 
  • 480mg/5ml
  • 960mg/10ml

 

13.08.02 Covermark ® 
  • Classic Foundation and Finishing Powder
08.01.05 Crizotinib 

 

13.03 Crotamiton Eurax®
  • Eurax Cream 10% , 30g, 100g
  • Apply twice or three times daily.
09.01.02 Cyanocobalamin 

Swindon and Salisbury - not on formulary

Green Bath only

NOTE: Care must be taken if low dose oral cyanacobalamin is used as this risks suboptimal treatment of latent and emerging pernicious anaemia with possible inadequate treatment of neurological features.

Only use where indicated on BCAP 'Investigation and treatment of Vitamin B12 (cobalamin) deficiency in primary care' guidance.

 

04.06 Cyclizine 
  • Tablet 50mg
  • Injection 50mg in 1ml
21 Cyclizine 
  • For nausea and vomiting
  • Can be used in syringe drivers
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
21.01 Cyclizine 
  • Community Just In Case Boxes
  • For nausea and vomiting
11.05 Cyclopentolate drops 
  • 0.5% and 1% ophthalmic drops
  • 0.5% and 1% minims

 

08.01.01 Cyclophosphamide 
  • 500mg,1g and 2g injection 
08.01.01 Cyclophosphamide 
  • 50mg tablets
08.03.04.02 Cyproterone 
  • 50mg and 100mg tablets
06.04.02 Cyproterone Acetate 
  • 50mg
08.01.03 Cytarabine 
  • 100mg/5ml, 500mg/25ml, 1g/10ml, 2g/20ml and 500g/5ml injection
02.08.02 Dabigatran 
  • 110mg, 150mg
  • For primary or secondary prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation (AF), in accordance with NICE TA below.
  • For the treatment and secondary prevention of DVT and/or PE. In accordance with NICE TA below. 
02.08.02 Dabigatran 
  • 110mg, 150mg
  • For the primary prevention of venous thromboembolic events (VTE) in adults who have undergone elective total hip replacement or total knee replacement surgery in accordance with NICE TA below. 
08.01.05 Dabrafenib 
  • 50mg and 75mg capsules

 

08.01.05 Dacarbazine 
  • 500mg and 1g infusion
  • 100mg and 200mg injection
05.03.03.02 Daclatasvir  Daklinza®
  •  Tablets 30mg/60mg
08.01.02 Dactinomycin 
  • 500microgram powder for reconstitution
02.08.01 Dalteparin 
  • Note - variation in TLS across trusts and also according to indication. See individual prescribing policies.
  • Pre filled syringes 2,500iu/0.2ml, 5000iu/0.2ml, 7,500iu/0.3ml, 10,000iu/0.4ml, 12,500iu/0.5ml, 15,000iu/0.6ml, 18,000iu/0.72ml for subcutaneous injection

 

 

02.08.01 Danaparoid 
  • SFT and GWH only and restricted for use on the advice of a haematologist for the treatment/prophylaxis of thromboembolic disease in patients with a history of heparin-induced thrombocytopenia
  • Non formulary at RUH
  • 750 units/0.6ml solution for injection ampoules
06.07.02 Danazol 
  • 100mg,200mg
10.02.02 Dantrolene 
  • Green Swindon and Salisbury
  • Amber BaNES
  • 25mg and 100mg capsules
  • Liver function tests should be performed before commencing dantrolene, and then repeated on discharge from hospital (or 6 weeks after starting therapy) and then at 3 monthly intervals. 
15.01.08 Dantrolene Sodium 
  •  20mg vial
06.01.02.03 Dapagliflozin 
  • 5mg, 10mg
  • Green 
  • Amber IN COMBINATION WITH INSULIN IN TYPE 2 DIABETES FOLLOWING NICE GUIDANCE ONLY
  • Red IN COMBINATION WITH INSULIN IN TYPE 1 DIABETES FOLLOWING NICE GUIDANCE ONLY. NOTE: Only the 5mg strength is licensed for this indication.
  • NOTEGPs will need to prescribe ketone test strips for type 1 diabetes patients to use whilst on dapagliflozin
05.01.10 Dapsone 
  • Amber for the treatment of dermatitis herpetiformis for stable patients.
  • Red for unlicensed indications.
  • GWH use for the treatment of PCP (Pneumocystis jirovecii pneumonia)
  • 50mg
  • 100mg
  • Needs monitoring as per DMARD shared care agreement on link below
13.05.03 Dapsone 
  • Amber with Shared Care for licensed conditions RUH/SFT
  • Amber for licensed conditions GWH, shared care agreement in process.
  • Red for unlicensed indications
  • Tablets 50mg, 100mg
  • Licensed for the treatment of dermatitis herpetiformis 
  • Maximum  daily dose 300mg
  • Restricted for use on dermatology recommendation.
  • Tablets disperse in water if needed. 
05.01.07 Daptomycin 
  • Use with microbiology advice only
  • GWH/RUH only
08.01.05 Daratumumab 

 

09.01.03 Darbepoetin Alfa Renal indications

Amber Swindon 

  • Non Formulary at RUH for renal indication (NBT specialist centre)
  • Non Formulary at SFT for renal indication (QAH specialist centre)
  • Aranesp®Prefilled syringes 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 130, 300, 500 micrograms
  • SureClick® 20, 40, 60, 80, 100, 150, 300, 500 micrograms

 

09.01.03 Darbepoetin Alfa  Non renal indications

Red SFT and RUH

Amber Swindon 

  • Non renal indications - Haematology / Oncology
  • Aranesp®Prefilled syringes 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 130, 300, 500 micrograms
  • SureClick® 20, 40, 60, 80, 100, 150, 300, 500 micrograms

 

05.03.01 Darunavir Prezista®
  • 400mg
  • 600mg
  • 800mg
05.03.01 Darunavir and Cobicistat Rezolsta®
  •  Tablet contains 800 mg of darunavir (as ethanolate) and 150 mg of cobicistat
05.03.03.02 Dasabuvir Exviera®
  •  Tablets 250mg
08.01.05 Dasatinib 
  • 20mg, 50mg, 80mg, 100mg and 140mg tablets

 

08.01.02 Daunorubicin 
  • 20mg infusion
09.01.03 Deferasirox 

Red SFT

  • 90mg,180mg,360mg
  • Commissioned by NHS England for iron chelation in thalassaemia and sickle cell anaemia.
09.01.03 Deferiprone Ferriprox®

GWH only

Non formulary RUH and SFT

  • Tablets 500mg,1000mg
  • Solution 100mg/ml
  • Commissioned by NHS England for iron chelation in thalassaemia and sickle cell anaemia.
08.01.05 Defibrotide 
  • 200mg (80 mg/mL concentrate for solution for infusion)
  • For the treatment of veno-occlusive disease in accordance with treatment of possible hepatic veno-occlusive disease as noted in link below
  • Formulary at RUH for this indication
08.03.04.02 Degarelix 
  • 80mg and 120mg infusion
05.01.03 Demeclocycline 
  • 150mg Capsules
  • Only on formulary to treat Syndrome of Inappropriate Anti-Diuretic Hormone (SIADH). 
  • Not on formulary for treatment of infections.
06.05.02 Demeclocycline 
  • Capsules 150mg      
  • Used in the treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone (SIADH). Requires specialist initiation.
06.06.02 Denosumab Prolia®

 

  • 60mg in 1ml injection 
  • Indication on formulary: Treatment of osteoporosis in postmenopausal women. In postmenopausal women Prolia significantly reduces the risk of vertebral, non-vertebral and hip fractures. Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
  • New monitoring - check calcium levels: before each dose and, in patients predisposed to hypocalcaemia within two weeks after the initial dose. If any patient presents with suspected symptoms of hypocalcaemia during treatment calcium levels should be measured. Consider monitoring calcium levels more frequently in patients with risk factors for hypocalcaemia (eg, severe renal impairment, creatinine clearance <30ml/min).
  • The optimal total duration of antiresorptive treatment for osteoporosis (including both denosumab and bisphosphonates) has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of denosumab on an individual patient basis, particularly after 5 or more years of use
06.06.02 Denosumab  Xgeva®
  • Each vial contains 120 mg of denosumab in 1.7 mL of solution (70 mg/mL).
  • Indication on formulary: Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.
  • Not to be prescribed in primary care. 
  • New monitoring - Monitoring of calcium levels should be conducted (i) prior to the initial dose of XGEVA, (ii) within two weeks after the initial dose, (iii) if suspected symptoms of hypocalcaemia occur Additional monitoring of calcium level should be considered during therapy in patients with risk factors for hypocalcaemia, or if otherwise indicated based on the clinical condition of the patient.
07.02.02 Dequalinium chloride Fluomizin®
  • Green Bath 
  • Amber Salisbury and Swindon
  • 10mg vaginal tablet
  • For the treatment of bacterial vaginosis where first line treatment (metronidazole) is not effective or not tolerated
13.08.02 Dermacolor ® 
  • Camouflage Cream and Fixing Powder
13.02.01 Dermatonics Heel Balm ® cream
  • Use after other emollients have been tried and failed to control symptoms. Expensive emollient.
  • 25% urea
  • Available as: 75g and 200g pack sizes.
  • Preparations containing lauromacrogols and/or urea are useful to stop itching or aid hydration.
13.09 Dermax® 
  • Benzalkonium chloride 0.5% 250ml 
13.02.01 Dermol ® Cream & Lotion

CONTAINS ANTIMICROBIALS

  • Use long-term if needed to prevent frequent skin infections, or for handwashing for carers with occupational irritant hand dermatitis.
  • Use short-term if there is a single episode of infection. Not for repeat prescription.
  • Cream 100g, 500g pump
  • Contains benzalkonium Cl and chlorhexidine HCL
  • Lotion 500ml pump
  • Can be used as hairwash and soap substitute
  • Contains benzalkonium Cl and chlorhexidine HCL
09.01.03 Desferrioxamine Mesilate 
  •   Commissioned by NHS England for iron chelation in thalassaemia and sickle cell anaemia.   
15.01.02 Desflurane 
  • 240ml
02.11 Desmopressin 
  • SFT only - for the treatment of mild haemophilia A or von Willebrand's disease. Consultant haematologist use only.
  • Non formulary at RUH and GWH
  • For non-haematology indications, please see chapter 6.5.2
06.05.02 Desmopressin 

Green Bath only.  Desmotabs Tablets (or generic) 200 micrograms for Primary nocturnal enuresis

Amber  All formulations in Salisbury. Tablets only Swindon. Bath - for diabetes insipidus, nocturia caused by MS.

Red Injection only BaNES and in Swindon.

  • DDAVP® tablets (or generic) 100, 200micrograms 
  • Injection 4 micrograms in 1ml,
  • Indicated for Diabetes Insipidus, Nocturia caused by MS, Renal Function Tests - see SPCs 
  • Desmotabs Tablets (or generic) 200 micrograms 
  • For Primary nocturnal enuresis
  • Nasal spray no longer licensed for primary nocturnal enuresis (bed wetting) due to adverse drug reactions including hyponatraemia.
06.05.02 Desmopressin Desmospray®
  • Nasal spray 10 micrograms per metered spray 60 dose unit
  • Nasal spray no longer licensed for primary nocturnal enuresis (bed wetting) due to adverse drug reactions including hyponatraemia.
  • DDAVP®/Desmopressin Intranasal Solution is indicated for:
  • The diagnosis and treatment of vasopressin-sensitive cranial diabetes insipidus.
  • The treatment of nocturia associated with multiple sclerosis where other treatments have failed.
  • Establishing renal concentration capacity.
07.03.02.01 Desogestrel Cerelle®
  • Tablets containing 75 microgram desogestrel
  • First line choice of oral progestogen-only contraceptive due to the 12 hour window to take the pill.
  • Cerelle is most cost effective generic brand (3 x 28 £3.50 December 2018). Cerazette is non-formulary as not cost effective (3 x 28 £8.68 December 2018) 

 

06.03.02 Dexamethasone 
  • For specific indications
  • Tablets 500 microgram, 2mg
  • Oral solution 2mg/5ml
  • 3.32 mg of dexamethasone (dexamethasone base) in 1 ml solution for injection
  • 6.64 mg of dexamethasone (dexamethasone base) in 2 ml solution for injection
  • Injection Red (BCAP only) Each ml of solution for injection contains 4.00 mg of dexamethasone phosphate (as 4.37 mg dexamethasone sodium phosphate) equivalent to 3.32 mg of dexamethasone base.
11.04.01 Dexamethasone Maxidex®
  • 0.1% ophthalmic drops

 

11.04.01 Dexamethasone Minims®
  • Amber Bath 
  • Red GWH - For post-operative use only
  • Non formulary in Salisbury
  • 0.1% eye drops 0.5ml unit dose 
11.04.01 Dexamethasone  Ozurdex®
  • For the treatment of adults with macular oedema following either branch retinal vein occlusion or central retinal vein occlusion ONLY in line with local commissioning criteria and NICE TA229.
  • For the treatment of patients with sight problems caused  diabetic macular oedema, in line with NICE TA349.
  • For the treatment of patients with non-infectious uveitis, in line with NICE TA460Only available in specialist centres (not RUH or SFT).

 

21 Dexamethasone 
  • 3.32 mg of dexamethasone (dexamethasone base) in 1 ml solution for injection which is equivalent to 4 mg dexamethasone phosphate (or 4.3 mg dexamethasone sodium phosphate)
  • For use in syringe pumps following advice from palliative care specialists
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
12.01.01 Dexamethasone with Antibacterial Otomize®
  • Dexamethasone 0.1%, neomycin sulfate 3250 units/ml, glacial acetic acid 2%
11.04.01 Dexamethasone with Antibacterials 
  • Salisbury only
  • Non formulary in Bath and Swindon
  • Dexamethasone 1 mg per 1 ml, tobramycin 3 mg per 1 ml
12.01.01 Dexamethasone with Antibacterials Sofradex®
  • Dexamethasone 0.05%, framycetin sulfate 0.5%, gramicidin 0.005%  
11.04.01 Dexamethasone with Neomycin and Polymyxin B sulphate 
  • Dexamethasone 0.1%, hypromellose 0.5%, neomycin 0.35%, polymixin B sulphate 6000 units/ml in 5ml container
16.05 Dexamfetamine Sulphate 
  • 5mg
  • Only for those whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile.
  • Local SCA being amended to include this drug (Feb 2020)
15.01.04.04 Dexmedetomidine  
  • GWH ICU/theatres only 
  • 100 micrograms/ml concentrate for solution for infusion, various ampoule sizes
09.02.02.02 Dextran 70 ® 

GWH only.

RUH/SFT - non formulary

04.07.02 Diamorphine  
  • Injection 5mg, 10mg, 30mg, 100mg, 500mg 
  • For use in Palliative Care see chapter 20
21 Diamorphine Injections 10mg /ml
  • For pain. 
  • Use Morphine first line in syringe drivers.
  • Can be used in syringe drivers
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
21.01 Diamorphine Injections 10mg /ml
  • Community Just In Case Boxes
  • For pain
04.01.02 Diazepam 
  • Tablets 2mg, 5mg, 10mg
  • Oral Solution 2mg in 5ml,
  • Suppositories
04.08.02 Diazepam  
  • 2.5mg, 5mg, 10mg
04.08.02 Diazepam Diazemuls®
  • 5mg/ml Intravenous injection (emulsion) (Diazemuls®)
10.02.02 Diazepam Muscle relaxant
  • 2mg, 5mg and 10mg tablets
  • 10mg/2ml injection
  • 2mg/5ml oral suspension
  • 2.5mg, 5mg and 10mg rectal tubes
  • For short term use only

 

15.01.04.01 Diazepam 
  • 10mg in 2ml Injection (emulsion - Diazemuls®
04.01.02 Diazepam injection  
  • Injection (emulsion - Diazemuls®) 10mg in 2ml
  • Injection 5mg/ml
06.01.04 Diazoxide 
  • 50mg
  • For the treatment of recurrent or chronic intractable hypoglycaemia caused by insulinoma or other tumour.
10.01.01 Diclofenac 
  • 12.5mg, 25mg, 50mg and 100mg suppositories
  • 75mg in 3ml injection
  • Cardiovascular risk is higher with diclofenac than other non-selective NSAIDs and similar to selective COX-2 inhibitors.
  • Diclofenac should be used for short courses only.
10.01.01 Diclofenac Akis®
  • Red - GWH ONLY - For the short-term prevention & treatment of post - operative pain.
  • Non- formulary - Bath & Salisbury.
  • 75mg in 1ml injection.
  • Cardiovascular risk is higher with diclofenac than other non-selective NSAIDs and similar to selective COX-2 inhibitors.
  • Diclofenac should be used for short courses only.
10.01.01 Diclofenac 
  • Green - Salisbury & Swindon.
  • Red - Bath  - Oral diclofenac is only included on the formulary for maternity services for a short course of inpatient treatment post delivery.
  • 25mg & 50mg gastro-resistant tablets
  • Cardiovascular risk is higher with diclofenac than other non-selective NSAIDs and similar to selective COX-2 inhibitors.
  • Oral diclofenac should be used for short courses only
11.08.02 Diclofenac 
  • Green Swindon - Pre-operative & immediately post - operatively. For short-term pain relief in episcleritis, cornial abrasion or foreign bodies. Avoid single use except in allergy to preservatives
  • Red RUH (Single use eye drops 0.1%)
  • Non formulary in Salisbury
13.08.01 Diclofenac Solaraze®
  • Gel 3% 50g, 100g Solaraze®
  • Prescribe by brand
  • Apply thinly twice daily for 60-90 days, maximum 8g daily
21 Diclofenac 
  • 75mg in 3ml injection
  • As recommended by palliative care specialists
  • Can be used in syringe drivers
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)

 

08.03.01 Diethylstilbestrol 
  • 1mg and 5mg tablets
13.04 Diflucortolone Valerate Nerisone Forte®
  • Very potent steroid
  • Oily cream, Ointment 0.3% 15g
  • Use for palms and soles. For severe and resistant dermatoses.

 

02.01.01 Digoxin 
  • Tablets 62.5 micrograms, 125 micrograms, 250 micrograms
  • Elixir 50 micrograms/ml
02.01.01 Digoxin 
  • 250 micrograms/ml 2ml ampoule
02.01.01 Digoxin specific antibody fragments DigiFab®
  • 40mg powder for solution for infusion vials DigiFab®
  • Note: For reversal of life-threatening digoxin overdose
04.07.02 Dihydrocodeine 
  • Tablets 30mg
  • Oral solution 10mg/5ml
  • The efficacy of dihydrocodeine does not increase above a certain dose, but the risks of side effects and dependence increase. Do not prescribe more than a 30mg per dose.
  • For post-operative analgesia on discharge.
  • Short-term use only.   
02.06.02 Diltiazem Tablets
  • Tablets 60mg
  • Although the means of formulation has called for the strict designation ‘modified-release’ the duration of action corresponds to that of tablets requiring administration 3 times daily.
02.06.02 Diltiazem 
  • Different versions of MR preparations containing more than 60 mg diltiazem hydrochloride may not have the same clinical effect. To avoid confusion between these different formulations of diltiazem, prescribers should specify the brand to be dispensed.
  • Once daily prep - Viazem XL® available as 120mg, 180mg, 240mg, 300mg, 360mg capsules. Please note Slozem (previous OD preferred brand) discontinued Jan 2020 due to manufacturing issues.  
  • Twice daily prep - Angitil® SR available as 90mg, 120mg, 180mg capsules.
01.07.04 Diltiazem 2%  Topical
  • 2% ointment.
  • 2% cream.
  • Please note: This is for use second- line for the treatment of chronic anal fissures, after GTN 0.4% ointment, prior to considering surgery, with maximum duration of use of 8 weeks. (Unlicensed).
  • Please note: 2% ointment is more cost-effective in primary care, whilst 2% cream is more cost-effective in secondary care.
08.02.04 Dimethyl fumarate 
  • 120mg and 240mg capsules
  • NB Tecfidera brand only licensed for Multiple Sclerosis
  • Check full blood counts before prescribing dimethyl fumarate and then every 6 to 12 months. Stop treatment immediately if progressive multifocal leukoencephalopathy is suspected.
13.05.02 Dimethyl Fumarate  Skilarence ®
  • Tablets 30mg, 120mg 
  • NICE TA 475 guidance Dimethyl fumarate for treating moderate-to-severe plaque psoriasis (Sept 2017)
  • The brand Fumaderm was previously used before the licensed product beccame available in the UK. There may still be some existing patients on this imported product, who will be reviewed by their specialist.
07.04.04 DIMETHYL SULPHOXIDE Bladder Instillation 50% 
  • GWH existing patients only
  • Not stocked at RUH or SFT
07.01.01 Dinoprostone 
  • Prostin E2® dinoprostone 3mg vaginal tablets
  • Prostin E2®  dinoprostone 400micrograms per 1ml, 800micrograms per 1ml vaginal gel. 
    NB Prostin E2 vaginal tablets and vaginal gel are not bioequivalent. 
  • Propess® dinoprostone 10mg vaginal pessaries with retrieval device. 
07.01.01.01 Dinoprostone 
  • GWH and SFT
  • note - off label use
08.02.04 Dinutuximab 
  • 20mg/4.5ml infusion

 

Checking if being used locally as specialist

13.02.01 Diprobase ® 
  • SFT only
  • Cream or ointment
  • NOT for use in primary care- use epimax as an alternative instead.
02.09 Dipyridamole 
  • 100mg tablet
  • 200mg MR capsule
11.99.99.99 Disodium edetate 
  • 0.37% eyedrop Unlicensed
  • RUH and GWH - for chelation of cornea for calcific band keratopathy.
  • Not on formulary at SFT
06.06.02 Disodium Pamidronate 
  • 15mg, 30mg, 60mg, 90mg 
  • For multiple myeloma and treatment of hypercalcaemia.           
02.03.02 Disopyramide 
  • Capsules 100mg
  • Tablets modified release 250mg
06.01.01.03 Disposable Insulin Syringes 
  • 0.5ml,1.0ml
04.10.01 Disulfiram 
  • Tablets 200mg
13.05.02 Dithranol  
  • Restricted: Specialist Prescribing Only. Various forms as per BAD specials list.
  • See section 13.14 for BAD specials information

 

 

13.05.02 Dithranol 
  • SelfCream: 0.1% 50g  0.25% 50g  , 0.5% 50g (Dithrocream Forte)  , 1% 50g (Dithrocream HP)
  • Green 2% 50g (Dithrocream 2%) (Prescription only)
  • For psoriasis. Increase strength gradually. Stains clothes
02.07.01 Dobutamine 
  • 250mg in 20ml
  • 250mg in 50ml
08.01.05 Docetaxel 
  • Various concentrations of infusion
01.06.02 Docusate Sodium 
  • 100mg capsules.
  • 50mg in 5ml oral solution SF.
  • 120mg micro enema.
05.03.01 Dolutegravir 
  •  Tablets 50mg
05.03.01 Dolutegravir, abacavir & lamivudine Triumeq®
  • 50 mg dolutegravir (as sodium), 600 mg of abacavir (as sulfate) and 300 mg of lamivudine
01.02 Domperidone 
  • Green - Swindon - For short term use.
  • Amber - Swindon - For long-term use (off-label).
  • Non- formulary (for this indication) - Bath & Salisbury.
  • 10mg tablets.
  • 5mg in 5ml suspension.
  • Please note: Domperidone should be used at the lowest effective dose for the shortest possible duration.
  • Domperidone is also available for prevention or treatment of nausea and vomiting. Please refer to Chapter 4 (CNS).
04.06 Domperidone 
  • Green for short-term use/ 1 week
  • Amber for long-term use (off-label)
  • Tablet 10mg
  • Suspension 5mg in 5ml
  • Suppository 30mg
  • Domperidone is the antiemetic of choice in Parkinsons Disease
  • Domperidone should be used at the lowest effective dose for the shortest possible duration (max. treatment duration should not normally exceed 1 week);

 

04.11 Donepezil 
  • Amber with Shared Care   BaNES CCG
  • Red  Swindon CCG
  • Green   Wiltshire CCG
  • Tablet 5mg, 10mg
02.07.01 Dopamine 
  • 200mg in 5ml
02.07.01 Dopexamine 
  • 50mg/5ml
03.07 Dornase Alfa Pulmozyme®
  • Nebuliser solution 2500 units in 2.5ml 
  • Notes:

    • A Jet Nebuliser used exclusively for dornase alfa is required for administration
    • To improve pulmonary function in cystic fibrosis patients with a FVC of greater than 40% predicted.
    • Use on specialist respiratory advice only.
    • Requirement for dornase alfa should be reviewed every 3 days.

 

11.06 Dorzolomide 
  • 2% eye drops
11.06 Dorzolomide 2% with Timolol 0.5% 
  • 5ml ophthalmic drops

 

03.05.01 Doxapram Dopram®
  • Injection 100mg in 5ml
02.05.04 Doxazosin 
  • 1mg, 2mg, 4mg
  • Use only if diuretics, beta-blockers, CCBs and ACEI fail or are unsuitable.  
  • Note: Doxazosin m/r is not included as it is less cost-effective
07.04.01 Doxazosin 
  • Tablets 1mg, 2mg, 4mg.
  • Only prescribe generic immediate-release formulations. 
13.03 Doxepin Xepin®
  • Amber For eczema associated pruritis only
  • Red for off-label use
  •  Cream (30g)
  • Specialist use only for "off label" urticaria. Apply thin film three or four times a day. Maximum 3g per application
08.01.02 Doxorubicin 
  • 10mg/5ml, 50mg/25ml, 100mg/50ml and 200mg/100ml injection
08.01.02 Doxorubicin Caelyx®
05.01.03 Doxycycline 
  • 50mg
  • 100mg

     

13.06.02 Doxycycline 
  • Capsules 100mg
  • 100mg once a day for 3 months then review
16.09 Doxycycline 
  • 50mg and 100mg
02.03.02 Dronedarone 
  • Tablets 400mg
  • In line with NHSE guidance (June 2019) prescribers should not initiate dronedarone in primary care for any new patient. If there is a clinical need for dronedarone to be prescribed it must be in line with individual trust Shared Care Agreements - see links below.
04.06 Droperidol 
  • GWH only for short-term peri-operative use on the advice of a consultant anaesthetist
06.01.02.03 Dulaglutide 

 

  • In combination with existing therapy (a sulphonylurea or prandial insulin). Amber specialist initiated.
  • 0.75mg/0.5ml prefilled syringe, 1.5mg/0.5ml prefilled syringe
  • Dose 0.75mg ONCE a week, increased to 1.5mg ONCE a WEEK
  • Bath - existing patients only
04.01.02 Duloxetine 
  • Capsules 30mg, 60mg
  • Useful for mixed anxiety and depression.
  • AWP guidance suggests it should not be prescribed except where other treatments are poorly tolerated or ineffective if being used for depression alone.
04.03.04 Duloxetine 
  • The starting and recommended maintenance dose is 60 mg once daily with or without food. 
04.07.03 Duloxetine 
  • Capsules 30mg, 60mg
  • For the treatment of diabetic peripheral neuropathic pain
  • Discontinue if inadequate response after 2 months, review treatment every 3 months.
13.05.03 Dupilumab 
  • 300mg in 2ml solution for injection in a pre-filled syringe
  • Use as per NICE TA

 

02.08.02 Edoxaban 
  • 15mg,30mg,60mg
  • For treating and for preventing DVT and PE. Use as per NICE TA below
  • For stroke prevention in non-valvular AF. Use as per NICe TA below 
  • Note: For NVAF, choice of DOAC should be based on individual patient characteristics. See here for example decision making tool. If clinically appropriate, edoxaban may be considered first line based on lowest acquisition cost (Aug 2019). 
10.02.01 Edrophonium Chloride 
  • Included on formulary as a diagnostic agent for myasthenia gravis.  
05.03.01 Efavirenz Sustiva®
  • Capsules 50mg, 100mg, 200mg
  • Tablets 600mg
  • Oral solution (SF) 30mg/ml
13.09 Eflornithine 11.5% 
  • SFT only
  • Commissioning policy in development (August 2019)
  • maximum supply of 30g per month
  • Discontinue if no beneficial effects are noticed within four months of commencing therapy
  • Hirsutism may be self-managed with mechanical and cosmetic means at no cost to the NHS
  • It is important that the patient is properly assessed and underlying causes addressed as hirsutism can result from serious medical conditions or from medication.
  • Eflornithine does not offer permanent hair removal, it slows hair growth such that users require less frequent hair removal by other methods (e.g. shaving, plucking, waxing). Hair removal will need to continue (regrowth occurs within 8 weeks).
05.03.03.02 Elbasvir/Grazoprevir Zepatier®
  •  Tablets 50mg/100mg
09.01.04 Eltrombopag 
  • See MHRA Drug Safety Update July 18 for information on reports of interferance with bilirubin and creatinine 
  • 25mg, 50mg
  • Third line options can be considered for patients with symptoms lasting longer than 12 months in whom first and second line treatment options have failed and there are on-going complications from their thrombocytopenia OR where second-line options are contra-indicated.
06.01.02.03 Empagliflozin 
  • Green
  • Amber IN COMBINATION WITH INSULIN IN TYPE 2 DIABETES FOLLOWING NICE GUIDANCE ONLY
  • 10mg, 25mg
  • Renal impairment: See SPC for patients with eGFR <60mL/minute/1.73m2
05.03.01 Emtricitabine Emtriva®
  • Capsules 200mg
  • Oral solution 50mg/5ml
05.03.01 Emtricitabine + tenofovir alafenamide Descovy®
  •  Emtricitabine/Tenofovir alafenamide 200mg/10mg or 200mg/25mg 
05.03.01 Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg Eviplera®
  •  Emtriciciabine 200mg, rilpivirine 25mg, tenofovir 245mg
05.03.01 Emtricitabine, rilpivirine, & tenofovir alafenamide Odefsey ®
  •  Rilpivirine 25mg, emtricitabine 200mg tenofovir alafenamide (TAF) 25mg
13.02.01 Emulsifying Ointment BP 

GREASY MOISTURISER FOR SEVERE DRY SKIN

  •    Ointment 500g
16.01 Enalapril 
  • 2.5mg, 5mg, 10mg and 20mg
02.01.02 Enoximone 
  • Injection 100mg in 20ml

 

A2.02.01.02 Ensure ® Plus Juce 

200 ml bottle.

28 day supply =  56 bottles, 12,320 ml

300 kcals, 10.6 g protein, 71.9 g carbohydrate

NOT SUITABLE FOR PEOPLE WITH COPD OR DIABETES

IDDSI level 1 - Slightly thick fluids

A2.02.02.01 Ensure ® Plus Milkshake style 

220 ml bottle

Provides 330 kcal, 13.8 g protein, 220 ml fluid

IDDSI Level 0 - Thin fluids

A2.02.02.01 Ensure ® Plus Fibre 

Consider for patients with constipation.

200 ml bottle

28 day supply = 56 bottles, 11,200 ml

310 kcals, 13 g protein, 5.0 g fibre, 200ml fluid

IDDSI Level 1 - Thin fluids

09.04.02 Ensure Plus 
  • For those unable to use powdered milkshakes but can tolerate larger volumes. (220ml bottles)
  • Flavours: Banana, chocolate, coffee, fruits of the forest, neutral, orange, peach, raspberry, strawberry, vanilla, blackcurrant, caramel 
  • 330 kcals 13.8g protein 220 ml fluid
  • Lactose free
  • IDDSI level  0
09.04.02 Ensure Plus Fibre 
  • Contains fibre, consider for those with constipation
  • Flavours: Banana, strawberry, chocolate, raspberry, vanilla
  • 200ml bottle
  • 310 kcals 12.5g protein, 5g fibre, 200 ml fluid
  • Lactose free
  • IDDSI level  1
09.04.02 Ensure Plus Juice Style 
  • Not suitable for people with diabetes, COPD and wounds - due to carbohydrate:protein ratio
  • Flavours: Apple, fruit punch, lemonlime, orange, peach, strawberry
  • 330 kcals 10.6g protein, 71.9g carbohydrate, 220 ml fluid
  • Lactose free
  • 220ml bottle
  • IDDSI level  1
04.09.01 Entacapone 
  •  200mg
  • Notes: Entacapone is licensed for use as an adjunct to co-beneldopa or co-careldopa for patients with Parkinson’s disease who experience ‘end-of-dose’ deterioration and cannot be stabilized on these combinations. It is important thtn Entacapone and co-beneldopa or co-careldopa are taken together at the same time of day.
05.03.03.01 Entecavir Baraclude®
  •   500 micrograms
  •   1mg
08.03.04.02 Enzalutamide 
  • 40mg tablets
02.07.02 Ephedrine 
  • Injection 30mg in 1ml
  • Tablets 30mg for treatment of persistent (12 hours) and orthostatic hypotension, refractory to fluid bolus, during attempts to mobilise patients following spinal anaethesia for total hip or total knee arthroplasty

 

12.02.02 Ephedrine  
  • Nasal drops 0.5%
  • 1% 10ml     

 

13.02.01 Epimax ® cream

CREAM FOR MILD TO MODERATE DRY SKIN

  • 500g flexi-dispenser which can be used by care homes. No pump pack available.
  • Primary Care Diprobase®alternative
13.02.01 Epimax ® Ointment

GREASY MOISTURISER FOR SEVERE DRY SKIN

  • YSP 30%, LP 40%, emulsifying wax 30%
  • 500g or 125g pack sizes available
08.01.02 Epirubicin 
  • 10mg/5ml and 50mg/25ml injection
  • 100mg/50ml, 200mg/100ml infusion
02.02.03 Eplerenone 
  • Tablet 25mg, 50mg
  • Use within licensed indication in line with NICE.
  • Eplerenone is only indicated as an adjunct in stable patients with left ventricular dysfunction with evidence of heart failure, following acute myocardial infarction. Start within 3-14 days of event.
02.08.01 Epoprostenol 
  •  Powder for reconstitution 500 micrograms
09.06.04 Ergocalciferol and calcium Calfovit D3®
  • Swindon:For patients unable to take chewable tablets or capsules.
  • Powder- calcium phosphate (calcium 1.2g/ 30mmmol) and 800 units/20micrograms colecalciferol per sachet.
  • For patients requiring calcium and vitamin D via enteral feeding. Calcium phosphate 1.2g or 30mmmol calcium and colecalciferol 20micrograms or 800 units per sachet. 
  • CALFOVIT D3 is indicated in adults and elderly. The safety and efficacy of CALFOVIT D3 in children has not been established; therefore, CALFOVIT D3 should not be used in this population. No data are available.
09.06.04 Ergocalciferol and calcium carbonate Calceos®
  • Salisbury- First line calcium and vitamin D product in primary care.
  • Chewable tablets containing 500mg/12.5mmol calcium and 400 units/ 10micrograms of Vitamin D (as Vitamin D3/colecalciferol) Dose: 1 tablet twice daily. 
  • For existing patients only.
07.01.01 Ergometrine Maleate 
  • Injection 500 micrograms in 1ml
07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®
  • Injection containing ergometrine maleate 500 micrograms and oxytocin 5 units in 1ml
08.01.05 Eribulin 
  • 0.88mg/2ml solution for injection

 

08.01.05 Erlotinib 
  • 25mg, 100mg and 150mg tablets
05.01.02.02 Ertapenem 
  • Red for use in acute trusts
  • Green for treatment of multi-resistant UTI in the community. Only available within the BaNES Health Community. The Virgin Care Community IV team provides and administers IV drugs.
  • IV infusion 1g vial
06.01.02.03 Ertugliflozin 
  • Green 
  • 5mg,15mg
  • Due to current lack of cardiovascular disease outcome data we would recommend ertugliflozin is only used in patients without established cardiovascular disease.
  • If patients and their clinicians consider ertugliflozin to be one of a range of suitable treatments including canagliflozin, dapagliflozin and empagliflozin, the least expensive should be chosen, which is ertugliflozin.
05.01.05 Erythromycin 
  • Tablets 250mg
  • Oral suspension (SF) (ethylsuccinate) 125mg/5ml, 250mg/5ml, 500mg/5ml
11.03.01 Erythromycin 
  • GWH only for suspected chlamydia in neonates on the advice of paediatrician
  • Non formulary at RUH and Salisbury
  • 0.5% eye ointment
13.06.02 Erythromycin 
  • Tablets 250mg
  • First line children less than 12 years of age and in pregnant or breastfeeding women
  • 500mg twice a day for 3 months then review (two tablets twice daily)
13.06.01 Erythromycin 40mg with Zinc Acetate 12mg/mL 
  • Topical lotion, powder for reconstitution, erythromycin 40mg/ml, Zinc acetate 12mg/ml 30ml, 90ml
  • Apply twice daily
  • Note that this product is not in local acne guidance due to high resistance levels. It was on the 3Ts and SFT formularies for children under 12 with acne only.

 

04.01.02 Escitalopram 
  • Licensed option for Generalised Anxiety Disorder (GAD)
  • 1st line option 
04.03.03 Escitalopram 
  • Tablets 5mg, 10mg
  • Drops 20mg/ml
  • 20 mg for adults;
  • 10 mg for patients older than 65 years;
  • 10 mg for those with hepatic impairment
04.08.01 Eslicarbazepine 
  • 200mg, 800mg
  • Adjunctive therapy in adolescents and adults Only to be used if other treatments have been ineffective or not tolerated.
  • Not approved for monotherapy use.
02.04 Esmolol 
  •  100mg/10ml, 2.5g/10ml
01.03.05 Esomeprazole 
  • Green - Bath, Salisbury & Swindon - For use in patients with swallowing difficulties, or patients with NG/PEG tubes in-situ.
  • Amber - Salisbury & Swindon - For use in patients with treatment- resistant severe GORD, confirmed by endoscopy, who have failed to respond to the use of high doses of generic omeprazole or generic lansoprazole.
  • Non-formulary - Bath - For use in patients with treatment- resistant severe GORD, confirmed by endoscopy, who have failed to respond to the use of high doses of generic omeprazole or generic lansoprazole.
  • 20mg & 40mg gastro-resistant tablets.
  • Please note: Tablets may be dispersed in non-carbonated water and the resultant suspension swallowed or flushed down a gastric tube immediately (licensed indication). 
10.01.03 Etanercept Benepali®, Enbrel®,Erelzi®
  • 25mg or 50mg solution for injection in pre-filled syringe or pen
  • Prescribe by BRAND. Biosimilar should be used 1st line. BENEPALI® is the biosimilar brand used locally in BSW. First-line etanercept brand. 

Commissioned by CCG for:

  • Rheumatoid arthritis in accordance with NICE TA 375 and local pathway.
  • Ankylosing spondylitis in accordance with NICE TA383 and local pathway
  • Psoriatic arthritis in accordance with NICE TA199 and local pathway

Commissioned by NHS England from specialist centres only for:

  • Juvenile idiopathic arthritis in line with NICE TA373.
  • Paediatric patients in line with adult NICE TAs.
  • Check Trust contracting arrangements.

 

13.05.03 Etanercept Benepali®, Enbrel®Erelzi®
  • Biosimilar available: BENEPALI® is the biosimilar brand used locally in BSW. First-line etanercept brand. Prescribe by brand.
  • Originator brand: Enbrel® usually for patients that cannot tolerate or do not respond to Benepali.
  • Injection 25mg, 50mg vial, 25mg, 50mg prefilled syringe
09.05.01.02 Etelcalcetide 
  • GWH only.
  • Non-Formulary RUH and SFT
  • Commissioned by NHS England in line with NICE TA448 for treating secondary hyperparathyroidism via specialist centres only. For initiation and follow-on prescribing by a Renal specialist for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis, in line with NICE TA448. 
  • Used if cinacalcet is not suitable.
  • 10mg/2ml ,2.5mg/0.5ml,5mg/1ml
05.01.09 Ethambutol  
  • 100mg
  • 400mg
06.04.01.01 Ethinylestradiol 

Green Bath

Amber Swindon and Salisbury 

  • Tablets 10 micrograms, 50 micrograms, 1mg.
  • Red 2 microgram strength is an unlicensed unlicensed special.
  • Licensed for short term use for short term treatment of oestrogen deficiency, female hypogonadism and menstrual disorders.
  • Also used for treatment of  gender dysphoria 

Note: Ethinylestradiol tablets are very expensive consider using estradiol where clinically appropriate as a more cost effective option.

07.03.01 Ethinylestradiol / levonorgestrel phased pill TriRegol®, Logynon®
  • Multiphasic tablets containing ethinylestradiol 30 micrograms, levonorgestrel 50 micrograms;  ethinylestradiol 40 micrograms, levonorgestrel 75 micrograms; ethinylestradiol 30 micrograms, levonorgestrel 125 micrograms. 3 x 21 tablets.
07.03.01 Ethinylestradiol 20 mcg / norethisterone 1mg Loestrin 20®
  • Tablets containing ethinylestradiol 20 micrograms and norethisterone acetate 1mg.
  • Please note: Sept 2019 manufacturers confirmed this product is being discontinued with no further supplies of Loestrin 20 to the UK market.
07.03.01 Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel®, Mercilon®
  • Tablets containing ethinylestradiol 20 micrograms and desogestrel 150 micrograms (21 days)
  • Gedarel 20/150 Most cost effective choice 3 x 21 £5.08, Mercilon 3 x 21 £8.44 December 2018. Mercilon for existing patients only OR if Gedarel 20/150 unavailable.

 

07.03.01 Ethinylestradiol 20mcg / gestodene 75 mcg Millinette 20/75®, Femodette®, Juliperla®
  • Tablets containing ethinylestradiol 20 micrograms and gestodene 75 micrograms.
07.03.01 Ethinylestradiol 30 mcg / drospirenone 3 mg Yasmin®, Lucette®
  • Tablets containing ethinyloestradiol 30 micrograms and drospirenone 3mg
  • Lucette most cost effective 3 x 21 £9.35 December 2018. Yasmin only for existing patients 3 x 21 £14.70 December 2018.
  • Note: Only for women with mild to moderate acne or symptoms of PMS when first and second choice have failed.
07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel®, Marvelon®
  • Tablets containing ethinylestradiol 30 micrograms and desogestrel 150micrograms.
  • Note: Useful for patients with acne which hasn't improved with Rigevidon.

 

07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg Millinette 30/75®, Femodene®,Sofiperla®
  • Tablets containing ethinylestradiol 30 micrograms and gestodene 75 micrograms.
07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg Femodene® ED
  • Each active tablet contains 75 micrograms gestodene and 30 micrograms ethinylestradiol. Each pack also contains seven placebo tablets which are larger.
07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg Rigevidon®, Microgynon 30®, Levest®
  • Tablets containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms (21 days)
  • Rigevidon® Most cost effective choice 3 x 21 £1.89 v Microgynon 30, 3 x 21 £2.82 December 2018. Microgynon 30® existing patients only OR if Rigevidon® unavailable.

 

07.03.01 Ethinylestradiol 30mcg / norethisterone 1.5mg Loestrin 30®
  • Tablets containing ethinylestradiol 30 micrograms and norethisterone 1.5 mgs.
  • Please note: Sept 2019 manufacturers confirmed this product is being discontinued with no further supplies of Loestrin 30 to the UK market.
07.03.01 Ethinylestradiol 35 mcg / noresthisterone 1mg Norimin®
  • Tablets containing ethinylestradiol 35 micrograms & norethisterone 1mg micrograms
07.03.01 Ethinylestradiol 35 mcg / noresthisterone 500mcg Brevinor®
  • Tablets containing ethinylestradiol 35 micrograms & norethisterone 500 micrograms x 21 tablets.
  • Note: Less progestogenic

 

07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg Cilique®
  • Tablets containing ethinylestradiol 35 micrograms and norgestimate 250 micrograms
  • Cilique most cost effective £4.65 x 63 tablets compared to Cilest £7.16 x 63 tablets December 2018 (NB Cilest is being discontinued from July 2019)
  • Note: Useful for irregular bleeding with Rigevidon

 

04.08.01 Ethosuximide 
  • 250 mg/5 ml oral solution
  • Used as per NICE CG137 for absence seizures
15.02 Ethyl Chloride 
  • 100ml
  • CAUTION: Extremely flammable liquified gas under pressure. Stable at room temperature 8ºC-20ºC. Use only with good ventilation. Avoid use near electrical equipment, naked flames or high temperature surfaces. Store in a metal cupboard in a ventilated room- never in a refridgerator. All empty or unused containers must be returned to pharmacy for destruction.
10.01.01 Etodolac 
  • Salisbury only
  • Non formulary in Bath and Swindon
  • 300mg capsules
  • 600mg tablets and 600mg MR tablets
15.01.01 Etomidate 
  • 20mg/10ml amps
07.03.02.02 Etonorgestrel Nexplanon®
  • Implant containing 68 mg of etonogestrel
  • The practitioner fitting (or removing) must be fully trained in the technique.
  • Nexplanon is licensed for 3 years.

 

08.01.04 Etoposide 
  • 50mg and 100mg capsules
08.01.04 Etoposide 
  • 100mg/5ml, 200mg/10ml and 500mg/25ml infusion
10.01.01 Etoricoxib 
  • Amber- Bath - Second line for treament of Ankylosing Spondylitis ONLY.
  • Amber - Swindon - Reserved for severe inflammatory arthritis unresponsive or intolerant to other NSAIDS.
  •  Red - GWH ONLY - For the short-term prevention & treatment of post-operative pain in patients with known hypersensitivity to conventional NSAIDs, or patients at high risk of hypersenstivitiy to conventional NSAIDs (e.g. asthmatics).
  • Non formulary - Salisbury.
  • 30mg, 60mg, 90mg and 120mg tablets.
05.03.01 Etravirine Intelence®
  •  Tablets 200mg
13.02.01 Eucerin ® Intensive 10% 
  • SFT only
  • Contains Urea
  • 250ml lotion or 100ml cream
08.01.05 Everolimus Afinitor®
  • 2.5mg, 5mg and 10mg tablets
  • Ensure correct brand is prescribed.

 

08.01.05 Everolimus Votubia®
  • Only at RUH
  • 2.5mg, 5mg and 10mg tablets
  • Ensure correct brand is supplied
  • To be prescribed by specialist centres in accordance with NHSE commissioning policies
02.12 Evolocumab Repatha®
  • 140mg/ml soln for injection Prefilled SureClick pen, 2 x 1ml
  • Consultant Lipid specialist only.
  • Adjunct to diet in primary hypercholesterolaemia or mixed dyslipidaemia: with a statin when LDL-C response to a statin alone is insufficient, and alone or with other lipid-lowering treatments if statins are contraindicated or not tolerated. With other lipid-lowering treatments in homozygous familial hypercholesterolaemia.
13.02.01 ExCetra ® cream

CREAM FOR MILD TO MODERATE DRY SKIN

  • Cream 100g and 500g flexi dispenser which can be used instead of a pump by care homes.
  • Contains the same ingredients as Cetraben® but is more cost effective choice
08.03.04.01 Exemestane 
  • 25mg tablets
06.01.02.03 Exenatide (prolonged release) Bydureon®

Green Bath

Amber Salisbury and Swindon

  • 2mg powder for reconstitution
  • Once weekly subcutaneous injection for the treatment of type 2 diabetes

 

02.12 Ezetimibe 
  • 10mg
  • Statin Intolerance - In hypersensitivity, elevated LFTs (ALT > 3 times normal limit) or previous myositis, ezetimibe 10mg daily may be substituted as monotherapy. 
  • Ezetimibe should only be prescribed to patients with difficult dyslipidaemia or familial hyperlipidaemia who are failing to reach target cholesterol on high doses of statin, or those who experience true adverse effects from high dose statins or in whom statins are contraindicated

 

05.03.02.01 Famciclovir 
  • SFT only for ophthalmology treatment protocol for keratitis
  • 125mg/250mg/500mg tablets
10.01.04 Febuxostat Adenuric®
  • 80mg and 120mg
  • To be prescribed only when patients have failed on Allopurinol in line with NICE TA below.
  • SFT Febuxostat guidelines


      

02.12 Fenofibrate 
  • Only to be prescribed after having had a telephone consultation with a specialist
  • Capsules 67mg, 200mg, 267mg
  • Tablets 160mg
  • NICE. Do not do recomendationDo not routinely offer fibrates for the prevention of CVD to any of the following: -people who are being treated for primary prevention -people who are being treated for secondary prevention -people with CKD -people with type 1 diabetes -people with type 2 diabetes.
04.07.02 Fentanyl 
  • Patch 12 microgram/hour, for 3 days
  • Patch 25 microgram/hour, for 3 days
  • Patch 50 microgram/hour, for 3 days
  • Patch 75 microgram/hour, for 3 days
  • Patch 100 microgram/hour, for 3 day
  • Fentanyl patches are only licensed for chronic intractable pain. For palliative care use.
  • Fentanyl patches are not suitable for use in the management of acute / intermittent pain.
  • Oral morphine 90mg over 24 hours is equivalent to one ’25 micrograms/hour’ patch.  
  • Only to be used in patients who require equivalent dose of at least 60mg morphine daily
  • Fentanyl is available both as a reservoir patch and a matrix patch (do not cut either)
  • Patients and/or their carers need to be aware that fentanyl patches need to be applied at appropriate 72-hour (three-day) intervals. Remember to remove the old patch before application of new patch
04.07.02 Fentanyl  Actiq ®
  • 200mcg,400mcg,600mcg,800mcg,1.2mg,1.6mg
  • lozenges with integral oromucosal applicator
  • Patients must be assessed by the palliative care or pain team before commencing treatment.
  • They should be used in the minority of patients with breakthrough pain that fail immediate release morphine or oxycodone. Review weekly.
  • For peri-operative analgesia (including fentanyl and alfentanil) see section 15.1.4     
  • Prescribe by brand name to ensure that the correct product is dispensed.

 

04.07.02 Fentanyl  PecFent®
  • 100micrograms/dose, 400micrograms/dose
  • Breakthrough cancer pain for patients in whom oral morphine sulphate solution is inappropriate.  Under the recommendation of a palliative care specialist only.
  • NOT approved for non cancer pain 

 

04.07.02 Fentanyl  
  • 100mcg, 200mcg, 300mcg, 400mcg, 600mcg, 800mcg sublingual tablet
  • Palliative care or pain specialist initiation only
  • Patients must be assessed by the palliative care or pain team before commencing treatment. They should be used in the minority of patients with breakthrough pain that fail immediate release morphine or oxycodone. Review weekly.

 

04.07.02 Fentanyl Effentora®
  • Buccal tablets 100 micrograms, 200 micrograms, 400 micrograms, 600 micrograms, 800 micrograms
  • Breakthrough cancer pain for patients in whom oral morphine sulphate solution is inappropriate.  Under the recommendation of a palliative care specialist only.
  • NOT approved for non cancer pain
  • Patients must be assessed by the palliative care or pain team before commencing treatment. They should be used in the minority of patients with breakthrough pain that fail immediate release morphine or oxycodone. Review weekly.
  • For peri-operative analgesia (including fentanyl and alfentanil) see section 15.1.4     
  • Prescribe by brand name to ensure that the correct product is dispensed.
15.01.04.03 Fentanyl 
  • 100 micrograms in 2ml amp
  • 500 micrograms in 10ml amp

 

 

 

21 Fentanyl 
  • 100 micrograms in 2ml amp
  • 500 micrograms in 10ml amp
  • Can be used in syringe drivers for in patients with renal impairment and an eGFR <30ml/min/1.73m2 or declining renal function on the advice of specialist palliative care service.

  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)

 

09.01.01.02 Ferric Carboxymaltose Ferinject®

 Please note Ferinject is considerably more expensive than Cosmofer.

  • Treatment of iron-deficiency in patients with asthma, allergic eczema or other atopic allergy, when oral iron preparations are ineffective or cannot be used
  •  50mg/ml for slow intravenous injection or intravenous infusion       

Anaphylactoid reactions can occur with parenteral administration of iron complexes. Facilities for cardio-pulmonary resuscitation must be at hand.

09.01.01.01 Ferric maltol Ferracru®
  • 30mg
  • GWH ONLY for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease and ONLY on the advice of a consultant gastroenterologist. Please note all supplies MUST be obtained via hospital outpatient prescription as GPs will not be able to follow on prescribe. 
  • RUH/SFT - not on formulary
09.01.01.01 Ferrous Fumarate 
  • Tablets 322mg (equivalent to 100mg ferrous iron per tablet). Treatment dose twice a day
  • Tablets 210mg (equivalent to 68mg ferrous iron per tablet) Treatment dose three times a day 
  • Oral solution 140mg/5ml
09.01.01.01 Ferrous Sulphate 

Contains 65mg iron.

Recommended doses:

  • Treatment: 1 tablet TDS
  • Prevention : 1 tablet OD
03.04.01 Fexofenadine 
  • Green  Bath
  • Green  Salisbury
  • Amber  Swindon
  • Tablets 180mg

Note: Fexofenadine has been added for the treatment of chronic idiopathic urticaria (usually Dermatology specialist initiated) in patients not adequately treated with cetirizine. More expensive than loratidine and certirizine. Not recommended for children under 12 years.

05.01.07 Fidaxomicin 
  • Tablets 200mg
  • For the treatment of intractable Clostridium Difficile on microbiologist
    advice only.
  • See local primary care antibiotic guidance for treatment advice in
    primary care or acute trust guidance for treatment in secondary care setting.
    See PHE management and treatment of Clostridium guidance on link below.
09.01.06 Filgrastim Accofil®

 

  • Pre-filled syring 38 million units (300 micrograms)/0.5 mL and 48 million units (480 micrograms)/0.8 mL
  • Biosimilar GCSF
  • Commissioned by NHS England for neutropenia according to Trust Guidelines. 
06.04.02 Finasteride 
  • 5mg      
  • For treatment of BPH only, not baldness.  Women of child-bearing potential should avoid handling crushed or broken finasteride tablets.

 

07.04.01 Finasteride 
  • Tablets 5mg
08.02.04 Fingolimod 
  • 0.5mg capsules
02.03.02 Flecainide 
  • Tablets 50mg, 100mg
02.03.02 Flecainide 
  • Injection 150mg in 15ml
01.06.05 Fleet Phospho-soda ® Solution
  • 24.4g/10.8g oral solution.
13.04 Flucinolone Acetonide 0.0025% Synalar 1 in 10 Dilution®
  • Mild potency steroid
  • Cream 0.0025% 50g
  • Use if hydrocortisone allergy.
13.04 Flucinolone Acetonide 0.00625% Synalar 1 in 4 Dilution®
  • Moderate potency steroid
  • Cream 0.00625%, 50g Synalar 1 in 4®
  • Apply sparingly. For short term use. Useful alternative to Eumovate, especially if hydrocortisone allergy
13.04 Flucinolone Acetonide 0.025% Synalar®
  • Potent steroid
  • Cream or gel 0.025% 30g, 60g Synalar
  • Useful in many patients including those allergic to hydrocortisone
13.04 Flucinolone Acetonide 0.025% with Neomycin Sulphate 0.5% Synalar N®
  • Potent steroid
  • Cream, Ointment Fluocinolone 0.025%, neomycin 0.5% 30g
05.01.01.02 Flucloxacillin  
  • Capsules 250mg, 500mg.
  • Oral solution 125mg/5ml, 250mg/5ml.
  • Cholestatic jaundice and hepatitis may occur, very rarely,
    up to two months after treatment with flucloxacillin has been stopped.
    Administration for more than 2 weeks and increasing age are risk factors.
    See BNF and SPC for further details.
05.01.01.02 Flucloxacillin 
  • 250mg
  • 500mg
  • 1g 
  • Cholestatic jaundice & hepatitis may occur, very rarely,
    up to two months after treatment with flucloxacillin has been stopped.
    Administration for more than 2 weeks and increasing age are risk factors.
    See BNF and SPC for further details.

 

05.02 Fluconazole 
  •  IV infusion 2mg/ml, 25ml bottle, 100ml bottle
05.02 Fluconazole 
  • Capsules 50mg, 150mg, 200mg
  • Oral suspension 50mg/5ml, 200mg/5ml
07.02.02 Fluconazole 
  • 150mg oral capsule
05.02 Flucytosine 
  • Infusion 10mg/ml
  • Under the guidance of a consultant mycologist ONLY
08.01.03 Fludarabine Phosphate 
  • 50mg/2ml injection
08.01.03 Fludarabine Phosphate 
  • 10mg tablets
06.03.01 Fludrocortisone 

Green Salisbury and Swindon

Amber Bath

  • 100 micrograms
  • Review regularly & to use the lowest dose possible to control the postural hypotension
  • Fludrocortisone may be given as a mineralocorticoid in combination with hydrocortisone in adrenocortical insufficiency.
  • Fludrocortisone may also be used in the treatment of postural hypotension (unlicensed).

 

13.04 Fludroxycortide  
  • Moderate potency steroid
  • Occlusive tape 4micrograms/cm2 50cm x 7.5cm, 200cm x 7.5cm Haelan Tape®
15.01.07 Flumazenil 
  • 500 micrograms in 5ml amp 
  • Used to reverse the effects of benzodiazepines. See SPC for full information on safe use.
12.01.01 Flumetasone 0.02% with Clioquinol 1% ear drops
  • Previously Locorten-Vioform®  (discontinued)
11.04.01 Fluocinolone Iluvien®
  • For the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy. In line with NICE TA301 Nov 2013.  Patients need to have gained 10 or more ETDRS letters of visual acuity between baseline and month 36 to receive a further implant at month 36 according to NICE TA301.
  • Note: concurrent treatment to both eyes not recommended (SPC).
  • A single implant releases fluocinolone for up to 36 months.
  • Implantation may not be repeated more frequently than every 36 months due to lack of evidence base of benefit.
13.04 fluocinolone acetonide 0.025% with clioquinol 3% Synalar C®
  • Potent steroid
  • cream,ointment 15g
11.08.02 Fluorescein 
  • 1% and 2% minims
  • Ophthalmic strips
  • GWH only
  • Non formulary at RUH and Salisbury
11.08.02 Fluorescein Sodium 
09.05.03 Fluorides Duraphat® (Mouthwash)
  • Swindon ONLY
  • Mouthwash: 0.05% and 2%
  • ONLY for initiation and follow-on prescribing by specialist, community or high-street dentists.
  • Salisbury and Bath - non formulary
  • Not for GP prescribing
09.05.03 Fluorides Duraphat® (Toothpaste)

Green Swindon: ONLY for initiation and follow-on prescribing by specialist, community or high-street dentists

Toothpaste: 0.619% and 1.1%

Bath - Not for GP primary care prescribing. Only for dental prescribing on NHS

When the fluoride content of drinking water is less than 700micrograms per litre (0.7 parts per million), daily administration of fluoride tablets or drops provides suitable supplementation. Systemic fluoride supplements should not be prescribed without reference to the fluoride content of the local water supply.  Infants need not receive fluoride supplements until the age of 6 months. (Ref BNF 76). Provision of such supplements should be via the dentist.

Salisbury - non formulary

11.04.01 Fluorometholone 
  • 0.1% ophthalmic solution
08.01.03 Fluorouracil 
  • 250mg/10ml, 500ml/20ml, 500mg/10ml and 1g/20ml injection
  • 2.5mg/100ml, 2.5mg/50ml and 5mg/100ml infusion
  • For topical cream see chapter 13.8.1

 

11.99.99.99 Fluorouracil 
  • Swindon only - used in theatre intra-operatively (trabeculectomy) and for needling of trabeculectomy post-op. Special chemotherapeutic agent manufactured for individual patients. 48 hours notice required. Consultant ophthalmologist prescription only.
  • For licensed indications for fluorouracil see chapter 8.1.3 and chapter 13.8.1(topical)
  • Non formulary at RUH and SFT

 

13.08.01 Fluorouracil Efudix®
  • Efudix® cream 5% 40g
  • Superficial malignant and pre-malignant skin lesions. Apply thinly to affected area once or twice daily, maximum area of skin treated at one time 500cm (23cm x 23cm); usual duration of inital therapy 3 to 4 weeks. Patients should be warned that skin will become inflamed sore & possibly weepy
13.08.01 Fluorouracil O.5% salicylic acid 10% Actikerall®
  • Fluorouracil 0.5%, salicylic acid 10%; solution 25ml
  • Apply once daily for up to 12 weeks
04.03.03 Fluoxetine 
  • Capsules 20mg, 30mg, 40mg, 60mg
  • Liquid 20mg in 5ml
  • 10mg tablets and 10mg capsules are available but are prohibitively expensive.
  • Note: Long half life, least likely SSRI to cause withdrawal reactions. 
04.02.02 Flupentixol Decanoate Depixol®
  • Amber in rest of Wiltshire, Swindon & BaNEs
  • Red in south Wiltshire via service commissioned at Fountain Way, Salisbury.
  • Depixol® injection 20mg/ml - 20mg in 1ml, 40mg in 2ml
  • Depixol® injection 100mg /ml ("Concentrate") - 50mg in 0.5ml, 100mg in 1ml
  • Depixol® injection 200mg/ml ("Low-volume") - 200mg in 1ml

 

04.02.02 Fluphenazine Decanoate 
  • injection 25mg/ml - 12.5mg in 0.5ml, 25mg in 1ml, 50mg in 2ml
04.02.02 Fluphenazine Decanoate Modecate® Concentrate
  • injection 100mg/ml ("Concentrate") - 50mg in 0.5ml, 100mg in 1ml
12.02.01 Fluticasone + Azelastine 
  • Azelastine 137 micrograms and Fluticasone propionate 50 micrograms per actuation
  • Only to be used 3rd line as per the local allergic rhinitis guidance  
12.02.01 Fluticasone furoate 
  • Fluticasone furoate nasal spray, 27.5 micrograms per spray
  • Second line for the treatment of allergic rhinitis

 

 

 

03.02.02 Fluticasone furoate & vilanterol Relvar Ellipta®
  • First choice ICS/LABA DPI for asthma and COPD. 
  • Use in COPD:
    • Combination of fluticasone furoate and vilanterol (92/22)
    • Breath actuated dry powder inhaler
    • Approved for COPD in use with local guidance and in line with NICE FEV1<50%. 
    • Once daily administration.
  • Use in asthma:
    • Combination of fluticasone furoate and vilanterol (92/22, 184/22)
    • Breath actuated dry powder inhaler for uncontrolled asthmatic patients only
    • Once daily administration

 

03.02 Fluticasone propionate Flixotide®
  • Green Bath
  • Green Salisbury
  • Amber Swindon
  • Existing patients ONLY.
  • Flixotide® Accuhaler dry powder for inhalation 50, 100, 250, 500 micrograms/dose
  • Flixotide® Evohaler aerosol inhalation MDI 50, 125, 250 micrograms/dose 

Restricted to use for adult patients for whom other therapy has proved unsuccessful and are uncontrolled on over 1000mcg daily of inhaled beclomethasone or budesonide. 

The evidence for reduced adrenal supression with fluticasone is poor. But, consider use in children of 4 years of age and older, if high doses of inhaled steroids (30kg 800mcg BD of beclometasone or budesonide) have been used for longer than three months. 

Prescribe fluticasone at half the dose prescribed for beclometasone or budesonide. 

12.02.01 Fluticasone Propionate 
  • Nasal drops 400 micrograms/unit dose  
  • Only for the treatment of nasal polyps and associated symptoms of nasal obstruction.
  • Only to be used 3rd line as per the Local allergic rhinitis guidance (see front page for guidance links) March 2018

 

 

 

03.02.02 Fluticasone propionate and salmeterol Sirdupla®, Airflusal®,Seretide®
  • Existing patients ONLY. No new prescribing. Please review existing patients, to see if could switch to first-line options.
  • Airflusal® aerosol inhalation MDI 25/125, 25/250. For asthma >18years of age. NB only to be used for new patients
  • Sirdupla ®aerosol inhalation MDI 125/25, 250/25 For asthma >18years of age - NB no lower strength. Prescribe by brand. 
  • Seretide® Evohaler aerosol inhalation MDI 50/25, 125/25, 250/25
  • Notes: The higher doses (125 and 250) are only advised in step 4 of the management of asthma in adults.

 Please note that in Swindon, for use in adults, all strengths of Seretide Evohaler (except Seretide 50 Evohaler) have been removed from formulary. It is envisaged that existing adult patients will be switched to either Sirdupla ® MDI / AirFluSal or Fostair ® MDI, depending on indication, although it is accepted that there may be a very small amount of non-formulary prescribing in the exceptional circumstance that all formulary options have been exhausted. 

 

03.02.02 Fluticasone propionate and salmeterol  Seretide Accuhaler®
  • No new prescribing. Please review existing patients, to see if could switch to first-line options. 
  • Seretide® Accuhaler dry powder for inhalation MDI 100/50, 250/50, 500/50
  • Seretide Accuhaler is licensed for COPD but the Evohaler is not - many patients with COPD are using the Seretide 250 Evohaler. The cost of Seretide Accuhaler 500 (one puff bd) is significantly less than Seretide 250 Evohaler (two puffs bd). It delivers exactly the same medication as for the same number of days but costs £20 less per unit.

 

  • Green  Bath
  • Green  Salisbury
  • Non-formulary  Swindon

Please note that in Swindon, for use in adults, all strengths of Seretide Accuhaler ® have been removed from formulary, although it is accepted that there may be a very small amount of non-formulary prescribing in the exceptional circumstance that all formulary options have been exhausted. 

 

09.01.02 Folic Acid 
  • Tablets: 5mg, 400micrograms 
  • SF Oral solution: 2.5mg / 5ml
  • Prevention of Neural Tube Defects

    • Please refer to BNF for guidance on the use of folic acid for prophylaxis in pregnancy and prevention of neural tube defects.
    • There is no justification for prescribing multiple-ingredient vitamin preparations containing vitamin B12 or folic acid.
    • Women with a BMI ≥30 wishing to become pregnant should be advised to take 5mg folic acid supplementation daily, starting at least one month before conception and continuing during the first trimester of pregnancy. (RCOG
06.05.01 Follitropin Alfa  Gonal-F®
  • Not on formulary SFT
  • Injection powder for reconstitution 450units/0.75ml, 1050units/1.75ml
  • prefilled pen 600units/ml 0.5ml, 0.75ml, 1.5ml

 

02.08.01 Fondaparinux 
  • See individual trust prescribing guidelines
A2.02.02.03 Foodlink ® Complete 

FIRST LINE CHOICE IN COMMUNITY

28 day supply = 56 sachets, 3192 g, 8 packs of 7

Make up with 200 ml whole milk.

Provides 385 kcal, 18.5 g protein, 200 ml fluid

OR Make with 200 ml juice providing 340 kcal, 12.9 g protein, 200 ml fluid - NOT SUITABLE FOR PEOPLE WITH DIABETES, WOUNDS

IDDSI level 0 - Thin Fluids

 

A2.02.02.03 Foodlink ® Complete with Fibre 

Consider for those with constipation

56 g sachet made with 200 ml whole milk

28 day supply = 56 sachets, 3528 g  8 packs of 7

Provides 413 - 421 kcals, 18.5 g - 19.7 g protein, 4.5 - 4.7 g fibre, 200 ml fluid

(depending on flavour)

IDDSI Level 0 - Thin fluids

09.04.02 Foodlink Complete 

First line powdered MILKSHAKE style ONS (to be mixed with 200ml full fat milk)

  • Consider whether patient has access to milk and ability to make up the drink with milk. Consider cost to patient. Not suitable for those with lactose intolerance.
  • Flavours: Banana, chocolate, natural, strawberry, vanilla
  • 57g sachets
  • 385 kcal, 18.5g protein, 200 ml fluid
  • Contains Lactose
  • IDDSI level  0
09.04.02 FOODLINK Complete 

FIRST LINE JUICE style ONS 

  • Not suitable for people with diabetes, COPD and wounds, due to carbohydrate:protein ratio
  • Sachet to be mixed with 200mls juice
  • Flavours: Banana, chocolate, natural, strawberry, vanilla
  • 340 kcal 12.9g protein, 200 ml fluid
  • Contains Lactose
  • IDDSI level  0
09.04.02 Foodlink Complete Powder with Fibre 

First Line Milkshake style PLUS Fibre ONS. 

  • Contains fibre, consider for those with constipation
  • Flavours: Banana, chocolate, natural, strawberry, vanilla 
  • 63g sachet
  • 413- 421 kcals, 18.5 - 19.7g protein, 4.5 - 4.7g fibre 200 ml fluid
  • Contains lactose 
  • IDDSI level  0
13.07 Formaldehyde 
  • 0.75% 15g Solution  
  • For keratinsed and non-keratinised  

 

03.01.01.01 Formoterol  Oxis Turbohaler®
  • No new prescribing. Existing patients only - see notes above.
  • Oxis®Turbohaler dry powder inhaler MDI 6 micrograms/dose, 12 micrograms/dose
  • Licensed 6 years +
  • Note: Formoterol - licensed for use when adequate treatment with corticosteroids is not sufficient. Salmeterol 50 micrograms is roughly equivalent to Formoterol 9 micrograms.

 

03.02.03 Formoterol fumarate, beclometasone dipropionate and glycopyrronium bromide  Trimbow®
  • Combination of formoterol fumarate, beclametasone diproprionate and glycopyrronium (5/87/9 micrograms per puff) MDI 120 doses
  • Two puffs twice a day 
  • Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2 agonist. 
A2.02.01.02 Fortijuce ®  

200 ml fluid

28 day supply = 56 bottles, 11,200 ml

300 kcals, 7.8 g protein, 67 g carbohydrate, 200 ml fluid

IDDSI level 0 - Thin fluids

NOT SUITABLE FOR PEOPLE WITH DIABETES

09.04.02 Fortijuice 
  • JUICE style ONS -ready to drink bottle
  • Not suitable for people with diabetes, COPD and wounds due to carbohydrate:protein ratio
  • Flavours: Apple, blackcurrant, forest fruits, lemon, orange, strawberry, tropical
  • 300 kcals, 9.6g protein, 65.4g carbohydrate, 200 ml fluid
  • Residual lactose
  • 200ml bottle
  •  IDDSI level  0
09.04.02 Fortisip 

First Line Ready to drink MILKSHAKE style ONS. 

  • For those unable to use powdered milkshakes but can tolerate larger volumes.
  • Prescribe patient's preferred flavours
  • Flavours: Neutral, vanilla, chocolate, caramel, banana, orange, strawberry, tropical
  • 200ml bottle
  • 300 kcals 11.8g protein,200 ml fluid
  • Lactose free
  • IDDSI level  0
A2.02.02.03 Fortisip ® Compact 

125 ml bottle

28 day supply = 56 bottles, 7000 ml

300 kcals, 12 g protein, 125 ml fluid

IDDSI level 1- Slightly thick fluids

A2.02.02.01 Fortisip ® Bottle 

200 ml bottle

28 day supply = 56 bottles, 11,200 ml

300 kcals, 11.8 g protein, 200 ml fluid

IDDSI Level 0 - Thin fluid

 

 

09.04.02 Fortisip Compact 

First Line Ready to drink COMPACT style ONS.

  • For those who require smaller volumes or with fluid restrictions
  • Flavours: Chocolate, vanilla, banana, strawberry, apricot, forest fruits, mocha 
  • 300 kcals 12g protein, 125 ml fluid
  • Contains lactose
  • 125ml bottle
  • IDDSI level  1
09.04.02 Fortisip Compact Protein 
  • Ready to drink MILKSHAKE style HIGH Protein ONS
  • 125ml bottle
  • Flavours: vanilla, strawberry, banana, mocha, peach/mango, berries, neutral, and hot tropical ginger.
  • 300 kcals 18g protein, 125 ml fluid
  • Residual lactose
  • IDDSI level  2
A2.02.02.03 Fortisip Compact Protein 

125 ml bottle

28 day supply = 56 bottles, 7000 ml

300 kcal, 18 g protein, 125 ml

IDDSI level 2 = mildly thick

05.01.07 Fosfomycin  
  • For use on consultant microbiologist advice only
  • 2g powder for solution for infusion vials
  • 4g powder for solution for infusion vials    
05.01.13 Fosfomycin 
  • 3g sachets
  • Use if high risk of resistance or penicillin allergy.
16.10 Freestyle Libre 
  • See information above
  • A Freestyle Libre Sensor lasts for 2 weeks, so one month’s supply is 2 sensors

 

06.01.06 Freestyle Libre® 
  • A Freestyle Libre Sensor lasts for 2 weeks, so one month’s supply is 2 sensors

Available for those patients that fit NHSE criteria ONLY. Not to be initiated in patients that do not fit the criteria.

Following NHS England’s (NHSE) announcement of National arrangements for funding of relevant diabetes patients for Freestyle Libre from 1st April 2019, the local formulary groups (BCAP/3Ts Swindon FWG/ICID SFT) have agreed to amend the status of Freestyle Libre (FSL) from red to amber (specialist recommendation). There will be some central funding made available for FSL but reimbursement to CCGs will only be based on primary care prescribing hence the change of Traffic light Status.

Existing patients

  • Responsibility for prescribing FSL sensors for existing patients can now be passed from secondary care to the patients GP practice.
  • The ongoing review and clinical care of existing patients will be retained by Specialist Teams.

New patients

  • FSL should not be initiated by GPs in primary care.
  • Specialist teams, (including diabetic specialist nurses DSNs) will identify patients meeting the criteria set out by NHSE (see link above) at the patient’s next routine review. Specialist teams will provide patient education, initiate a patient contract, review benefits after 6 months and provide ongoing clinical care.
  • GPs should take on the prescribing of FSL sensors when asked to do so by the Specialist teams for patients that fit the NHSE criteria.

Patients currently self-funding Freestyle Libre

  • These patients should be assessed to see if they meet the criteria set out by NHSE (see above link) at the patient’s next routine review with the Specialist Teams.
  • Patients should not be referred to a specialist just to access FSL on the NHS.
A2.02.02.01 Fresubin ® Energy 

200 ml bottle

300 kcals, 11.2 g protein, 200 ml fluid

IDDSI Level 0 - Thin fluids 

09.04.02 Fresubin 3.2 kcal 
  • Ready to drink MILKSHAKE style HIGH Protein ONS
  • 125ml bottle
  • Flavours: Hazel, mango, vanilla caramel
  • 400 kcals 20g protein, 125ml fluid
  • Residual lactose
  • IDDSI level  3
04.07.04.01 Frovatriptan 
  • 2.5mg tablets
  • Current evidence base supports the use of Frovatriptan as a first-line acute treatment for Menstrual Migraine and for perimenstrual prophylaxis. No triptan is specifically licensed for this indication (off-label).
  • For the treatment of menstrual migraine only when other triptans (sumatriptan / zolmitriptan) have proven ineffective. Give 2.5mg twice daily on days when migraine expected.
  • Frovatriptan is distinctive from other triptans due to its long elimination half-life of 26 hours, which confers a longer duration of action.
02.02.02 Furosemide 
  • Tablets 20mg, 40mg, 500mg (NOTE: 500mg tablets RED in BaNES)
  • Oral solution 20mg in 5ml, 40mg in 5ml, 50mg in 5 ml
02.02.02 Furosemide Injection
  • Injection 20mg/2ml, 50mg/5ml, 250mg/25ml
11.03.01 Fusidic Acid 
  • 1% ophthalmic drops

Fusidic acid ophthalmic drops are no longer included in primary care guidance for the management of bacterial conjunctivitis due to high cost (£29.06 per 5g May 2019) and poor activity for a self-limiting condition. 

Use should be restricted to people who:
- Are pregnant
- Have a personal or family history of blood dyscrasias, such as aplastic anaemia
- Are intolerant of chloramphenicol
- Need a twice-a-day treatment for infective conjunctivitis
See CKS topic for more information

 

13.10.01.02 Fusidic Acid 2% 
  • Cream 2%, 15g, 30g
  • Ointment 2% 15g, 30g
  • Note: Topical fusidic acid is included for the treatment of impetigo, see primary care antibiotic guidance for further details.
04.07.03 Gabapentin 
  • Capsules 100mg, 300mg, 400mg
  • Elderly patients require the lowest possible initial dose of gabapentin.

 

04.08.01 Gabapentin 
  • Capsule 100mg, 300mg, 400mg (Category 3 MHRA)
  • Tablets 600mg, 800mg
  • Schedule 3 CD, exempted from safe custody requirements.
  • Oral solution 50mg/ml is available but is expensive. Use only if no other option is suitable and there are significant swallowing problems.

     

04.11 Galantamine 
  • Amber with Shared Care NHS BaNES and Wiltshire CCG
  • Red NHS Swindon CCG
  • Capsules MR 8mg, 16mg, 24mg
  • Tablet 8mg, 12mg

 

05.03.02.02 Ganciclovir 
  •  IV infusion 500mg
11.03.03 Ganciclovir 
  • Green in Salisbury
  • Amber in Swindon - ONLY for patients with corneal stromal herpes simplex keratitis, aciclovir- resistant herpes simplex keratitis& herpetic keratouveitis on the advice of a Consultant Ophthalmologist
  • Non formulary in Bath
  • 0.15% ophthalmic gel

 

06.07.02 Ganirelix 

 

Not on formulary in GWH

  • 500micrograms/ml 0.5ml
  • Treatment of infertility

 

01.01.02 Gaviscon Advance® Oral
  • Liquid (Contains 4.6 mmol of sodium in 10ml, plus 2 mmol of potassium).
  • Tablets (Contains 2.25 mmol of sodium per tablet, plus 1 mmol of potassium).
16.15 Gaviscon Infant® 
  • 1 dose = half a dual sachet
  • Prescribe as doses
08.01.05 Gefitinib 
  • 250mg tablets
09.02.02.02 Gelatin Gelofusine®

GWH only - for endoscopy use only 

RUH/SFT not on formulary

  • Gelofusine® Infusion 500ml, 1 litre            
12.03.01 Gelclair ®Oral gel sachet Medical device
  • GWH ONLY 
  • Contains sodium hyaluronate and polyvinylpyrrolidone
  • Used as a mouthwash for oropharyngeal lesions in Oncology patients
08.01.03 Gemcitabine 
  • Various strengths of infusion
07.01.01 Gemeprost 
  • Pessaries 1mg
05.01.04 Gentamicin 
  • Red Blood level monitoring is mandatory for continued therapy.
  • Used for Non-CF bronchiectasis within RUH (injection nebulised) 
  • Green Primary care IM use for prophylaxis during the insertion
    and removal of catheters. Only use for catheter changes if history of
    catheter change-associated UTI or trauma.
  • 20mg/2ml
  • 40mg/2ml - Not in the Drug Tariff do not prescribe on FP10 
  • 80mg/2ml. 
11.03.01 Gentamicin 
  • 0.3% ophthalmic drops
12.01.01 Gentamicin 0.3% 
  • Ear drop 0.3%   
07.04.04 Gepan Instill irrigation solution 
  • First line at GWH
  • Non formulary at RUH or SFT
12.03.05 Glandosane ® 
  • RUH and SFT
  • ACBS
  • 50ml spray
  • Lemon, Peppermint or natural
08.02.04 Glatiramer Acetate 
  • 20mg/1ml and 40mg/1ml injection
05.03.03.02 Glecaprevir / Pibrentasvir Maviret
  • 100mg/40mg tablet
  • Chronic hepatitis C genotypes 2,3 and 5/6 non-cirrhotic or with compensated cirrhosis
06.01.02.01 Gliclazide 
  • 80mg (not MR) - if MR required consider prescribing glimepiride which is a long acting sulfonylurea. NB glimepiride not suitable for use in elderly patients due to the risk of precipitating hypoglycaemia.
  • Only consider gliclazide MR in exceptional circumstances if there are major compliance issues
06.01.02.01 Glimepiride 
  • 1mg, 2mg, 3mg, 4mg
  • Not suitable for use in elderly patients due to the risk of precipitating hypoglycaemia.
  • Swindon - NON FORMULARY
  • Salisbury - to be initiated only on the advice of the diabetic team.

 

06.01.04 Glucagon GlucaGen® HypoKit
  • 1mg vial
  • If glucagon is not effective within 10 minutes, intravenous glucose should be given
06.01.04 GlucoGel ® Oral
  • Oral ampoule, 23g x 3 
  • Formerly known as Hypostop 
  • Glucogel® should be reserved for patients unable to swallow fluids and is designed to be rubbed onto the patient's gums.
06.01.01.03 GlucoRx ® Finepoint Pen needles 
  • To be considered for first line use (compatable with all UK pen devices)
06.01.04 Glucose Injection 50% 

Green Salisbury

Red Swindon

09.02.02.01 Glucose Intravenous 

Glucose 50%: 50ml Min-I-jet

Additional products for infusion available for use in secondary care  
Glucose 5%  100ml, 250ml, 500ml, 1 litre
Glucose 10%  500ml, 1 litre
Glucose 20%  500ml
Glucose 50%  500ml
13.07 Glutaraldehyde 
  • Glutaraldehyde 10.0% w/v. 10ml bottle.
  • For the topical treatment of warts, especially plantar warts.
01.06.02 Glycerol  
  • 1g, 2g & 4g suppositories.
02.06.01 Glyceryl Trinitrate 
  • Tablets 500 micrograms
  • Spray 400 micrograms
02.06.01 Glyceryl Trinitrate Patch
  • Patches 5mg/24 hours, 10mg/24 hours, 5mg/ 24 hours
  • GWH - For use only by nutrition team.
  • RUH - Short-term secondary care use only.
  • SFT - Non-formulary.

 

02.06.01 Glyceryl Trinitrate solution for infusion
  • GWH and SFT only
  • Non formulary at RUH
  • 1mg/ml, 5mg/ml
01.07.04 Glyceryl Trinitrate 0.4% Rectogesic®
  • 0.4% ointment (Rectogesic®) (Licensed).
  • Please note: This is for use first-line for the treatment of chronic anal fissures prior to considering surgery. Max. duration of use 8 weeks. (Licensed).
07.04.04 Glycine 

 

03.01.04 Glycopyrrolate/ indacaterol inhaler Ultibro Breezhaler®
  • Combination of Indacaterol / Glycopyrronium
  • Breezehaler device with inhalation powder hard capsules each capsule contains equivalent of 110 micrograms of indacaterol and 50 micrograms of glycopyrronium

 

 

03.01.02 Glycopyrronium Seebri breezhaler®

 

  • Each capsule contains 63 micrograms of glycopyrronium bromide equivalent to 50 micrograms of glycopyrronium.
  • Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 55 micrograms of glycopyrronium bromide equivalent to 44 micrograms of glycopyrronium.

 

16.13 Glycopyrronium Sialanar®
  • 320micrograms/ml
  • Licensed for symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders
  • For short term intermittent use
13.12 Glycopyrronium Bromide Hyperhidrosis
  • Various glycopyrronium products are used:
    • 1mg and 2mg tablets
    • 3g/5g/10g powder for solution for iontophoresis
    • unlicensed unlicensed: Solution 0.05% 500mL and topical cream in various strengths (0.5%-4%) (both unlicensed preparation) for use in iontophoretic threatment of hyperhydrosis
  • A specific CCG commissioning policy for the use of this for hyperhydrosis is under development (August 19).
15.01.03 Glycopyrronium Bromide injection
  • 200 micrograms in 1ml amp
  • 600 micrograms in 3ml amp
21 Glycopyrronium Bromide injection
  • 200 micrograms in 1ml amp
  • As an alternative to hyoscine butyl bromide for respiratory tract secretions
  • Can be used in syringe drivers
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
01.05.03 Golimumab Simponi®
  • 50mg or 100mg prefilled pens.
  • 50mg or 100mg prefilled syringes.
  • Please note: Golimumab should be prescribed in accordance with the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway.
10.01.03 Golimumab Simponi®
  • 50mg or 100mg pre-filled pen or syringe
  • Commissioned by NHS England for paediatric indications.
  • Commissioned by CCG for:
    • Psoriatic arthritis in accordance with NICE TAs and local pathway.
    • Rheumatoid arthritis in accordance with NICE TAs and local pathway.
    • Ankylosing spondylitis in accordance with NICE TAs and local pathway.
06.05.01 Gonadorelin 

Red  For assessment of pituitary function (adults).

  • 100 micrograms powder for solution for injection

 

06.07.02 Goserelin Zoladex®

Amber Endometriosis / fibroids

Red RUH/ SFT for fertility

  • 3.6mg    

 

08.03.04.02 Goserelin 
  • 3.6 mg Implant - 1 month
  • 10.8mg Implant - 3 monthly
  • For locally advanced,non-metastatic prostate cancer, as an alternative to surgical castration, or metastatic prostate cancer within the product licence.
13.07 Green tea leaves extract 10% ointment 
  • Second line option for anogenital warts
16.05 Guanfacine Intuniv®
  • Use as per NICE NG87
  • Offer guanfacine to children aged 5 years and over and young people if:
    • they cannot tolerate methylphenidate or lisdexamfetamine or
    • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses.
13.05.03 Guselkumab 
  • Pre-filled syringe 100 mg  in 1 mL 
09.08.02 Haem Arginate Normasang

Red GWH only

  • Concentration for IV infusion: 25mg / ml
  • Non Formulary - RUH and SFT
  • Commissioned by NHS England (for hepatic porphyria) according to NHS England Service Specification. For highly specialised criteria only. 
14.04 Haemophilus influenzae type B Combined Vaccine Menitorix®

Bath - not on formulary

04.02.01 Haloperidol  
  • Tablets 500 micrograms, 1.5mg, 5mg, 10mg
  • Oral liquidSF 1mg in 1ml
  • Notes: Baseline ECG is recommended prior to treatment with haloperidol in all patients, especially in the elderly and patients with a positive personal or family history of cardiac disease or abnormal findings on cardiac clinical examination. 
04.02.01 Haloperidol  
  • Green for palliative care use
  • Red  for rapid tranquillisation
  • Injection 5mg in 1ml for palliative care see guidance for BaNES CCG/RUH patients on link below
  • Injection 5mg in 1ml (Rapid traquilisation) 
  • Notes: Baseline ECG is recommended prior to treatment with haloperidol in all patients, especially in the elderly and patients with a positive personal or family history of cardiac disease or abnormal findings on cardiac clinical examination.

 

21.01 Haloperidol  
  • Community Just In Case Boxes
  • For hallucinations and agitation
04.02.02 Haloperidol Decanoate Haldol ®
  • Amber in rest of Wiltshire, Swindon & BaNEs
  • Red in south Wiltshire via service commissioned at Fountain Way, Salisbury.
  • Haldol® injection 50mg in 1ml
  • Haldol®injection 100mg in 1ml

 

02.08.01 Heparin 
  • Note - variation in TLS across trusts. See individual prescribing policies
  • 1000iu/ml 5ml amps, 5ml vials (contains preservative), 10ml amps, 20ml amps
  • 25000iu/ml – 5000iu/0.2ml amps, 125000iu/5ml vials (contains preservative)

 

 

 

02.08.01 Heparin 
  • Red SFT and RUH
  • Amber GWH as per GWH Line Insertion Service protocol.
  • 50iu/5ml for IV flush
  • 200iu/2ml for IV flush (contains preservative)
14.04 Hepatitis A vaccine Single Component Avaxim®
14.04 Hepatitis A vaccine Single Component Epaxal®
14.04 Hepatitis A vaccine Single Component Havrix Monodose®
  • Adult and Junior
14.04 Hepatitis A vaccine Single Component Vaqta®
  • Adult and Paediatric
14.04 Hepatitis A vaccine with Hepatitis B vaccine  Twinrix®
  • Adult and Paediatric 
  • Hepatitis B NOT routinely available on the NHS for the purposes of travel therefore combination vaccine not commissioned locally on the NHS.
14.04 Hepatitis A vaccine with Hepatitis B vaccine  Ambirix ®
  • Hepatitis B NOT routinely available on the NHS for the purposes of travel therefore combination vaccine not commissioned locally on the NHS.
14.04 Hepatitis A vaccine with typhoid vaccine Hepatyrix®
14.04 Hepatitis A vaccine with typhoid vaccine VIATIM®
14.05.02 Hepatitis B immunoglobulin HBIG

 

  • Advice on the usage and availability can be obtained from the Microbiologist. 
14.04 Hepatitis B vaccine Single Component Engerix B®
  • This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
14.04 Hepatitis B vaccine Single Component Fendrix®
  • Bath - not on formulary
  • This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
14.04 Hepatitis B vaccine Single Component HBvaxPRO®
  • This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
07.04.04 Hexaminolevulinate 
  • SFT only
  • Non formulary at RUH and GWH
13.11.02 Hibitane Obstetric ® 
  • Chlorhexidine gluconate 10 mg per 1 gram
  • 250ml
13.10.05 Histoacryl ® 
  • Enbucrilate (Histoacryl®) adhesive  5 x 200mg, 10 x 200mg,5 x 500mg
  • Tissue adhesives are used for closure of minor skin wounds and for additional suture support/ This should be applied by a trained healthcare professional

 

06.05.01 Human Menopausal Gonadotrophins Menopur®
  • Not on formulary GWH
  • powder for reconstitution 75units FSH & 75units LH, 150units FSH & 150units LH, 600units FSH & 600 units LH, 1200units FSH 1200units LH.
14.05 Human normal immunoglobulin 
  • Commissioned by NHS England in line with 'Updated Commissioning Criteria for the use of therapeutic immunoglobulin (Ig) in immunology, haematology, neurology and infectious diseases in England (January 2019)'. For indications not covered by these commissioning criteria, commissioning is in line with the 'DoH Clinical Guidelines for Immunoglobulin Use (second edition update, July 2011)'.

  • Note: Guidance from NHS England (October 2017) states that the recommended dose of IVIg for the treatment of ITP is a single dose of 1g/kg. A repeat dose of 1g/kg should only be considered at day 7 if there is a failure to achieve a haemostatically adequate platelet count (approval from the local immunoglobulin approval panel is required if earlier use is contemplated in cases of exceptional clinical circumstances such as active mucosal bleeding or the need for emergency surgery).

  • Prescribe by brand. Various brands available.
14.04 Human papilloma virus vaccine Gardasil®
  • Vaccine of choice for the national immunisation program (see Green Book)
  • a quadravalent vaccine which also covers anal lesions, anal cancer and   genital warts
  • Gardasil® is currently the only HPV vaccine supplied for the national HPV programme (for both adolescents and MSM).

02.05.01 Hydralazine 
  • Tablets 25mg, 50mg
  • Injection 20mg ampoule
  • Note: Hydralazine may be used in combination with long acting nitrates in moderate to severe chronic congestive cardiac failure when an ACE inhibitor is contra-indicated or not tolerated.
  • Note: Hydralazine injection is Red at RUH

 

01.05.02 Hydrocortisone  Colifoam®
  • 10% rectal aerosol. 
06.03.02 Hydrocortisone Alkindi®
  • On formulary in Salisbury and Swindon only - for doses less than 5mg 
06.03.02 Hydrocortisone 
  • 10mg, 20mg (M/R tablets (Plendaren®) are NOT included in the formulary)
13.04 Hydrocortisone 
  • Mild potency steroid
  • Ointment: 0.5%, 15g, 30g, 1% 15g, 30g, 50g, 2.5%, 15g
  • Cream: 0.5%, 15g, 30g, 1% 15g, 30g, 50g, 2.5%, 15g
  • Apply thinly once or twice a day
  • Note: Hydrocortisone ointment & cream (1%) is available over the counter  for allergic contact dermatitis, irritant dermatitis, insect bite reactions and mild to moderate eczema. It cannot be sold for application to eyes/face, anogenital region, on broken or infected skin or for use in pregnancy or children under 10 years.
10.01.02.02 Hydrocortisone acetate Hydrocortistab®
  • 25mg/1ml injection
13.04 Hydrocortisone 1% with Clotrimazole 1% Canesten HC®
  • Mild potency steroid
  • Cream, Hydrocortisone 1%, clotrimazole 1% 30g
  • Fungal infections accompanied by inflammation. Apply thinly twice daily for up to 7 days.
13.04 Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort®
  • Mild potency steroid
  • Cream or ointment, Hydrocortisone 1%, miconazole nitrate 2% 30g
  • Cream also comes in a 15g size which is more expensive than the 30g size (Aug 19)
  • For facial seborrhoeic dermatitis, paronychia, intertrigo
13.04 Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H ®
  • Mild potency steroid
  • Cream, Hydrocortisone 1%, fusidic acid 2% 30g, 60g
  • For infected eczema at thin skin sites in infants and children (where S Aureus is fucidin-sensitive).
  • Not for long-term use.
12.01.01 Hydrocortisone Acetate 1% with Gentamicin 0.3% ear drops
  • Previously Gentisone HC (discontinued)
13.04 Hydrocortisone Butyrate Locoid Lipocream®
  • Potent steroid
  • Lipocream 30g, 60g
  • Instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.
12.03.01 Hydrocortisone muco-adhesive buccal tablets 
  •  2.5mg   (as sodium succinate)  
  • P medicine can be purchased OTC
11.04.01 Hydrocortisone sodium phosphate. 
  • 3.35mg/ml eye drops 0.4ml unit dose
06.03.02 Hydrocortisone sodium succinate Solu-Cortef
  • Green Salisbury and Swindon (and Bath for anaphylaxis )
  • Amber BCAP In patients with known adrenal insufficiency, hydrocortisone injection is TLS amber.
  • Endocrinology will remain responsible for patient education, training in recognition of an Addisonian crisis and injection technique and the initial supply of an emergency injection kit.
  • Primary care can replace supplies of hydrocortisone and water for injection that have been used or expired following clear communication to the GP via a clinic letter.
  • Suitable contents of an emergency injection kit include:
    - 3-5 vials of hydrocortisone sodium succinate 100mg (Solu-Cortef®)
    - 3-5 vials of 2mL water for injection
    - Intramuscular needles and 2mL syringes
    - 1L Sharps box
    Further information for patients and prescribers can be found at https://www.addisons.org.uk/articles.html/articles-for/emergencies/obtaining-your-emergency-injection-kit-r36 
  • Please see the addisons.org.uk website for videos explaining how to give an emergency injection of hydrocortisone sodium succinate in the event of an adrenal crisis.
  • Each vial contains hydrocortisone sodium succinate 133.7 mg equivalent to hydrocortisone 100 mg.
  • Red  Bath - all other indications

 

12.01.01 Hydrocortisone with Antibacterial Otosporin®
  • Hydrocortisone 10 mg /Neomycin sulfate 3400 unit /Polymyxin B sulfate 10000 unit per 1 ml
  • 10ml

 

12.03.04 Hydrogen Peroxide  
  • Use as mouthwash
  • 20vols (6%) 
  • 10vols (3%)
13.02.01 Hydromol  

GREASY MOISTURISER FOR SEVERE DRY SKIN

  • Ointment 125g, 500g, 1kg
  • Excellent greasy emollient for night time or very dry skin. Prescribe with a less greasy emollient for day time use.
  • Can be used as soap substitute
  • NOTE: Hydromol CREAM is non-formulary due to cost.
09.01.02 Hydroxocobalamin 
  • 1mg in ml 
  • Intramuscular injection
08.01.05 Hydroxycarbamide 
  • Red  RUH 
  • Amber with Shared Care Salisbury and Swindon
  • 500mg capsules
13.05.03 Hydroxycarbamide 
  • Dermatology use: off-label.
  • Capsules 500mg  
10.01.03 Hydroxychloroquine 
  •  Amber with Shared Care - Bath, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH)
  •  Red - Swindon DAWN patients
  • 200mg tablets
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information

 

13.05.03 Hydroxychloroquine 
  •  200mg  

   Red -In Swindon only for DAWN patients.

03.04.01 Hydroxyzine 
21 Hyoscine Butlybromide  
  • For respiratory tract secretions
  • For colic/reduce secretions in inoperable bowel obstruction
  • See SPS website for Stock shortages 
  • Can be used in syringe drivers
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
21.01 Hyoscine Butlybromide  
  • Community Just In Case Boxes
  • For respiratory tract secretions
  • For colic/reduce secretions in inoperable bowel obstruction
01.02 Hyoscine Butylbromide Tablet & Injection
  • 10mg tablets. 
  • 20mg/ml injection (Salisbury & Swindon only).
  • Please note: Hyoscine butylbromide injection is also available for use in Palliative Care. Please refer to our Palliative Care chapter.
04.06 Hyoscine Hydrobromide 
  • Red 400mcg per ml injection
  • Green if for palliative care use. 
04.06 Hyoscine Hydrobromide 
  • 150mcg ,300mcg tablet
  • Scopoderm® TTS Patch 1mg/ 72hrs
15.01.03 Hyoscine Hydrobromide injection
  •  400 micrograms in 1ml amps
16.13 Hyoscine hydrobromide Scopoderm®
  • 1.5mg patch
  • Unlicensed indication
  • Only licensed from 10 years for travel sickness.
21 Hyoscine Hydrobromide  
  • For respiratory tract secretions
  • Can be used in syringe drivers
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
21.01 Hyoscine Hydrobromide  
  • Community Just In Case Boxes
  • For respiratory tract secretions
11.08.01 Hypromellose 
  • 0.3% drops 10ml
11.08.01 Hypromellose 
  • 0.3% drops 10ml
  • Evolve is the most cost-effective preservative-free hypromellose preparation in primary care
  • Swindon only - use Hydromoor brand in secondary care
06.06.02 Ibandronic Acid 

At RUH and GWH only

  • 1mg/ml injection licensed for:
    • Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases
    • Treatment of tumour-induced hypercalcaemia with or without metastases

 

06.06.02 Ibandronic Acid 

Green Swindon

Amber Salisbury

Amber with Shared Care Bath

  • 150mg tablet licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fracture
  • 150mg tablet once a month. The tablet should preferably be taken on the same date each month.

 

08.03.04.01 Ibandronic Acid 
  • Amber with Shared Care Bath only -Adjuvant bisphosphonates for breast cancer (see shared care agreement)
  • Red GWH for use as an oral alternative to disodium pamidronate in patients with metastatic breast cancer. For use by oncology only.
  • Ibandronic Acid 'off label' indication
  • Tablets 50mg daily

 

08.01.05 Ibrutinib 
07.01.01.01 Ibuprofen Pedea® injection
  • GWH and SFT only
  • Non formulary at RUH
10.01.01 Ibuprofen 
  • 200mg, 400mg and 600mg tablets
  • Oral suspension
  • For minor conditions associated with pain and inflammation, patients should self-care in the first instance.

 

10.03.02 Ibuprofen 
  • 100g gel containing 5% ibuprofen
  • Fenbid brand is most cost effective    
  • NICE clinical guideline 177 Osteoarthritis: Feb 2014 Paracetamol and/or topical NSAIDs should be offered to patients with knee or hand osteoarthritis before considering oral NSAIDs, COX-2 inhibitors or opioids
03.04.03 Icatibant Firazyr®
  • Injection 10mg/ml - 3ml pre-filled syringe

  • Non Formulary RUH 
  • Available from SFT
  • Commissioned by NHS England for Hereditary Angioedema and Acquired Angioedema for acute treatment or short-term prophylaxis prior to planned procedures. See NHS England Policy: B09/P/b.

    Restricted Item May only be initiated by (or on advice of) Specialist Centres where:

  • C1inh is unsuitable due to adverse effects or administration difficulties
  • the specialist clinician determines that Icatibant is the most suitable or cost-effective preparation for the patient
    Drug costs for emergency use in other hospitals will be reimbursed through the Specialist Centre
08.01.02 Idarubicin 
  • 5mg, 10mg and 25mg capsules
  • 5mg and 10mg injection
02.08.03 Idarucizumab 
  • 2.5g vial for intravenous injection
  • When rapid reversal of dabigatran is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. On Consultant Haematologist advice only.

 

08.01.05 Idelalisib 
  • 100mg and 150mg tablets
08.01.01 Ifosfamide 
  • 1g and 2g injection
02.05.01 Iloprost injection  
  • When used for digitial ischaemia and ulceration in Raynaud's Disease and scleroderma as per NHSE policy below within Specialist Services
08.01.05 Imatinib Gilvec®
  • 100mg and 400mg tablets
  • Ensure correct brand supplied

 

 

08.01.05 Imatinib (Generic) 
  • 100mg and 400mg tablets
  • Also for treatment of Philadelphia Positive Guidelines ALL as per BCSH Guidelines

 

05.01.02.03 Imipenem with Cilastatin  Injection
  • Used in GWH and SFT 
  • RUH – not routinely stocked
  • 500mg/500mg powder for solution for infusion
04.03.01 Imipramine 
  • Tablets 10mg
  • Liquid SF   25mg/5ml
04.07.03 Imipramine 
  • Not licensed for neuropathic pain but a widely accepted treatment (off-label).
13.07 Imiquimod 
  • Cream 5% 12 sachets
  • Genital warts. Apply 3 times a week until lesions resolved (maximum 16 weeks) 
  • Note: Imiquimod cream is also licensed for the treatment of superficial basal cell carcinoma and actinic keratosis-see seperate entry in 13.8.1 for its traffic light status. 
13.08.01 Imiquimod Aldara®
  • Green Photodamage/Actinic Keratoses. Apply 3 times a week for 4 weeks. 
  • Amber Superficial Basal Cell Carcinoma. Apply daily for 5 nights of each week for 6 weeks. (Initiation by consultant dermatologist or GP with special interest in Dermatology)
  • See entry in 13.7 for its use in the treatment of anogenital warts
  • Cream 5% 12 sachets Aldara®
13.02.01 Imuderm ®  cream
  • Use after other emollients have been tried and failed to control symptoms. Expensive emollient. 
  • Urea 5%, Glycerine 5%
  • Available as 500g pump pack
  • Preparations containing lauromacrogols and/or urea are useful to stop itching or aid hydration.
03.01.01.01 Indacaterol Onbrez Breezhaler®
  • No new prescribing. Existing patients only - see notes above.
  • Inhalation powder, hard capsule 150, 300 micrograms (via Onbrez Breezhaler® device)

 

 

02.02.01 Indapamide 
  • Tablets 2.5mg
  • Note: Indapamide 2.5mg daily is considered the optimal dose for hypertension
07.01.01.01 Indometacin Indocid PDA®
  • GWH and RUH only
  • Non formulary SFT
10.01.01 Indometacin 
  • Non formulary in Salisbury
  • 25mg and 50mg
  • 100mg suppositories
13.11.01 Industrial Methylated Spirit BP 
  • Solution 95%
14.04 Infanrix hexa ® 
  • Powder and suspension for suspension for injection.
  • Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).
  • Infanrix hexa is indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b.
  • (schedule at 2, 3, 4 months)
14.04 Infanrix IPV ® 
  • Infanrix®-IPV, suspension for injection in pre-filled syringe
  • Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed) (schedule between 3yrs & 4/12 to 5 years)
01.05.03 Infliximab Remsima®Inflectra®Remicade®
  • 100mg vials.
  • Prescribe BY BRAND. Biosimilar first-line option.
  • Please note: Infliximab should be prescribed in accordance with either the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway or the BSW STP Crohn's Disease Biologic / Biosimilar Commissioning Pathway.
10.01.03 Infliximab Remsima®Inflectra®Remicade®
  • 100mg powder for concentrate for solution for infusion
  • All products should be prescribed by brand. Biosimilars should be used 1st line.
  • For rheumatoid arthritis in accordance with NICE recommendations TA130 and TA195 and local pathway.
  • For ankylosing spondylitis in accordance with NICE TA145 and TA140 and local pathway.
  • For psoriatic arthritis in accordance with NICE TA199 and local pathway.
  • Commissioned by NHS England for paediatric indications (where adult TA available). According to adult TAs (TA130, TA134, TA140, TA143, TA163, TA199) for the range of arthritis-related indications. 
  • Check Trust contracting arrangements first before prescribing 
  • Not routinely commissioned by NHS England for: connective tissue disease - interstitial lung disease, graft versus host disease, renal indications, sarcoidosis, progressive pulmonary sarcoidosis, uveitis or hidradenitis suppurativa.  

 

13.05.03 Infliximab Remsima®Inflectra®
  • Biosimilar available: Remsima® or Inflectra® used locally.
  • Prescribe by brand.  Biosimilar first-line option.
  • Originator product: Remicade usually used for patients that do not tolerate or do not respond to a biosimilar version.
  • Injection 100mg vial
14.04 Influenza vaccine  
  • Brands include: Inactivated Influenza Vaccine (Split Virion), Agrippal CSL, Inactivated Influenz Vaccine Enzira Imuvac Influvac Optaflu, Fluarix Tetra, Intanza, Fluad
14.04 Influenza vaccine ®  Fluenz Tetra
  • Primary Care Only : Please note that flu vaccines for children should be ordered via IMMFORM and should NOT be reclaimed via NHS prescription services (PPA).
06.01.01.03 Injection Device JuniorSTAR®
06.01.01.03 Injection Device Autopen 24 (1 and 2 unit)®
06.01.01.03 Injection Device ClikSTAR®
06.01.01.03 Injection Device NovoPen 5
06.01.01.03 Injection Device NovoPen Echo®
06.01.01.03 Injection Device HumaPen Savvio®
06.01.01.03 Injection Device Autopen Classic (1 and 2 unit)®
08.01.05 Inotuzumab Ozogamicin 
  • 1mg infusion

 

06.01.01.01 Insulin Humulin® S
  • Type 2 diabetes only
06.01.01.01 Insulin Actrapid®
  • Type 2 diabetes only
06.01.01.01 Insulin Insuman® Rapid
  • Type 2 diabetes only
06.01.01.01 Insulin 500 units in 1mL Humulin R®
  • GWH only. For severe insulin resistance.
  • Approx £800 (1x 20 ml vial) – imported unlicensed from US
  • HUMULIN R IS 5 TIMES THE STRENGTH OF OTHER INSULINS - TAKE GREAT CARE WHEN PRESCRIBING OR ADMINISTERING!
06.01.01.01 Insulin Aspart  NovoRapid®
  • Type 1 diabetes only
06.01.01.01 Insulin aspart Fiasp®
  • Type 1 diabetes only
  • Specialist recommended only for patients with difficult to manage significant post prandial hyperglycaemia
  • The safety and efficacy of Fiasp in children and adolescents below 18 years of age have not been established (see SPC).
  • SAFETY INFORMATION: From 1 June 2018, the colour of Fiasp cartridges, pre-filled pens and vials is changing from yellow to red and yellow, following cases where patients have mistakenly injected it instead of Tresiba or vice versa.
06.01.01.02 Insulin degludec Tresiba®
  • 100 units per ml format: Please note different prescribing criteria for each locality and ensure correct strength is prescribed.

BCAP - Type 1 diabetes only

  • This is reserved as a last resort when all other options have been trialled.
  • Criteria for use:
    •  Treatment limiting recurrent severe hypoglycaemia despite optimized analogue basal bolus insulin treatment
    • Have recurrent disabling hypoglycaemia prior to insulin pump therapy
    • Patients with recurrent DKA due to delayed/irregular  administration due to compliance or lifestyle factors requiring hospital admission
  • Review criteria (at 6/12):

    • No. of episodes of hypoglycaemia
    • Acute unplanned admissions
    • Improved blood glucose control

Salisbury 

  • Only for Type 1 diabetic patients with treatment limiting recurrent hypoglycaemia despite optimal treatment prior to insulin pump therapy, patients with recurrent DKA requiring hospital admission due to delayed administration. Patients receiving insulin form a carer where irregular administration times may contribute to hyper/hypoglycaemia
  • Only for Type II diabetic patients with significant insulin resistance requiring over 200units per day and over 80units per injection of basal insulin

Swindon - Type 1 only

  • This is reserved as a last resort when all other options have been trialed
  • Criteria for use:
    • Treatment limiting recurrent severe hypoglycaemia despite optimized analogue basal bolus insulin treatment
    • Have recurrent disabling hypoglycaemia prior to insulin pump therapy
    • Patients with recurrent DKA due to delayed/irregular  administration due to compliance or lifestyle factors requiring hospital admission

Review criteria (at 6/12):

  • No. of episodes of hypoglycaemia
  • Acute unplanned admissions
  • Improved blood glucose control 

 

06.01.01.02 Insulin degludec Tresiba®
  • 200 units per ml format: Please note different prescribing criteria for each locality and ensure correct strength is prescribed.

Bath - not on formulary at this strength

Salisbury 

Criteria for use

  • Only for Type 1 diabetic patients with treatment limiting recurrent hypoglycaemia despite optimal treatment prior to insulin pump therapy, patients with recurrent DKA requiring hospital admission due to delayed administration. Patients receiving insulin form a carer where irregular administration times may contribute to hyper/hypoglycaemia
  • Only for Type 2 diabetic patients with significant insulin resistance requiring over 200units per day and over 80units per injection of basal insulin

Swindon

This is not a standard choice and use should be minimised.

Criteria for use in type 2 only:

  • High volume of 100 unit/ml injections of insulin with dose greater than 1.2 units /kg body weight.
  • Morbidly obese (BMI >35)
  • Severe insulin resistance
  • Poor blood glucose control (HbA1c >70)
  • Pt must be able to selfadminister

Swindon Review criteria (at 6/12):

  • Improved blood glucose control
06.01.02.03 Insulin degludec and liraglutide Xultophy®

RUH only - not on formulary GWH or SFT

  • Xultophy®  insulin degludec (1 unit/dose-step) with liraglutide (36 micrograms/dose-step) injection
  • For Secondary Care prescribing Only (discrete group of Type 2 Diabetics) Review in January 2017
  • Multi-dose prefilled pen containing 100 units of insulin degludec and 36mg liraglutide per ml  3 x 3ml (300 dose step) prefilled pens
  • Single daily injection
06.01.01.02 Insulin Detemir Levemir®
  • Type 1 and Type 2 diabetes
  • includes Innolet
06.01.01.02 Insulin Glargine Toujeo®

Amber - Bath and Salisbury

Non-formulary - Swindon

  • 300 units per ml HIGH STRENGTH. Ensure correct strength is prescribed, also available as 100 units per ml.
  • Toujeo 100units/ml and 300units/ml are not bioequivalent and so are not interchangeable without dose adjustment.
  • Bath Criteria for use:
    • Pt must be able to self-administer
    • High volume of 100 unit/ml injections of insulin with dose greater than 1.2 units /kg body weight.
    • Morbidly obese (BMI >35)
    • Severe insulin resistance
    • Poor blood glucose control HbA1c >70
  • Specialist Initiated Review criteria (at 6/12):
    • Improved blood glucose control
  • July 2019 CAUTION PRODUCT SELECTION:
    • Toujeo® Solostar is the only Toujeo® formulation on formulary.
    • Toujeo® SoloStar 300units/ml. Each pen       contains 450units/1.5ml. This device uses a 1-unit dosage step       increments.  
    • A new product is now available, Toujeo®       DoubleStar Strength 300units/ml. Each pen contains       900units/3ml. This device uses 2-unit dosage step increments. Toujeo®  Doublestar is non-formulary and should not currently be prescribed. 
06.01.01.02 Insulin Glargine Lantus®
  • Type 1 and Type 2 diabetes
  • EXISTING patients/those with dexterity problems and needing greater than 60 units per dose
06.01.01.02 Insulin Glargine biosimilar Abasaglar®
  • Formulary choice for new patients needing a basal analogue insulin. 
  • Type 1 and Type 2
06.01.01.01 Insulin Glulisine Apidra®
  • Type 1 diabetes only
06.01.01.01 Insulin Lispro 100 units/ml Humalog®
  • Type 1 diabetes only
06.01.01.01 Insulin Lispro Sanofi 100 units/ml 
  • GWH only
  • Type 1 diabetes only
08.02.04 Interferon Beta Rebif®
  • 22micrgoram/0.5ml and 8.8microgram/0.2ml cartridges and pre-filled pens/syringes
  • 44microgram/0.5ml cartridges and pre-filled pens/syringes
08.02.04 Interferon Beta Extavia®
  • Extavia® 250 microgram/ml powder and solvent for solution for injection
  • After reconstitution, each ml contains 250 microgram (8.0 million IU) of recombinant interferon beta-1b
08.02.04 Interferon Beta 
  • 30microgram/0.5ml pre-filled (6 million units) syringes
07.03.02.03 Intra-uterine Progestogen Only System Levosert®
  • Intra-uterine system containing 52mg levonorgestrel releasing 20micrograms per 24 hours
  • Levosert is effective for 4 years and licensed for use as a contraceptive and for the treatment of primary menorrhagia.
07.03.02.03 Intra-uterine Progestogen Only System Kyleena®
  • Intra-uterine system containing 19.5mg levonorgestrel releasing 17.5micrograms per 24 hours.
  • Kyleena is effective for 5 years and licensed for use as a contraceptive only.
07.03.02.03 Intra-uterine Progestogen Only System Jaydess®
  • Intra-uterine system containing 13.5mg of levonorgestrel.
  • Jaydess is effective for 3 years and licensed for use as a contraceptive only.
07.03.02.03 Intra-uterine Progestogen Only System Mirena®
  • Intra-uterine system releasing 20 micrograms of levonorgestrel per 24 hours
  • Mirena is effective for 5 years and licensed for use as a contraceptive and for the treatment of primary menorrhagia. Also licensed for use in HRT see 6.4.1.2
06.02.02 Iopanoic Acid  
  • 500mg
  • GWH - Useful in thyroid storm.
  • NOTE not on formularly in RUH or SFT
08.01.05 Ipilimumab 
03.01.02 Ipratropium Bromide Atrovent®
  •  Inhaler 20 micrograms/dose

 

12.02.02 Ipratropium Bromide 0.03%  
  • nasal spray 0.03%      
  • Useful for watery rhinorrhoea
03.01.02 Ipratropium Bromide Nebuliser Solution Ipratropium Steri-Neb®
  • Green Bath
  • Green Salisbury
  • Amber Swindon
  • Nebuliser solution 250 micrograms in 1 ml, 500micrograms in 2ml

 

03.01.04 Ipratropium bromide with salbutamol Combivent®
  • Green Bath
  • Green Salisbury
  • Non-formulary - Swindon
  • Ipratropium bromide 500micrograms & salbutamol sulphate 2.5mg / 2.5ml Unit Dose Vial  (nebulised)
  • NB - less suitable for prescribing. Licensed for bronchospasm in patients with COPD. BNF states flexibility of dosing is lost with a compound bronchodilator but it may be appropriate for patients stabilised on the individual components in the same proportion.
  • Consider if compliance an issue.

 

08.01.05 Irinotecan hydrochloride 
  • 500mg/25ml, 300mg/15ml, 100mg/5ml and 40mg/2ml infusion
09.01.01.01 Iron and Folic Acid Pregaday®
  •  ferrous fumarate (equivalent to 100mg of iron), folic acid 350 micrograms

 

 

Iron Salt Content Amount Ferrous iron / day
Ferrous Sulphate Tablets 200mg three times daily 195mg
Ferrous Fumarate Tablets 210mg three times daily 204mg
Ferrous Fumarate Syrup 280mg (10ml) twice daily 180mg
Sodium Feredate Liquid 380mg (10ml) three times daily 165mg
09.01.01.02 Iron Dextran CosmoFer®

Red SFT and GWH

  • 50mg/ml

RUH not on formulary

Anaphylactoid reactions can occur with parenteral administration of iron complexes. Facilities for cardio-pulmonary resuscitation must be at hand.

09.01.01.02 Iron Isomaltoside Monofer®
  • RUH only - Treatment of iron-deficiency when oral preparations are ineffective and cannot be used
  • 100mg/ml for slow intravenous injection or intravenous infusion 
  • GWH/SFT - Not on formuary
  • Anaphylactoid reactions can occur with parenteral administration of iron complexes. Facilities for cardio-pulmonary resuscitation must be at hand.
09.01.01.02 Iron Sucrose Venofer®
  • 100mg/5ml
  • GWH only - For use only on Renal Unit in GWH
  • RUH/SFT not on formulary
  • Anaphylactoid reactions can occur with parenteral administration of iron complexes. Facilities for cardio-pulmonary resuscitation must be at hand.
05.02 Isavuconazole 
  • Formulary at RUH only
  • Non Formulary GWH SFT

 

  • 100 mg hard capsules
  • 200 mg powder for concentrate for solution for infusion
  • To treat mucormycosis as per Trust Guidelines

 

15.01.02 Isoflurane 
  • 250ml
13.02.01 Isomol ® gel

VERY LIGHT MOISTURISER FOR MILD DRY SKIN

  • 500g flexi dispenser which can be used instead of a pump by care homes
  • Low paraffin content (15%)
  • Primary care Doublebase® gel alternative
  • Useful for dermatitis of the hands and as a light moisturiser for the body
05.01.09 Isoniazid 
  • Tablets 50mg, 100mg
  • Elixir (SF) 50mg/5ml (unlicensed)
06.01.01.02 Isophane Insulin Insulatard®
  • Type 2 diabetes only
06.01.01.02 Isophane Insulin Humulin® I
  • Type 2 diabetes only
06.01.01.02 Isophane Insulin Insuman® Basal
  • Type 2 diabetes only
  • NOTE - Insuman Basal vials are being discontinued.
02.07.01 Isoprenaline 
  • Available as an unlicensed product
13.11.01 Isopropyl Alcohol 
  • Hard surface wipes
02.06.01 Isosorbide Dinitrate 
  • RUH only
  • Non formulary at GWH and SFT
  • 10mg in 10ml, 25mg in 50ml (half strength)
02.06.01 Isosorbide Mononitrate Tablet
  • Tablets 10mg, 20mg
  • If a once daily Modified Release preparation is required, for example patients who have problems with compliance, specify brand. 
  • Chemydur® 60XL MR tabs 60mg or Monomax® XL MR tabs 60mg or Monomil® XL MR tabs 60mg are preferred brands of choice in primary care. 

 

13.06.02 Isotretinoin 
  • Capsules 5mg, 10mg, 20mg
  • Women of child bearing age must be enrolled in the pregnancy prevention program.
01.06.01 Ispaghula Husk 
  • 3.5g sachets.
05.02 Itraconazole 
  • For use by haematology
  • GWH and SFT only
  • Please note liquid is expensive
05.02 Itraconazole 
  • Capsules 100mg
  • Treatment for most fungal skin and nail infections are a low clinical priority for local CCGs.

 

02.06.03 Ivabradine 
  •  Tablets 5mg, 7.5mg
  • To be used only for symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm for whom heart rate control is desirable and for whom beta-blockers and calcium-channel blockers are inappropriate or not tolerated.
  • Please see MHRA Drug Safety Update for information on risk of bradycardia.
02.06.03 Ivabradine 
  • Tablets 5mg, 7.5mg
  • Use according to NICE TA267 below. In patients with New York Heart Association (NYHA) class II or IV stable chronic heart failure with systolic dysfunction and who are in sinus rhythm with a heart rate of 75 beats per minute (bpm) or more and who are given ivabradine in combination with standard therapy including beta-blocker therapy, angiotensin-converting enzyme (ACE) inhibitors and aldosterone antagonists, or when beta-blocker therapy is contraindicated or not tolerated and with a left ventricular ejection fraction of 35% or less. 
  • Ivabradine should only be initiated after a stabilisation period of 4 weeks on optimised standard therapy with ACE inhibitors, beta-blockers and aldosterone antagonists.
  • Ivabradine should be initiated by a heart failure specialist with access to a multidisciplinary heart failure team. Dose titration and monitoring should be carried out by a heart failure specialist or in primary care by either a GP with a special interest in heart failure or a heart failure specialist nurse.
03.07 Ivacaftor 

 

 

05.05.06 Ivermectin 
  • GWH only for filaricide infections
13.06 Ivermectin 
  • Cream 1% 30g
  • Treatment of moderate to severe inflammatory lesions of rosacea
  • Second line to metronidazole

 

13.10.04 Ivermectin 
  • GWH for norwegian scabies
  • Ivermectin is unlicensed in the UK and can be supplied from 'special order' manufacturers or specialist importing companies.
08.01.05 Ixazomib 
  • 2.3mg, 3mg and 4mg capsules
  • To treat relapsed/defractory myeloma in combination with Lenalidomaide and Dexamethasone
  • To treat multple myeloma via the Cancer Drugs Fund
10.01.03 Ixekizumab  Taltz®
  • 80mg solution for injection in pre-filled syringe or pen
  • CCG commissioned as per NICE TA537 for psoriatic arthritis
13.05.03 Ixekizumab  
  • Pre-filled syringe contains 80 mg ixekizumab in 1 ml.
  • Use in accordance with NICE guidance
13.08.02 Keromask ® 
  • Finishing Powder and Masking Cream
15.01.01 Ketamine  
  • 200mg in 20ml vial
  • 500mg in 10ml vial
13.09 Ketoconazole 
  • Ketoconazole 2% 120ml
  • For seborrhoeic dermatitis apply  twice weekly for 2-4 weeks (prophylaxis apply once every 1-2 weeks); treatment of ptyriasis versicolor apply once daily for maximum 5 days
  • Can be sold to the public for prevention and treament of dandruff and seborrheic dermatitis of the scalp as a shampoo - see BNF for details 
11.08.02 Ketorolac 
  • 0.5% ophthalmic drops
  • Note at GWH - For inflammation requiring extended treatment (up to 21 days) following ocular surgery
15.01.04.02 Ketorolac 
  • 30mg in 1ml amp
  • Licensed for use in short-term management of moderate to severe post operative pain only.
  • Contains a small amount of ethanol per dose (100mg)
  • See palliative care section Chapter 21
21 Ketorolac 
  • 30mg in 1ml amp
  • GWH: ONLY for specialist initiation and ongoing prescription by the Palliaitve Care team, for the treatment of neuropathic cancer pain and bone pain in palliative care patients by sc injection / sc infusion (off-label use).
11.04.02 Ketotifen Ketofall®
  • Salisbury only
  • Non formulary in Bath and Swindon
  • 0.25mg/ml single dose unit drops SPC here
01.06.05 Klean-prep® Oral powder
  •  69g sachet containing polyethylene glycol 3350 59g, potassium chloride 742.5 mg, sodium bicarbonate 1.685g, sodium chloride 1.465g & sodium sulfate anhydrous 5.685g.
02.04 Labetalol 
  • Tablets 100mg, 200mg, 400mg

 

02.04 Labetalol 
  • 100mg/20ml
04.08.01 Lacosamide  
  • Tablets 50mg, 100mg, 150mg, 200mg (Category 3 MHRA)
  • For the adjunctive treatment of partial seizures with or without secondary generalisation
01.06.04 Lactulose 
  • 3.1-3.7g/5ml oral solution.
  • Please note: Lactulose takes up to 48 hours to work, making it unlikely to produce immediate relief, but is often prescribed “when required”. It can be unpleasant to take and compliance may be a problem. Its main clinical benefit is in the management of hepatic encephalopathy.
05.03.03.01 Lamivudine 
  • Tablets 100mg, 150mg, 300mg
  • Oral solution 10mg/ml

 

04.02.03 Lamotrigine 
  • Tablet 25mg, 50mg, 100mg, 200mg 
  • Dispersible tablet 2mg, 5mg, 25mg, 100mg  
  • Prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes

 

04.08.01 Lamotrigine 
  • Tablet 25mg, 50mg, 100mg, 200mg (Category 2 MHRA)
  • Dispersible tablet 2mg, 5mg, 25mg, 100mg  
06.01.01.03 Lancets 
06.01.01.03 Lancets 
06.01.01.03 Lancets Accu-check Fastclik Lancets ®
08.03.04.03 Lanreotide 
  • Amber Swindon - relief of symptoms associated with acromegaly
  • Commissioned by NHS England, as per agreed Trust Guidelines. Use product with lowest procurement cost.
  • 60mg/0.5ml, 90mg/0.5ml and 120mg/0.5ml pre-filled syringe
  • Carcinoid Syndrome and Neuroendocrine Tumours
  • For the treatment of acromegaly
01.03.05 Lansoprazole 
  • 15mg & 30mg capsules.
  • 15mg & 30mg oro-dispersible tablets.
  • Please note: Lansoprazole oro-dispersible tablets are ONLY for use in patients with swallowing difficulties.
09.05.02.02 Lanthanum 

Amber with Shared Care  Salisbury and Bath

 

  • Bath: Fosrenol Tablets (chewable) 500mg, 750mg, 1g
  • See BNSSG shared care guidelines
  • For intiation by Renal team only (3rd line treatment)
11.06 Latanoprost 
  • 50microgram/ml ophthalmic drops
  • Preservative free available if indicated as per BSW glaucoma guidance

 

11.06 Latanoprost 0.005% with Timolol 0.5% 
  • Latanoprost 50micrograms, Timolol 5mg/ml
  • Note: Fixapost® preservative free included on formulary at SFT 
05.03.03.02 Ledipasvir and Sofosbuvir Harvoni®
  •  Tablets 90mg/400mg
10.01.03 Leflunomide 
  •  Amber with Shared Care - Bath, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH)
  •  Red - Swindon DAWN patients
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information
  • 10mg, 15mg, 20mg and 100mg tablets
08.02.04 Lenalidomide 
09.01.06 Lenograstim Granocyte®

SFT and RUH

GWH - not on formulary

  • Pre-filled syringe 13.4 million-unit (105 micrograms), 33.6 million-unit (263 micrograms)
  • Recombinant human granulocyte-colony stimulating factor (rHuG-CSF)  
  • Commissioned by NHS England for neutropenia according to Trust Guidelines
  • RUH Used for the mobilisation of STEM cells.
08.01.05 Lenvatinib  
  • 4mg and 10mg capsules
  • Different brand depending upon indication

 

08.01.05 Lenvatinib with Everolimus 
  • 4mg and 10mg capsules
  • Different brand depending upon indication

 

02.06.02 Lercanidipine 
  • Swindon only
  • Non formulary in Bath and Salisbury
  • 10mg and 20mg tablets
08.03.04.01 Letrozole 
  • Amber - Bath, Salisbury & Swindon - For treatment of breast cancer.
  • Red - GWH ONLY - For the second-line treatment of patients with anovulatory infertility unresponsive to Clomifene.
  • Non- formulary - Bath & Salisbury - For the second-line treatment of patients with anovulatory infertility unresponsive to Clomifene.
  • 2.5mg tablet
06.07.02 Leuprorelin Prostap®

Amber Endometriosis / fibroids

Red RUH and SFT for fertility

  • Prostap SR DCS prefilled syringe - powder for reconstitution 3.75mg (one month)
  • Prostap 3 DCS prefiled syringe - powder for reconstitution 11.25mg (three months)
  • For endometriosis
08.03.04.02 Leuprorelin Acetate 
  • 3.75mg pre-filled syringes (SR DCS) - one month injection
  • 11.25mg pre-filled syringes (3 DCS)  - 3 month injection
  • For locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration, or metastatic prostate cancer as per the licensed indication
  • Lutrate® has been discontinued (Jun 19)
04.08.01 Levetiracetam 
  • Tablets 250mg, 500mg, 750mg, 1g (Category 3 MHRA)
  • Oral solutionSF 100mg/ml
  • Granules in sachets, 250mg, 500mg and 1000mg Desitrend (second line use only)
04.08.01 Levetiracetam 
  • Concentrate for I/V infusion 100mg/ml 5ml vial (Category 3 MHRA)
16.06 Levetiracetam 
  • 250mg, 500mg, 750mg and 1g (category 3 MHRA)
  • Oral solution SF 100mg/ml
  • Granules in sachets 250mg, 500mg and 1000mg Desitrend (second line use only)
16.06 Levetiracetam 
  • 100mg/ml 5ml vial
21 Levetiracetam 
  • 100mg/ml 5ml vial
  • For use in syringe pumps following advice of palliative care specialists
  • To be used an alternative to midazolam for the treatment of seizures where sedation is not desirable.
  • Can be used in syringe drivers
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
15.02 Levobupivacaine 
  • 25mg in 10ml (0.25%) amp
  • 50mg in 10ml (0.5%) amp
15.02 Levobupivacaine with Fentanyl 
  • GWH only.
  • Epidural
05.01.12 Levofloxacin 
  • The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information. 
  • 250mg
  • 500mg
  • Consultant microbiologist recommendation ONLY.
05.01.12 Levofloxacin 
  • The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information. 
  • IV infusion 5mg/ml 100ml bottle, 100ml infusion bag
11.03.01 Levofloxacin 
  • Green Salisbury
  • Amber Bath and Swindon
  • 5mg/ml eye drops
13.03 Levomenthol -Menthol in aqueous cream 
  • Prescribe as the brand Dermacool® in primary care. 
  • Cream 0.5%, 1%, 100g, 500g pump
  • For severe pruritus and can be used long term if necessary
04.02.01 Levomepromazine 
  • Tablet 25mg
  • Injection 25mg in 1ml
  • For palliative care for the management of pain, associated restlessness, distress or vomiting.
21 Levomepromazine 
  • For nausea and vomiting
  • Can be used in syringe drivers
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
21.01 Levomepromazine 
  • Community Just In Case Boxes
  • For nausea and vomiting
07.03.05 Levonorgestrel 
  • Tablet contains 1.5 mg of levonorgestrel
  • Licensed to prevent pregnancy when taken within 72 hours of unprotected intercourse or failure of a contraceptive method. Emergency contraceptive pills do not prevent 100% of pregnancies and are more effective the sooner they are taken after unprotected sex.
  • Please be aware of the updated FSRH advice (2017) to provide a 3mg dose in patients women weighing >70 kg or with a BMI >26 kg/m2
  • FP10s for levonorgestrel should be written generically as levonorgestrel 1.5mg. Levonelle One Step, the pharmacy pack, is significantly more expensive.
  • Levonelle One Step pharmacy pack of levonorgestrel 1.5mg is available to purchase from Community Pharmacies. Pharmacist checklist and patient information leaflet here.
06.04.01.02 Levonorgestrel Intrauterine System 

Bath and Swindon only

  • Intra-uterine system releasing 20 micrograms of levonorgestrel per 24 hours
  • Prescribe by Brand Name.
  • Mirena is effective for 5 years in the indications for contraception and idiopathic menorrhagia so should be removed after 5 years use.
  • In the indication for protection from endometrial hyperplasia during oestrogen replacement therapy, clinical data (from clinical trials conducted in women of 18 years and over) beyond 4 years of use are limited. Mirena should therefore be removed after 4 years.

 

06.02.01 Levothyroxine 
  • 12.5 micrograms, 25 micrograms, 50 micrograms, 75 micrograms, 100 micrograms tablets
02.03.02 Lidocaine 
  • Infusion 1g in 5% Glucose (500ml)
  • Injection (prefilled syringe) 100mg in 5ml
04.07.03 Lidocaine  
  • Red to be used in patients with multiple rib fractures in acute trusts on the advice of Pain Consultant only.
  • Amber for the following indications:
    • Post-Herpetic Neuralgia (licensed indication) 
    • Focal neuropathic pain with allodynia, as advised by a pain specialist (off-label). Locally agreed indication (August 2019).
    • Also can be used as per Palliative Care specialist recommendation (off-label). Locally agreed indication (August 2019).
  • Medicated plasters lidocaine 5%. Prescribe by the brand name: Ralvo®
15.02 Lidocaine Xylocaine
  • SFT only
  • This product is non-sterile and therefore not recommended for use prior to procedures that require aseptic techniques
  • Lidocaine 10 mg/metered dose.
  • Used for the prevention of pain related to specific procedures
  • Contains ethanol
  • 50 ml glass spray bottles (approx. 500 spray doses) with a metering spray pump.
15.02 Lidocaine 2.5% with Prilocaine 2.5% EMLA®
  •  Lidocaine 2.5%, Priolocaine 2.5%, 30g, 5g with dressings
11.07 Lidocaine 4% with Fluorescein 0.25% 
  • Lidocaine 4% with Fluorescein 0.25%
15.02 Lidocaine 5% and Phenylephrine 0.5% spray
  •  Each bottle contains 2.5ml of solution to be used as a spray, equivalent to 125mg lidocaine and 12.5mg phenylephrine hydrochloride.
12.03.01 Lidocaine 5% ointment 
  • GWH only
15.02 Lidocaine Hydrochloride injection
  • 50mg in 10ml (0.5%) vial
  • 20mg in 2ml (1%) amp
  • 50mg in 5ml (1%) amp
  • 200mg in 20ml (1%) amp
  • 200mg in 20ml (1%) vial preserved
  • 100mg in 5ml (2%) amp
  • 100mg in 5ml (2%) prefilled syringe
  • 400mg in 20ml (2%) amp
15.02 Lidocaine with Adrenaline injection
  • Xylocaine 1% with adrenaline 1:200,000 multi-dose vial, 20ml and xylocaine 2% with adrenaline 1:200,000 multidose vial, 20ml.
  • Red for use in acute trusts
  • Green for use by GPs in primary care undertaking minor procedures/surgery
  • Red for GWH only: Lidocaine dental cartridges -Lignospan Special® (Lidocaine hydrochloride 2% + adrenaline 1:80000).
15.02 Lidocaine2% with Chlorhexidine 0.25% Instillagel®
  •  Lidocaine 20mg/ml and chlorhexidine gluconate 500mcg/ml. 60ml or 110ml
01.06.07 Linaclotide 
  •  290 micrograms capsules.
  • Please note: This is ONLY for the treatment of moderate to severe irritable bowel syndrome with constipation, in line with our Guidance on the Management of IBS with constipation (IBS-C) in Adults (2018).
06.01.02.03 Linagliptin 
  • 5mg
  • Note: Licensed as monotherapy, dual therapy with metformin, triple therapy (SU+metformin), Insulin add on (plus or minus metformin). 
  • No dose reduction in renal impairment
05.01.07 Linezolid 
  • Tablets 600mg
  • IV infusion 600mg/300ml
  • FBC monitoring (including platelets) should be performed weekly.
06.02.01 Liothyronine sodium  Injection
  • 20 micrograms
  • For emergency treatment of hypothyroid coma, OR in patients exhibiting signs and symptoms of hypothyroidism following failure to administer/absorb usual oral replacement therapy (typically after 5-7 days).
  • Please note this this a high cost medicine

 

06.02.01 Liothyronine sodium  Tablet

 

  • Prescribers in primary care should not initiate liothyronine for any new patient
  • Please note - only the 20 microgram strength is on formulary. For lower doses the tablet can be dispersed in water. See SPC for details.
  • Liothyronine is non formulary for monotherapy
  • Please note this is a high cost medicine
  • The British Thyroid Association (BTA) advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction.
  • In these circumstances, where levothyroxine has failed and in line with BTA guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least 3 months duration of liothyronine.
  • Liothyronine is used for patients with thyroid cancer, in preparation for radioiodine ablation, iodine scanning, or stimulated thyroglobulin test. In these situations it is appropriate for patients to obtain their prescriptions from the centre undertaking the treatment and not be routinely obtained from primary care prescribers.
13.10.05 Liquiband® adhesive 
  • GWH only
  • 0.5g
13.02.01 Liquid and White Soft Paraffin Ointment (50:50) 

VERY GREASY MOISTURISER FOR SEVERE DRY SKIN &/OR ACUTE FLARES (low risk of sensitivity):

  • 50/50 ointment
11.08.01 Liquid Paraffin eye ointment Lacri-lube®
  • GWH for recurrent erosions only
  • Not on formulary in Bath or Salisbury
06.01.02.03 Liraglutide Victoza®

Green Bath

Amber Salisbury and Swindon

  • 6mg/ml prefilled pens
  • Dose: 0.6mg OD for 2 weeks, increased to 1.2mg OD. Further increase of dose up to 1.8mg is not advised.
  • NB Liraglutide Saxenda for weight loss has not been approved for addition to the formulary see here 
04.04 Lisdexamfetamine 
  • Capsules 20mg, 30mg, 40mg, 50mg, 60mg, 70mg 
  • Once daily dosing.

 Note: SCA for Adults link below. SCA for Paeds see Chapter 16

16.05 Lisdexamfetamine Elvanse®
  • 20mg, 30mg, 40mg, 50mg, 60mg and 70mg
  • Once daily dosing
  • See relevant locality SCA (link below) 
02.05.05.01 Lisinopril 
  •  2.5mg, 5mg, 10mg, 20mg
     
04.02.03 Lithium Carbonate Camcolit ® 400mg/ Essential Pharma 250mg
  • 250mg
  • 400mg MR
  • Prescribed by brand name.
  • Monitor lithium levels. Samples should be taken 12 hours after the preceding dose.
  • The proprietary (brand) name of “Camcolit 250mg tablets” has changed to “Lithium Carbonate Essential Pharma 250 mg film-coated tablets”, effective from 1st October 2015. The product strength and formulation have not changed, only the name has changed.
  • This name change only applies to Camcolit 250mg. Please note, the product name for “Camcolit 400mg prolonged release Lithium carbonate film-coated tablet” is not affected.
  • Please refer to shared care information on links below. Please note the SCAs are old and a new version is almost ready for publication (August 2019). 
04.02.03 Lithium Carbonate Liskonum®
  • 450mg MR
  • Prescribed by brand name.
  • Monitor lithium levels. Samples should be taken 12 hours after the preceding dose.
  • Please refer to shared care information on links below. Please note the SCAs are old and a new version is almost ready for publication (August 2019). 
04.02.03 Lithium Carbonate Priadel®
  • Priadel® M/R tablet 200mg,
  • Priadel® M/R tablet 400mg
  • Prescribed by brand name.
  • Monitor lithium levels. Samples should be taken 12 hours after the preceding dose.
  • Please refer to shared care information on links below. Please note the SCAs are old and a new version is almost ready for publication (August 2019). 

 

04.02.03 Lithium Citrate Liquid Priadel®
  • Priadel® SF syrup 520mg (equivalent to 5.4mmol Li+) in 5ml
  • Li-Liquid® (5ml ≡ 200mg lithium carbonate MR tablets)
  • Prescribed by brand name.
  • See the National Patient Safety Agency safer lithium therapy alert link below. 
  • Monitor lithium levels. Samples should be taken 12 hours after the preceding dose.
  • Please refer to shared care information on links below. Please note the SCAs are old and a new version is almost ready for publication (August 2019). 
06.01.02.03 Lixisenatide 

 Green Bath ONLY

 Amber Salisbury and Swindon 

  • 10 microgram, 20microgram - 14 dose pre-filled pen (50 microgram/ml)
  • Note: Once daily subcutaneous injection for the treatment of type 2 diabetes within license and in combination with oral hypoglycaemics.
  • Dose 10 micrograms OD for 2 weeks, increased to 20micrograms OD.
  • First choice GLP1 due to cost in Bath and Swindon

 

 

04.03.01 Lofepramine 
  • Tablets 70mg
  • Oral suspension 70mg in 5ml
  • Probably the safest TCA in overdose
08.01.01 Lomustine 
  • 40mg capsules
01.04.02 Loperamide 
  • 2mg capsules.
  • 1mg in 5ml oral syrupSF.
  • 2mg tablets (RUH only) Loperamide tablets are restricted to use in patients with feeding tubes, where loperamide liquid has been unsuitable due to hypertonicity. Tablets can be crushed and administered via feeding tube without risk of blocking the tube. 
  • Please note: The maximum total daily dose of loperamide is 16mg in routine use, although stoma patients may require higher doses.
05.03.01 Lopinavir and Ritonavir Kaletra®
  • Tablets lopinavir/ritonavir 100mg/25mg and 200mg/50mg
  • Oral solution lopinavir 400mg and ritonavir 100mg
03.04.01 Loratadine 
  • Self Self Care Medicine for primary care.
  • Tablets 10mg
  • Oral solution 5mg in 5ml
04.01.02 Lorazepam  
  • Injection 4mg in 1ml
  • For short term use in status epilepticus or rapid tranquilisation. By intramuscular or slow intravenous injection (into a large vein). 
  • Note: Only use intramuscular route when oral and intravenous routes not possible. For intramuscular injection it should be diluted with an equal volume of water for injections or physiological saline (but only use when oral and intravenous routes not possible).
  • See NICE NG10: Violence and aggression: short-term management in mental health, health and community settings
  • Shorter half life and no active metabolites, but carries a greater risk of withdrawal symptoms.
  • Also used in chemotherapy antiemetic regimens
04.01.02 Lorazepam 
  • Tablets 1mg
  • For short term use . Shorter half life and no active metabolites, but carries a greater risk of withdrawal symptoms.

 

04.08.02 Lorazepam  
  •  4mg in 1ml
  • By slow intravenous injection (into large vein) 
15.01.04.01 Lorazepam 
  •  4mg in 1ml Injection
02.05.05.02 Losartan 
  •  Tablets 25mg, 50mg, 100mg
11.04.01 Loteprednol 
  • Salisbury only
  • Non formulary at RUH and GWH
06.02.02 Lugols iodine 
08.03.04.03 Lutetium (177Lu) oxodotreotide Lutathera
05.01.03 Lymecycline 
  • 408mg capsules
  • More expensive option
13.06.02 Lymecycline 
  • Capsules 408mg
  • 408mg once a day for 3 months then review
  • Better compliance due to once daily dose.
01.01.01 Maalox Plus 
  • Suspension containing aluminium hydroxide 35 mg & magnesium hydroxide 40 mg per 1 ml.
01.06.04 Macrogol  
  • Sachet containing macrogol 3350  105g, potassium 5.4 mmol, sodium 65mmol, bicarbonate 17mmol & chloride 53mmol per litre.
  • Please note: Macrogol use is restricted to faecal impaction, or chronic cases where other laxatives have been ineffective or are unsuitable. It may cause electrolyte disturbances, and there is insufficient evidence to support its routine use before well-established, less expensive drugs.
  • Please prescribe BY BRAND. Laxido® is more cost-effective in primary care and Movicol® is more cost-effective in secondary care.
09.05.01.03 Magnesium Aspartate Magnaspartate®

 

  • Magnaspartate Sachets each contain 10mmol magnesium (mix with water)
  • Licensed for the treatment and prevention of magnesium deficiency, where clinically indicated in adults, adolescents and children aged 2 years and older. 
09.05.01.03 Magnesium Glycerophosphate Neomag ®

Amber Salisbury, Swindon and Bath

Licensed for the treatment of chronic magnesium loss or hyomagesaemia, where clinically indicated, in adults, adolescents and children aged 4 years and older

Also licensed for adult patients with hypomagnesaemia due to the concomitant administration of look and thiazise diuretics or other drugs which cause hypomagnesaemia.

 

Green Bath - short term use

01.06.04 Magnesium Hydroxide  Mixture
  • 7.45-8.35% oral suspension BP  (magnesium hydroxide 79 mg per 1 ml).
  • Phillip's Milk of Magnesia 415mg/5ml oral suspension.
  • Please note: Use with caution in the elderly.
09.05.01.03 Magnesium Sulphate  
  • Injection 50% (approximately 2 mmol magnesium per ml) 10ml amps.
  • Injection 1g in 10mls (10%W/V)       
13.10.05 Magnesium Sulphate Paste BP 
  • Paste, dried magnesium sulfate 45g, glycerol 55g, phenol 500mg 25g, 50g    
01.01.01 Magnesium Trisilicate Mixture
  • MixtureSF (Contains about 6mmol of sodium in 10ml).  
13.10.04 Malathion 0.5%  
  • aqueous liquid 50ml, 200ml (can be used if permethrin is inappropriate.)
02.02.05 Mannitol 
  • 10% - 500ml
  • 20% - 500ml
03.07 Mannitol inhalation Osmohale ®/Aridol®
  • RUH (For inhalation for mannitol bronchial challenge test.)
  • SFT (For inhalation for mannitol bronchial challenge test.)
  • Non-formulary - GWH

 

03.07 Mannitol inhalation Bronchitol ®
  • Non Formulary at RUH and SFT
  • Inhalation powder, hard capsule (for use with disposable inhaler device) mannitol 40mg 
  • Commissioned by NHS England for use in CF as per policy A01/P/b and NICE TA266.
05.03.01 Maraviroc Celsentri®
  •  Tablets 150mg
14.04 Measles, Mumps and Rubella Vaccine, Live (MMR) MMRvaxPro® Priorix®
05.05.01 Mebendazole 
  • Tablets (chewable) 100mg
  • Suspension 100mg/5ml.
  • Recommended for all children >6 months and adults. Repeat in 2/52 if infestation persists.
  • A prescription for treatment of threadworm should not routinely be offered in primary care as the condition is appropriate for self-care.

 

05.05.02 Mebendazole 
  •  Chewable tablets 100mg
05.05.04 Mebendazole 
  •  100mg chewable tablets
01.02 Mebeverine 
  • 135mg tablets.
  • Please note: Modified-release preparations are NOT included on our formulary.
13.02.02 Medihoney® 

Medihoney barrier cream contains only natural products with the addition of 30% active 100% Pure Medical Grade Manuka Honey. 50g pack size.

INDICATION: Moderate to severe Incontinence Associated Dermatitis

• Protects at risk skin from breakdown associated with incontinence. Can be used under incontinence pads

• Can be used around wound edges to protect skin from irritation
  and breakdown caused by wound exudate

• Suitable for injured skin or areas that are inflamed or excoriated

• Suitable for all ages including paediatrics and neonates

06.04.01.02 Medroxyprogesterone Acetate 

Green  Bath and Salisbury. Used for endometriosis & dysfunctional uterine bleeding.

 

Red  Bath - specialist use only for the treatment of infertility

  • 5mg and 10mg tablets

Not on formulary Swindon.

07.03.02.02 Medroxyprogesterone Acetate Depo-Provera®
  • 150mg in 1ml for administration as deep intramuscular injection every 12 weeks.
07.03.02.02 Medroxyprogesterone acetate Sayana Press®
  • Green Patients > 18 years
  • Amber Patients and adolescents (12-18 years), use of Sayana Press is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with Sayana Press during the critical period of bone accretion. Sayana Press has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate (MPA) in this population.
  • Single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection.
  • Licensed for self-administration. Please note company provide sharps bins BUT patients must organise safe disposal of full sharps bins via their local council.
  • Dose (no hormonal contraceptive use in previous month) 104 mg within first 5 days of cycle or within 5 days postpartum (delay until 6 weeks postpartum if breast-feeding). For long-term contraception, repeat every 13 weeks (if interval greater than 13 weeks and 7 days, rule out pregnancy before next injection)
  • Especially effective in patients with a BMI > 30

 

08.03.02 Medroxyprogesterone Acetate 
  • 2.5mg, 5mg, 10mg, 100, 200mg and 400mg tablets
  • Specialist initiation only for endometrial cancer
10.01.01 Mefenamic Acid 
  • 500mg tablets
  • 250mg capsules
05.04.01 Mefloquine Lariam®
  • Treatment for Malaria is available on the NHS.
  • Patients requiring Malaria prevention must acquire this on a private prescription
  • BNF caution: mefloquine and driving - dizziness or a disturbed sense of balance may affect performance of skilled tasks e.g. driving; effects may occur and persist upto several months after stopping mefloquine.
  • Tablets 250mg
08.03.02 Megestrol Acetate 
  • 160mg tablets
  • Specialist initiation only for endometrial cancer.
04.01.01 Melatonin Circadin MR 2mg ®

For short-term treatment of insomnia in ADULTS in the following circumstances:

  • Red In-patient use (maximum 3 weeks treatment) by Consultant Care of the Elderly as short-term treatment of insomnia. Not for continuation in Primary Care.
  • Amber GWH and SFT only: For epileptic adults with insomnia, who cannot have Z drugs due to effect on seizure threshold.
  • Tablets 2mg m/r
  • ONLY prescribe as the brand Circadin® 
  • Maximum licensed duration of use is 13 weeks.
  • For use in paediatrics see paediatric section (chapter 16).
  • Please note, the brand Slenyto for paediatric use is not on formulary.
16.04 Melatonin Circadin MR 2mg®
  • 2mg
  • Melatonin MR 2mg tablets are approved for use only to aid sleep cycle synchronisation in children with sensory impairment, autistic spectrum disorder, in other neurodisability/neuropsychiatric/neurodevelopmental disorders (including ADHD when behaviour measures have been insufficient) and also to induce sleep in children undergoing sleep EEG.
  • Melatonin MR 2mg tablets are licensed for use in adults over 55 years. Use in children is an 'off label' use. 

 

16.04 Melatonin 5mg/5ml 
  • Melatonin 5mg/5ml oral solution or suspension (alcohol free) Unlicensed DrugUnlicensed only in line with melatonin policy see here - link to add - 22/02/2020
  • Melatonin is approved for use only to aid sleep cycle synchronisation in children with sensory impairment, autistic spectrum disorder, in other neurodisability/neuropsychiatric/neurodevelopmental disorders (including ADHD when behaviour measures have been insufficient) and also to induce sleep in children undergoing sleep EEG.

 

10.01.01 Meloxicam 
  • Green - Swindon - Second-line after conventionals NSAIDs.
  • Amber - Bath and Salisbury.
  • Red - GWH ONLY - For the short-term prevention and treatment of post-operative pain in patients at high risk of bleeding with conventional NSAIDs (e.g. adult tonsillectomy, colorectal surgery, etc).
  • 7.5mg and 15mg tablets. 
08.01.01 Melphalan 
  • 2mg tablets
08.01.01 Melphalan 
  • 50mg powder and solvent for injection
04.11 Memantine 
  • Amber with Shared Care NHS BaNES 
  • Red NHS Swindon and Wiltshire CCG
  • Tablet 10mg, 20mg

 

09.06.06 Menadiol Sodium Phosphate 
  • 10mg
  • Menadiol sodium phosphate is water soluble and is included for use where patients have fat malabsorption.
  • Water soluble and should be used to prevent vitamin k deficiency in malabsorption syndromes. Not licensed to reverse over anticoagulation with oral anticoagulants.
14.04 Meningococcal A, C, W135, and Y conjugate vaccine Menveo®
  • Menveo powder and solution for solution for injection
  • Meningococcal Group A, C, W-135 and Y conjugate vaccine
  • This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
14.04 Meningococcal group A, C, W-135 and Y conjugate vaccine Nimenrix®
  • This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
14.04 Meningococcal group B Vaccine Bexsero®
14.04 Meningococcal Group C Polysaccharide Conjugate Vaccine Adsorbed NeisVac-C®
14.04 Meningococcal Group C Polysaccharide Conjugate Vaccine Adsorbed Menjugate ®
14.04 Meningococcal polysaccharide A, C, W135 and Y vaccine ACWY Vax®
  • This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
03.08 Menthol and Eucalyptus Inhalation BP 1980 

Self 

09.08.01 Mercaptamine Cystagon

Red GWH only

  • 50mg, 150mg
  • Non formulary - RUH and SFT
  • Commissioned by NHS England (for nephropathic cystinosis) as per NHS England Service Specification according to highly specialised criteria.

    For initiation by specialist centres only 
01.05.03 Mercaptopurine 
  • Amber with Shared Care - Bath, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH).
  • Red - GWH - Swindon DAWN patients. 
  • 50mg tablets
  • Note: 50mg tablets are licensed but used 'off-label' for gastro indications e.g. severe ulcerative colitis and Crohn’s. 10mg tablets are unlicensed specials 
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information.
08.01.03 Mercaptopurine 
  • 10mg and 50mg tablets
  • For use in Crohn's disease, see chapter 1
05.01.02.02 Meropenem 
  •  500mg
  • 1g
01.05.01 Mesalazine 
  • Granules
    • Salofalk® 500mg, 1g, 1.5g & 3g gastro-resistant, modified release granule sachets (First- line for all new UC patients, with 1.5g or 3g sachets most cost- effective).
    • Pentasa® 1g, 2g & 4g modified-release granule sachets (Salisbury & Swindon ONLY).
  • Tablets
    • Octasa® 400mg & 800mg MR tablets (Second- line).
    • Asacol MR® 400mg & 800mg MR tablets (Existing patients only).
    • Salofalk® 250mg, 500mg & 1g gastro-resistant tablets.
    • Pentasa® 500mg & 1g MR tablets (Salisbury & Swindon ONLY).
    • Pentasa® 500mg MR tablets (Bath - Existing patient only).
01.05.01 Mesalazine 
  • Suppositories
    • Salofalk® 500mg & 1g suppositories (First-line).
    • Pentasa® 1g suppositoires.
  • Foam Enemas
    • Salofalk® 1g/application foam enema. 
  • Liquid Enemas
    • Salofalk® 2g/59ml enema (First- line).
    • Pentasa® 1g/100ml enema.
  • Please note: Asacol suppositories and foam enema have been removed from formulary, as they have been discontinued.
08.01 Mesna 
  • 400mg or 600mg tablets
  • Chemotherapy induced neutropenic infection and nephrotoxicity
08.01 Mesna 
  • 1m/10ml solution for injection
  • Chemotherapy induced neutropenic infection and nephrotoxicity
13.02.02 Metanium® Barrier ointment
  • Ointment 30g,
  • Contains titanium
02.07.02 Metaraminol 
  • 10mg/ml
06.01.02.02 Metformin 
  • 500mg, 850mg tablets
  • Note: Liquid preparation is very expensive. Patients with swallowing difficulties should be switched to an alternative drug rather than metformin liquid if they cannot take the tablets. This should be a Sulphonylurea (or a Gliptin if they are on a Sulphonylurea already)  
  • The EMA has concluded that metformin-containing medicines can now be used in patients with moderately reduced kidney function (GFR [glomerular filtration rate]=30–59 ml/min) for the treatment of type 2 diabetes.

 

 

06.01.02.02 Metformin MR 
  • 500mg, 750mg, 1g  (Sukkarto SR 500mg, 1g)
  • Prescribe by brand
  • Note: Metformin MR should only be used where the standard-release tablets have been tried and are not tolerated due to GI problems. Metformin SR tablets are supported purely as an attempt to ensure the largest number of patients are able to stay on metformin therapy, hopefully delaying progression to other new drugs which often have a reduced evidence base and/or additional safety concerns.
04.07.02 Methadone 
  • Tablets 5mg 
  • Oral Solution 1mg/ml
  • For treatment of substance misuse see section 4.10.3
04.10.03 Methadone  
  • Oral solution 1mg/1ml
  • Oral solutionSF 1mg/1ml
04.10.03 Methadone  
  • Injection 10mg/1ml, 20mg/2ml, 50mg/1ml
05.01.13 Methenamine Hippurate Tablet
  • Tablets 1g
  • Methenamine can be considered if there is no renal or hepatic impairment.
  • Might be recommended by a urologist for prophylaxis in patients with
    recurrent UTIs.
15.01.01 Methohexital 
  • GWH ONLY for use by appropriated trained staff, and ONLY for the induction of anaesthesia prior to ECT (unlicensed use).

01.05.03 Methotrexate 
  • Amber with Shared Care - Bath, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH).
  • Red - GWH - Swindon DAWN patients.
  • 2.5mg tablets ONLY.
  • Please note: Methotrexate is administered weekly.
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information.
08.01.03 Methotrexate 

 

10.01.03 Methotrexate 
  • 2.5mg tablets ONLY. There should be no prescribing of 10mg tablets. Please refer to NPSA guidance on reducing the risks of oral methotrexate. Patients should have patient held records while they are receiving treatment with any DMARD requiring regular monitoring (record cards and GP protocol advice available from rheumatology).
  • The label on prescribed/dispensed methotrexate should state the instructions clearly, for example: ‘methotrexate 2.5mg tablets: (number of tablets) to be taken as a single dose ONCE A WEEK on XXX  DAY’.
  • Note: Folic Acid 10mg is usually given ONCE A WEEK with methotrexate to reduce side effects. It should NOT be taken on the same day as the methotrexate.
  •  Amber with Shared Care - Bath, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH).
  •  Red - Swindon DAWN patients.
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information.
10.01.03 Methotrexate 
  • When self-adminstering subcutaneous methotrexate, patients should be maintained on the product they were initiated / trained on. Local formulary brands listed below: 
    • Metoject® 50mg/ml Injection prefilled pen 0.15ml (7.5mg), 0.2ml (10mg), 0.3ml (15mg), 0.4ml (20mg), 0.5ml (25mg), 0.6ml (30mg)
      Metoject is a pre-filled pen type device Local brand of choice
      Instruction guide for Metoject
    • Zlatal® 25mg/ml Injection prefilled syringe 0.3ml (7.5mg), 0.4ml (10mg), 0.5ml (12.5mg), 0.6ml (15mg), 0.7ml (17.5mg), 0.8ml (20mg), 0.9ml (22.5mg), 1ml (25mg)
      Zlatal is a prefilled syringe For those who need to use a syringe and needle
      Instruction guide for Zlatal

 

  • Amber with Shared Care Bath, Salisbury & some Wiltshire patients - see note below.
  • Red for Swindon DAWN, Swindon non-DAWN and Kennet & North East Wiltshire patients. 
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information.
13.05.03 Methotrexate 
  • Tablets 2.5mg
  • For severe psoriasis 
13.05.03 Methotrexate 
  • sc injection
  • Prescribe by brand
  • Metoject® 50mg/ml Injection prefilled pen 0.15ml (7.5mg), 0.2ml (10mg), 0.3ml (15mg), 0.4ml (20mg), 0.5ml (25mg), 0.6ml (30mg)
  • Zlatal® 25mg/ml Injection prefilled syringe 0.3ml (7.5mg), 0.4ml (10mg), 0.5ml (12.5mg), 0.6ml (15mg), 0.7ml (17.5mg), 0.8ml (20mg), 0.9ml (22.5mg), 1ml (25mg) For patients who need to use a syringe and needle.
  • sc injection
  • For severe psoriasis in patients unable to tolerate oral methotrexate
04.07 Methoxyflurane Penthrox®
  • 3 ml inhalation vapour, liquid

RUH ONLY - for emergency relief of moderate to severe pain and to facilitate the treatment of fractures and joint dislocations, in conscious adult patients who have suffered a traumatic injury.

Not on formulary at SFT or GWH

13.05.02 Methoxypsoralen  
  • 8-methoxypsoralen 10mg tablets (Puvasoralen®). Also known as methoxsalen.
  • 5-methoxypsoralen 20mg tablets (Pentaderm®)
  • 8-methoxypsoralen 1.2 % bath solution 30 ml
  • Puvasoralen gel 0.005%
  • Dermatology specialist only
  • Used in photochemotherapy combining long-wave ultraviolet A radiation with a psoralen (PUVA) 
01.06.01 Methycellulose 
  • Self - Bath - For use in patient with high output ileostomies.
  • Non-formulary - Salisbury & Swindon.
  • 500mg tablets.
13.08.01 Methyl-5-Aminolevulinate Metvix®
  • 160 mg/g cream
  • SFT and GWH; Restricted for use by the dermatology treatment centre only as part of photodynamic therapy.
02.05.02 Methyldopa 
  • Tablets 250mg, 500mg
  • For the treatment of hypertension in pregnancy only

 

21 Methylnaltrexone 
  • 12 mg/0.6 mL
  • Opioid induced constipation in terminal illness when response to other laxatives inadequate.
  • Formulary status under review
16.05 Methylphenidate Concerta® XL, Xaggitin XL, Medikinet XL, Equasym® XL
  • Xaggitin® XL  Modified release tablet 18mg, 27mg, 36mg, 54mg - First line for new patients as the most cost-effective formulary choice locally
  • Concerta® XL Modified release tablet 18mg, 27mg, 36mg: existing patients only.
  • Equasym® XL Modified release capsule 10mg, 20mg, 30mg
  • Prescribe by brand Modified release brands provide different release profiles of methylphenidate and switching brands should only be considered following specialist advice.
  • See relevant locality SCA (link below) 
04.04 Methylphenidate Hydrochloride MR 
  • Xaggitin® XL  Modified release tablet 18mg, 27mg, 36mg, 54mg - First line for new patients as the most cost-effective formulary choice locally
  • Concerta® XL Modified release tablet 18mg, 27mg, 36mg: existing patients only.
  • Equasym® XL Modified release capsule 10mg, 20mg, 30mg

Note: SCA for Adults link below. SCA for Paeds see Chapter 16

06.03.02 Methylprednisolone 
  • Green Salisbury only
  • Amber Swindon only
  • Bath- not on formulary
  • 2mg,4mg,16mg,100mg

 

06.03.02 Methylprednisolone acetate Depo-Medrone ®
  • Injection (as acetate - Depot-Medrone) 40mg in 1ml, 80mg in 2ml
  • Bath and Swindon only
10.01.02.02 Methylprednisolone Acetate Depo-Medrone®
  • 120mg/3ml, 40mg/1ml and 80mg/2ml injection

 

06.03.02 Methylprednisolone Sodium Succinate Solu-Medrone ®
  • 40mg, 125mg, 500mg, 1g, 2g.
  • RUH and GWH only
01.02 Metoclopramide 
  • Green - For short-term use.
  • Amber - For long-term use (off-label).
  • 10mg tablets.
  • 5mg in 5ml SF oral solution (Salisbury & Swindon ONLY).
  • Please note: Metoclopramide should be used with caution in patients under 20 years of age due to the risk of extrapyramidal effects. 
  • Metoclopramide is also available for prevention or treatment of nausea and vomiting. Please refer to Chapter 4 (CNS).
04.06 Metoclopramide 
  • Green for short-term use (maximum 5 days)
  • Amber for long-term use (off-label)
  • Tablet 10mg
  • Syrup 5mg in 5ml
  • Injection 10mg in 2ml
  • Metoclopramide and prochlorperazine are associated with a high risk of dystonias and oculogyric crises particularly in children, young adults and the elderly. 
  • Severe reactions to metoclopramide should be treated with procyclidine injection
  • Metoclopramide should not be prescribed for patients with Parkinson's disease.
02.02.01 Metolazone 
  • Tablets 2.5mg 
  • Metolazone is significantly more potent than bendroflumethiazide and will cause profound diuresis in combination with furosemide. Careful monitoring is required to avoid electrolyte disturbance and dehydration.

 

02.04 Metoprolol 
  • Injection 1mg/ml 5ml

 

02.04 Metoprolol  
  • Tablets 50mg, 100mg
  • Specialist initiation only. Consider changing to alternative beta blocker once stable. See BNF for details.
05.01.11 Metronidazole  
  •  IV infusion 500mg/100ml
05.01.11 Metronidazole 
  • Tablets 200mg, 400mg
  • Oral suspension 200mg/5ml
  • Suppositories 500mg, 1g
05.04.02 Metronidazole 
  •  400mg
05.04.04 Metronidazole 
  •  400mg
07.02.02 Metronidazole Zidoval®
  • 0.75% vaginal gel
  • Antibiotic guidance recommends metronidazole (both vaginally and orally) for the treatment of bacterial vaginosis.
13.06 Metronidazole 0.75% Rozex
  • Cream 0.75% 30g, 40g
  • Treatment of pustules and erythema of rosacea
  • Notes: Topical metronidazole preparations are licensed for different indications: rosacea (Rozex®) and malodorous tumours and skin ulcers (Anabact®). Therefore, it is important to prescribe the appropriate branded product.

 

13.10.01.02 Metronidazole 0.75%  Anabact
  • 15g, 30g
  • Notes: Topical metronidazole preparations are licensed for different indications: rosacea (Rozex®) and malodorous tumours and skin ulcers (Anabact®). Therefore, it is important to prescribe the appropriate branded product.
06.07.03 Metyrapone 

Not on formulary in Great Western Hospital

Note: Metyrapone is used for Cushing’s syndrome, often in a lower dose combination with aminoglutethamide to reduce side effects.

  • 250mg capsules 
07.02.02 Miconazole Gyno-Daktarin®
  • 2% vaginal cream 78g
  • Patients should be advised that miconazole products might damage latex condoms and diaphragms.
12.03.02 Miconazole 
  • Oral gel 20mg/g 15g/80g
13.10.02 Miconazole 2%  
  • Cream 2%, 20g, 45g    
15.01.04.01 Midazolam 
  • 5mg in 5ml injection
  • 10mg/2ml injection
21 Midazolam 
  • For restlessness, anxiety and agitation
  • Can be used in syringe drivers
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
21.01 Midazolam 
  • Community Just In Case Boxes
  • For restlessness, anxiety and agitation
04.08.02 Midazolam Maleate  Epistatus®
  • Epistatus® Oromucosal solution prefilled single syringe 10mg/1ml  (licensed in adolescents - 10 years and over and adults
  • Epistatus® Oromucosal solution 10mg/ml prefilled syringes: 2.5mg/0.25ml, 5mg/0.5ml, 7.5mg/0.75ml, (unlicensed).  Individually wrapped in a pack of 4.
  • Do not prescribe Oromucosal solution 10mg/ml multidose 5ml bottle. In primary care, all patients should use the pre-filled syringe format as this is what the specialist primary care nursing team can provide training on for carers/schools/nurseries/after-school clubs etc.
  • Prescribe by BRAND (NB Buccolam brand is a different salt, STRENGTH and volume) 

 

16.07 Midazolam Maleate Oromucosal Epistatus®
  • Epistatus® Oromucosal solution prefilled single syringe 10mg/1ml  (licensed in adolescents - 10 years and over and adults
  • Epistatus® Oromucosal solution 10mg/ml prefilled syringes: 2.5mg/0.25ml, 5mg/0.5ml, 7.5mg/0.75ml, (unlicensed).  Individually wrapped in a pack of 4.
  • Do not prescribe Oromucosal solution 10mg/ml multidose 5ml bottle. In primary care, all patients should use the pre-filled syringe format as this is what the specialist primary care nursing team can provide training on for carers/schools/nurseries/after-school clubs etc.
  • Prescribe by BRAND (NB Buccolam brand is a different salt, STRENGTH and volume) 
  • See Shared Care Guidelines: Use of Oromucosal Midazolam as an intervention for prolonged seizures and prevention od Status Epilepticus in children under 10 years of age

Red Swindon only - when used for sedation and pre-med in theatres

16.07 Midazolam Maleate Oromucosal Epistatus®
  • 10mg/ml solution
02.07.02 Midodrine 
  • 2.5mg, 5mg (licensed alpha agonist)
  • For the treatment of orthostatic postural hypotension and intradialytic hypotension 
08.01.05 Midostaurin 
  • 25mg capsules
08.02.04 Mifamurtide 
  • 4mg infusion
  • When used in line with NICE TA235 (as below) and initiated by specialist centres ONLY 

 

07.01.02 Mifepristone Mifegyne®
  • ONLY for consultant obstetrician and gynaecologist prescribing AND in accordance with RCOG guidelines.

 

07.04.02 Mirabegron Betmiga®
  • Tablets MR 25mg, 50mg 
  • Mirabegron can be used FIRST line ONLY in patients contra-indicated to antimuscarinics – glaucoma, myasthenia gravis, GI obstruction or specific problems with dry mouth e.g Sjogren's.
  • Contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both).
04.03.04 Mirtazapine 
  • Tablets 15mg, 30mg, 45mg
  • Orodispersible tablets 15mg, 30mg, 45mg
  • Oral solution 15mg/ml
  • Mirtazapine soluble tablets are more expensive than standard formulation. They should be reserved for patients with swallowing difficulties only.
  • Mirtazepine oral solution is only for use via enteral feeding tubes.
  • Mirtazapine appears to be safe in overdose and is thought to cause less insomnia, anxiety and agitation.
  • Sexual dysfunction is rare and the likelihood of drug interactions is low. Weight gain may be significant.
07.01.01 Misoprostol 
  • Misoprostol 200micrograms tablets
  • Unlicensed indication/route of administration. Such use of misoprostol is supported by the Royal College of Obstetricians and Gynaecologists guideline development group.
08.01.02 Mitomycin 
  • 2mg and 10mg injection
08.01.02 Mitoxantrone 
  • 20mg/10ml infusion
15.01.05 Mivacurium 
  • GWH only
  • Injection 2 mg/ml
04.03.02 Moclobemide 
  • Tablets 150mg, 300mg 
  • Patients should avoid consuming large amounts of tyramine-rich food (such as mature cheddar, yeast extracts, red wine and fermented soya bean products) and sympathomimetics (such as ephedrine, pseudoephedrine and phenylpropanolamine).
  • Patients should be advised to take last dose before 3pm in order to minimise sleep disturbance / insomnia.
  • Refer the patient to the patient information leaflet (PIL) supplied with the product for dietary restrictions or go to https://patient.info/health/depression-leaflet/antidepressants for a full list.
04.04 Modafinil 
  • Tablet 100mg, 200mg
  • Narcolepsy should be diagnosed and treatment initiated by a specialist physician.

 

 

12.02.01 Mometasone Furoate 
  • Nasal spray 50 micrograms per spray
  • First line for treatment of allergic rhinits (prescribe generically)
  • For ENT initiation only for the treatment of nasal polyps.

 

 

 

13.04 Mometasone Furoate 0.1% Elocon®
  • Potent steroid
  • Cream, ointment 0.1% 30g, 100g
03.03.02 Montelukast 
  • NICE guidance (NG80, November 2017) recommends an LTRA as the first add-on maintenance therapy with ICS and SABA inhalers for the treatment in asthma. A LABA is an option (with/without the LTRA) in addition to an ICS if asthma remains uncontrolled. This is a more cost effective model. 
  • Existing BTS/SIGN continues the long-held view that low dose ICS should be followed by addition of LABA (in line with international guidelines such as GINA).
  • Head to head comparisons of ICS/LABA compared to ICS/LTRA have favoured ICS/LABA for effectiveness in adults (inconclusive in children).
  • Granules 4mg sachets sugar-free (6 months to 5 years of age)
  • Chewable tablets 4mg (2 to 5 years of age)
  • Chewable tablets 5mg (6 to 14 years of age)
  • Tablets 10mg (>14 years of age)

    Notes:

    • Not to be used to relieve an attack of severe acute asthma.
    • Leukotriene receptor antagonists should be withdrawn if no significant response after 6 weeks

 MHRA Drug Safety Update Sept 2019 Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions

21 Morphine Injections 10mg /ml
  • For pain
  • Can be used in syringe drivers
  • See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
21.01 Morphine Injections 10mg /ml
  • Community Just In Case Boxes
  • For pain
  • Where diamorphine shortages
03.09.01 Morphine Hydrochloride 

Non-formulary - RUH

Red - SFT (for intractable cough)

Non-formulary - GWH

 

04.07.02 Morphine Sulphate 
  • Injection 10mg/1ml, 30mg/1ml
04.07.02 Morphine Sulphate Sevredol®
  • 10mg,20mg,50mg immediate release tablets
  • Sevredol® tablet - 4 hourly dosing
21 Morphine Sulphate Sevredol®
  • 10mg,20mg,50mg immediate release tablets
  • Sevredol® tablet - 4 hourly dosing
04.07.02 Morphine Sulphate 5mg MST Continus
  • 5mg prolonged-release tablets ONLY on formulary to allow dose titration 
04.07.02 Morphine Sulphate M/R Zomorph®
  • m/r capsule 10mg, 30mg, 60mg, 100mg, 200mg
  • 12 hourly dosing
  • Zomorph can be opened and the contents administered in semi-solid food for patients with swallowing difficulties.
  • Zomorph is also licensed for use via gastric or gastronomy tubes (diameter >16F.G.).
  • There is no evidence of superior clinical analgesic effect of other opioids over morphine.
  • Prescribe by brand name.
21 Morphine Sulphate M/R Zomorph®
  • m/r capsule 10mg, 30mg, 60mg, 100mg, 200mg
  • 12 hourly dosing
  • Zomorph can be opened and the contents administered in semi-solid food for patients with swallowing difficulties.
  • Zomorph is also licensed for use via gastric or gastronomy tubes (diameter >16F.G.).
  • There is no evidence of superior clinical analgesic effect of other opioids over morphine.
04.07.02 Morphine Sulphate solution 10mg/5ml Oramorph®
  • 10mg/5ml   Schedule 5 (CD Inv)
  • 100mg/5ml Schedule 2 (CD)
  • 4 hourly dosing

 

21 Morphine Sulphate solution 10mg/5ml Oramorph®
  • 10mg/5ml   Schedule 5 (CD Inv)
  • 100mg/5ml Schedule 2 (CD)
  • 4 hourly dosing

 

01.06.05 Moviprep® Oral Sachet
  • 1 pair of sachets (A+B), providing when reconstituted to 1 litre with water Na+ 181.6  mmol (Na+ 56.2 mmol absorbable), K+ 14.2 mmol & Cl 59.8 mmol.
05.01.12 Moxifloxacin 
  • GWH only for use by ophthalmology for endophthalmitis and for sexual health indications.
  • The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information.
  • 400mg tablets
11.03.01 Moxifloxacin 
  • GWH only - For the treatment of endophthalmitis, 400mg OD for 10 days.
  • Non formulary in RUH and Salisbury
  • 400mg tablets
02.05.02 Moxonidine 
  • Tablets 200, 300, 400 micrograms
  • The BNF recommends that moxonidine may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. Use outside these indications is not recommended.

 

09.06.07 Multivitamin  Renavit®

  Amber with Shared Care Bath only

Salisbury and Swindon - non formulary

  • Tablets containing vitamins B1, B2, B3, B5, B6, B8, B9, B12
  • Vitamin deficiencies are common in patients with renal disease due to dietary restrictions, changes to metabolism and vitamin loss during dialysis.
  • Renavit® should only be initiated by a renal dietician- ongoing prescribing in primary care is acceptable.
  • Haemodialysis: 1 tablet post dialysis 3 times a week Peritoneal Dialysis: 1 tablet daily
09.06.07 Multivitamin preparations Abidec®
  • Contains less vitamin A than Dalivit®.
  • For neo-nates prescribe as per SCBU guidelines.
  • Substitute with Dalivit® if Abidec® unavailable - Dalivit® dose should not exceed 0.3ml daily in neo-nates.   
09.06.07 Multivitamin preparations Dalivit®
  • Used for cystic fibrosis patients and adults, as Abidec® is not suitable for anyone > 12years.   
12.02.03 Mupirocin 2% Bactroban ®
  • Mupirocin (Bactroban® nasal) is of value when the carriage of Staphlococcus aureus in the nose or ears has to be cleared.
  • To avoid the development of resistance, the treatment course should not exceed 7 days and the course not repeated on more than one occasion

 

 

13.10.01.01 Mupirocin 2% Bactroban®
  • Topical Cream, 2%
  • Notes: Mupirocin ointment and cream are not interchangeable - the prescription should specify formulation required.
09.06.07 Mutivitamin tablets  

GWH only

 

10.01.03 Mycophenolate 
  •  Amber with Shared Care - Bath, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH).
  •  Red - Swindon DAWN patients
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information
  • 500mg tablets
13.05.03 Mycophenolate  
  • Tablets 500mg
  • Severe refractory inflammatory disease and pemphigus (unlicensed use)
08.02.01 Mycophenolate Mofetil 
  • 250mg capsules
  • 500mg tablets
06.07.02 Nafarelin 
  • Not on formulary in SFT
  • For fertility treatment.
  • 200 micrograms / metered spray  

 

02.06.04 Naftidrofuryl 
  • 100mg
  • For the treatment of intermittent claudication in people with peripheral arterial disease in according to NICE TA below. 
04.10.01 Nalmefene 
  • Red (BANES due to commissioned service)
  •  Green (Wiltshire & Swindon) 
  • Tablets 18mg
  • NICE recommended for reducing alcohol consumption in people with alcohol dependance- see link below
  • Notes: Prescribing should be an adjunct to psychological therapy. Detoxification from alcohol should not take place in isolation and be supported with a post detoxification care plan. 
01.06.06 Naloxegol 
  • 12.5mg & 25mg tablets.
  • Please note: This may be considered as an option for treatment of opioid- induced constipation in adults, whose constipation has failed to adequately respond to laxatives appropriately escalated in accordance with our BSW Guidance on the Management of Constipation in Adults (2018), and in whom stopping opiates would be clinically inappropriate.
04.10.03 Naloxone 
  • 400 micrograms in 1ml amp
  • Reversal of CNS/Respiratory Depression
15.01.07 Naloxone 
04.10.01 Naltrexone 
  • Tablets 50mg (generic) for AWP / CDAS
  • For abstinence from alcohol for people who have already undergone detoxification within the treatment pathway 
  • Naltrexone is supported by NICE (CG 115) following assisted withdrawal or for harmful drinkers and people with mild alcohol dependence who have requested a pharmacological intervention in combination with an individual psychological intervention.
04.10.03 Naltrexone 
  • BaNES and Swindon CCG only
  • Tablets 50mg (generic) for AWP / CDAS
  • Notes: Naltrexone should be initiated by a specialist in the field of substance misuse. However, it may be prescribed on an on-going basis by a primary care prescriber for the maintenance of abstinence from opioids (or alcohol or for mild alcohol dependence) following advice from a specialist practitioner.
10.01.01 Naproxen 
  • 250mg and 500mg tablets
  • Oral suspension and effervescent tablets available 
  • No evidence for GI benefit of EC preparation - use standard tablets.
08.02.04 Natalizumab 
  • 300mg/15ml infusion
02.04 Nebivolol 
  • 2.5 and 5mg tablets
  • Note: not on formulary in BaNES
A2.03.01 Neocate Active 

(AAF) for over one year (can continue with LCP in most cases) 

A2.03.01 Neocate Advance 

(AAF) Specialist milk for children over one year who are not having significant amounts of solid foods

A2.03.01 Neocate LCP 

 (AAF) from birth to one year

11.04.02 Neodocromil 
  • Salisbury only
  • Non formulary in Bath and Swindon
  • 2% eye drops
15.01.06 Neostigmine 
  •  2.5mg in 1ml injection
15.01.06 Neostigmine with Glycopyrronium injection
  • 500 micrograms in 1ml amp 

 

11.08.02 Nepafenac Nevanac
  • Salisbury only
  • Non formulary in Bath and Swindon
05.03.01 Nevirapine Viramune®
  • Tablets 200mg
  • Tablets 400mg M/R
  • Suspension 50mg/5ml
02.06.03 Nicorandil 
  • Tablets 10mg, 20mg
  • Not to be used as first line treatment for angina; risk of ulcerations and progression to complications - stop treatment if ulceration occurs.
  • Treatment of stable angina only in patients whose angina is inadequately controlled by first line anti-anginal therapies or who have contraindications or intolerance to first line anti-anginal therapies such as beta-blockers and/or calcium antagonists. 
  • Can cause serious skin, mucosal and eye ulceration which persists unless treatment is discontinued. 
09.06.02 Nicotinamide 

 

13.05.03 Nicotinamide 
  • RUH/GWH only
  • Tablets 500mg (Niacinamide)
  • For blistering diseases as a safer alternative to prednisolone, usually in combination with tetracycline.

 

04.10.02 Nicotine 
  • Chewing gum 2mg, 4mg, 6mg
  • Lozenge 2mg, 4mg
  • Inhalator 15mg cartridge
  • QuickMist oromucosal spray 1mg per dose
  • Cools lozenge 2mg, 4mg
  • 16 hour patch 5mg, 10mg, 15mg, 25mg
  • 24 hour patch TTS 10 (7mg), TTS 20 (14mg), TTS 30 (21mg)
02.06.02 Nifedipine 
  • Immediate Release Capsules 5mg, 10mg. NOTE: for Raynaud’s phenomenon only. Please also note that immediate release brand Adalat is discontinued; Generic version now available from Relonchem but at higher price (Dec 2019 – approx. £60 per 90 capsules).

  • Modified Release capsules 30mg, 60mg (once daily preparation) and Modified Release tablets 20mg, 30mg, 60mg (once daily preparation).
  • Different versions of MR nifedipine preparations may not have the same clinical effect. Prescribers should specify the brand to be dispensed.
  • Note: Supply problems

 

07.01.03 Nifedipine 
  • GWH only - For the initial management of preterm labour (off-label indication)
  • Non formulary at RUH and SFT
  • For use in hypertension or angina and note on supply problems see section 2.6.2  
08.01.05 Nilotinib 
  • 150mg and 200mg capsules
02.06.02 Nimodipine 
  • Infusion 200mg/ml
  • Tablets 30mg
  • For the prevention and treatment of ischaemic neurological deficits following subarachnoid haemorrhage.

 

 

08.01.05 Nintedanib 
  • 100mg and 150mg capsules

 

08.02.04 Niraparib 
05.01.13 Nitrofurantoin 

Nitrofurantoin may be used with caution if eGFR 30-44ml/min, if potential benefit outweighs risk. 

  • Tablets 50mg or 100mg.
  • Modified release capsules 100mg
15.01.02 Nitrous oxide 
  • Nitrous oxide cylinders size D, E, G
15.01.02 Nitrous oxide 50% with oxygen 50% Entonox ®
  • Nitrous oxide 50% with oxygen 50% (Entonox) cylinders size D,F,G
  • Note: MHRA safety notice Neurological and haematological toxic effects can occur with prolonged use of nitrous oxide. Neurological effects can occur without preceding overt haematological changes.
    Assessment of vitamin B12 levels should be considered before nitrous oxide anaesthesia in people with risk factors for deficiency.
08.02.04 Nivolumab 
02.07.02 Noradrenaline / Norepinephrine 
  • 8mg in 50ml pre-filled syringe (unlicensed)
06.04.01.02 Norethisterone 
  • 5mg 
  • This  preparation is not licensed for HRT

 

07.03.02.01 Norethisterone Noriday®
  • Tablets containing norethisterone 350 micrograms
  • Recommended for patients previously on Micronor - discontinued 2017
  • Note: If administration is delayed for 3 hours or more it should be regarded as a ‘missed pill'.

 

08.03.02 Norethisterone 
  • 350microgram and 5mg tablets
  • Specialist initiation only for endrometrial cancer.
07.03.02.02 Norethisterone enantate Noristerat®
  • 200mg norethisterone enantate in 1ml oily solution
  • Noristerat® oily injection provides contraception for 8 weeks. Intended for short-term use when a high level of efficacy independent of possible errors by the patient is required. It has been licensed for short-term use by women whose partners undergo vasectomy, until the vasectomy is effective, and women immunised against rubella, to prevent pregnancy during the period of activity of the virus.
04.07.03 Nortriptyline 
  • Tablets 10mg, 25mg
  • 'Off label' use for neuropathic pain
  • Specialist initiation
  • Should only be used if amitriptyline isn't tolerated or is contra indicated
  • More expensive than amitriptyline. NB 1x25mg significantly more cost effective than 3 x 10mg tablets
09.03 Nutilis Clear® 

Preferred choice

175g tub

09.04.02 Nutilis Fruit Dessert Level 4 
  • For Dysphagia Level 4 ONS
  • Flavours: Apple and Strawberry
  • 150g pot (3/day) 
  • 206 kcals 10.5g protein
  • Lactose free
  • IDDSI level  4
A2.02.02.02 Nutilis Fruit Dessert Level 4 

150 g pot

28 day supply = 84 desserts, 12,600 ml

206 kcals, 10.5 g protein

IDDSI Level 4 - Extremely thick

A2.03.01 Nutramigen 1 with LGG 

From birth

A2.03.01 Nutramigen 2 with LGG 

From 6 months

A2.03.01 Nutramigen Puramino 

(AAF) from birth

09.04.02 Nutricrem 

FIRST LINE for Dysphagia Level 4 ONS

  • Flavours: Chocolate-orange, strawberry, vanilla, mint-chocolate
  • 125g pot (3/day) 
  • 225 kcals 12.5g protein
  • Lactose free
  • IDDSI level  4
A2.02.02.01 Nutricrem®  

DYSPHAGIA LEVEL 4 - Only for those who require level 4 thickened fluids

125 g pot

28 day supply = 84 desserts, 10,500 ml

225 kcals, 12.5 g protein

IDDSI Level 4 - moderately thick

12.03.02 Nystatin 
  • Always prescribe by BRANDNAME in primary care to get most cost-effective version.
  • 100,000 units/ml 30ml bottle
  • Dose:  ADULT and CHILD over 2 years, 100 000 units 4 times daily
  • Due to the high sucrose content of nystatin suspension, 500mg/1ml, ensure that diabetic patients are aware of this.
  • Nystatin is the first line choice, however miconazole may be considered due to the differing formulations.
13.04 Nystatin 100,000IU/g / Chlorhexidine 1% / Hydrocortisone 0.5% 
  • Mild potency steroid
  • Previously known as Nystaform HC which is discontinued. Prescribe generically.
  • Cream, Ointment x 30g
  • Cream Useful for babies and children with recurrently infected eczema on face due to antiseptic content.
  • Ointment Useful for babies and very young  children with recurrently infected eczema on trunk and limbs due to antiseptic content

 

01.09.01 Obeticholic acid Ocaliva®
  • Non- formulary - GWH, RUH & SFT - Not specialist centres.
  • 5mg & 10mg tablets.
  • Please note: This is ONLY available via specialist tertiary centres, in accordance with NHSE's circular "Technology Appraisal 443: Obeticholic acid for treating primary biliary cholangitis (PBC)" dated 26th June 2017.
08.02.03 Obinutuzumab 
08.02.03 Ocrelizumab 
  • 300mg vial
13.11.05 Octenidine Octenisan®
  • Antimicrobial hair and body wash containing octenidine.
  • 150ml or 500ml bottles
  • GWH and SFT use as part of MRSA decolonisation protocols
08.03.04.03 Octreotide Sandostatin Lar®
  • Amber Swindon - relief of symptoms associated with acromegaly
  • 10mg, 20mg and 30mg injection
  • Commissioned by NHS England, as per agreed Trust Guidelines. Use product with lowest procurement cost
  • Carcinoid Syndrome and Neuroendocrine Tumours
  • For the treatment of acromegaly
08.03.04.03 Octreotide 
  • 50microgram/1ml, 100microgram/1ml
  • For the short term management of high output stomas and fistulas and in palliative care (see separate chapter)
06.04.01.01 Oestrogen only HRT Elleste-Solo®
  • estradiol (1mg, 2mg)
  • 1 prescription charge

 

06.04.01.01 Oestrogen only HRT Evorel
  • estradiol (25 micrograms, 50 micrograms, 75 micrograms, 100 micrograms)
  • Change twice a week.

 

06.04.01.01 Oestrogen only HRT Oestrogel
  • 0.06% oestradiol gel
  • 0.75mg estradiol per measure, 2 measures=standard regime

 

06.04.01.01 Oestrogen only HRT  Premarin
  •  conjugated oestrogens (300 micrograms, 625 micrograms, 1.25 milligram)
  • 1 prescription charge
06.04.01.01 Oestrogen only HRT  Estradot
  • estradiol (25, 37.5, 50, 75, 100 micrograms)
  • Change twice a week.

 

06.04.01.01 Oestrogens for HRT Progynova®

RUH only Specilaist use fertility treatment (not HRT)

  • Not on formuary in Salisbury or Swindon.
  •  1mg or 2mg estradiol valerate
06.04.01.01 Oestrogens for HRT Elleste-Duet Conti®
  •  2mg estradiol and 1mg norethisterone
  • 1 prescription charge. 

 

06.04.01.01 Oestrogens for HRT Indivina
  • Estradiol valerate 1mg /Medroxyprogesterone 2.5mg
  • Estradiol valerate 1mg /Medroxyprogesterone 5mg

 

 

 

07.02.01 Oestrogens, Topical Estring®
  • Vaginal ring, releasing estradiol approx. 7.5 micrograms/24 hours
07.02.01 Oestrogens, Topical Gynest®
  • Vaginal Cream 0.01% estriol
  • Licensed for Hormone Replacement Therapy (HRT) for treatment of atrophic vaginitis and kraurosis in post-menopausal women and
  • Licensed for treatment of pruritis vulvae and dyspareunia associated with atrophic vaginal epithelium. 
  • Note: Gynest® has arachis oil as an excipient
07.02.01 Oestrogens, Topical Ovestin®
  • Vaginal Cream 0.1% estriol
  • Licensed for Hormone Replacement Therapy (HRT) for treatment of atrophic vaginitis (due to estrogen deficiency) in peri- and post-menopausal women and
  • Licensed as pre-surgery therapy for vaginal operations and during subsequent convalescence.
07.02.01 Oestrogens, Topical Vagifem®
  • Vaginal Tablet 10 micrograms
05.01.12 Ofloxacin 
  • The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information. 
  • Tablets 200mg
11.03.01 Ofloxacin 
  • Amber in Bath and Swindon
  • Green in Salisbury
  • 0.3% ophthalmic drops

 

12.01.01 Ofloxacin 0.3% 
  • Eye drops 0.3% (off label use)
  • For chronic otitis media
13.02.01 Oilatum ® Cream

CREAM FOR MILD TO MODERATE DRY SKIN

  • Available as 500ml pump or 500g tub
  • Exactly the same as Oilatum Junior cream in constituents and price

 

 

13.02.01.01 Oilatum ® Plus  emollient bath additive
  • BCAP area only
  • This product has been included on formulary for the specific indication of MRSA decolonisation ONLY due to it containing Triclosan.
  • See MRSA decolonisation guidance (BCAP) below.
04.02.01 Olanzapine 
  • Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg
  • Orodispersible tablet (Velotab®) 5mg, 10mg, 15mg, 20mg
  • Can be initiated in primary care with advice from the Primary Care Liaison Service (PCLS) (AWP) and specialist psychiatry health care professionals. 
  • Note: Olanzapine has been associated with an increased risk of hyperglycaemia, diabetes mellitus and exacerbations of diabetes. In patients with risk factors for diabetes mellitus, appropriate clinical and blood glucose monitoring is conducted.
04.02.01 Olanzapine  
  • Injection 10mg/2ml (Rapid tranquilisation)
  • Note: Olanzapine has been associated with an increased risk of hyperglycaemia, diabetes mellitus and exacerbations of diabetes. In patients with risk factors for diabetes mellitus, appropriate clinical and blood glucose monitoring is conducted.
08.02.04 Olaparib 
  • 50mg capsules
  • NB other strengths exist these are not formulary

 

12.01.03 Olive Oil Ear Drops 
  • Please note: Patients should self-care in the first instance
03.01.01.01 Olodaterol Striverdi Respimat®
  • No new prescribing. Existing patients only - see notes above.
  • The delivered dose is 2.5 microgram Olodaterol (as hydrochloride) per actuation.

 

11.04.02 Olopatadine 
  • Non formulary in Bath
  • 1mg/1ml ophthalmic drops
03.04.02 Omalizumab Xolair®
  • Injection, 150mg vial
  • Commissioned by NHS England (for uncontrolled asthma) in accordance with NICE TA278.

    Patients must be assessed and approved for a 16 weeks trial by MDT decision. Trial outcome to be assessed at regional MDT to decide if ongoing treatment is appropriate. Blueteq registration and approval is necessary for all new initiations and continuations.
13.05.03 Omalizumab 
  • Commissioned by CCG (for chronic spontaneous urticaria) in accordance with NICE TA339
  • 150 mg solution for subcutaneous injection in a pre-filled syringe
05.03.03.02 Ombitasvir/ paritaprevir/ ritonavir Viekirax®
  •  Tablets 12.5mg/75mg/50mg
01.03.05 Omeprazole  
  • 40mg powder for solution for infusion.
01.03.05 Omeprazole 
  • 10mg & 20mg capsules.
  • 40mg capsules (Salisbury & Swindon ONLY).
  • Please note: Omeprazole capsules are more cost-effective than tablets.
  • Omeprazole dispersible tablets are available for use in Paediatrics ONLY. Please refer to our Paediatric chapter.
04.06 Ondansetron 
  • Tablet 4mg, 8mg
  • SyrupSF 4mg in 5ml
  • Injection 4mg in 2ml, 8mg in 4ml
  • Long term treatment is rarely justified or necessary. 
  • Ondansetron is used for the following groups of patients:
    • For the prevention of PONV: in patients classified as ‘high risk’.
    • In the treatment of PONV: for patients requiring rescue medicine.
    • In general patients: those with protracted nausea and vomiting who have failed to respond to two conventional anti-emetics at full dose. If the symptoms are severe, ondansetron may be prescribed after trying only one conventional anti-emetic.
  • See MHRA safety update link below: Recent epidemiological studies suggest exposure to ondansetron during the first trimester of pregnancy is associated with a small increased risk of the baby having a cleft lip and/or cleft palate. 
04.09.01 Opicapone 
  • Capsules 50mg
  • Notes: Opicapone is significantly more expensive than entacapone. Opicapone is included in the formulary as a second line COMT inhibitor for the treatment of Parkinson's disease in patients who have been unable to tolerate a trial of a reasonable duration of entacapone (typically experiencing intolerable GI disturbances or unmanageable isues relating to stained secretions).
07.03.02.01 Oral Progestogen Only Contraceptives Norgeston®
  • Tablets containing levonorgestrel 30 micrograms.
  • Note: If administration is delayed for 3 hours or more it should be regarded as a ‘missed pill'

 

09.02.01.02 Oral Rehydration Salts Dioralyte® Electrolade®
  • Oral Powder Sachets
  • For oral rehydration therapy (ORT)

    Self Care Self Care Medicine for primary care.

12.03.05 Oralieve® 
  • GWH only
  • Xylitol/peroxidase and oxidase enzymes
  • 50ml
16.15 Oralvac Compact 
  • Unlicensed named patient product
  • Consultant Specialist initiation only
  • For treatment of severe allergic rhinitis and severe allergic conjunctivitis not responding to standard treatment
04.05.01 Orlistat 
  • Capsules 120mg
04.09.02 Orphenadrine 
  • Orphenadrine 50mg/5ml oral solution sugar free
05.03.04 Oseltamivir Tamiflu®
  • Endorse SLS
  • Capsules 30mg, 45mg, 75mg
  • Suspension (SF) 6mg/ml
  • Some drugs are restricted to prescribing in certain circumstances under the NHS and a list can be found under Part XVIIIA of the Drug Tariff. The prescriber must endorse any prescription with 'SLS' if the patient and purpose complies with that specified in the list. An example of such is where specific patient criteria are set. The drugs affected are highlighted throughout the formulary and the explanatory notes provide further guidance.

    Where prescribing falls outside of the regulations, the drug may not be prescribed on the NHS.
08.02.04 Osimertinib 
08.01.05 Oxaliplatin 
  • 50mg/10ml, 100mg/20ml and 200mg/40ml infusion
04.08.01 Oxcarbazepine 
  • 150mg,300mg ,600mg tablets
  • 60mg/ml oral suspension
11.07 Oxybuprocaine 
  • 0.4% single use drops
07.04.02 Oxybutynin 
  • Immediate release tablets 2.5mg, 3mg, 5mg - twice daily dosing. Side-effects may limit the use of immediate-release preparation.
  • Modified release tablets 5mg, 10mg.
  • Cost warning: oxybutynin liquid 5mg/5ml £154.50 per 150mL and oral solution 2.5mg/5ml £214.85 per 150mL (prices March 2019).
  • Avoid in frail elderly patients.
07.04.02 Oxybutynin Hydrochloride Kentera®
  • 36mg patch applied twice weekly.
  • Restricted for those unable to take oral medicines. Not for use in frail older patients.
04.07.02 Oxycodone immediate release
  • For cancer patients for break through pain 
  • Tablets 5mg, 10mg, 20mg.
  • Oral solution 5mg/5ml, or concentrate 10mg/ml
  • Oxycodone may be initiated in preference to morphine for the management of pain by a GP with experience in palliative care or on the advice of the palliative care team or pain team. 

 

04.07.02 Oxycodone 
  • For palliative care use, specialist initiation
  •  Injection 20mg/2ml, 50mg/1ml

 

04.07.02 Oxycodone 
  • Amber  for non cancer patients and for all other indications for BaNES/West Wilts. (TLS under review feb 2020)
  • Red in GWH for use as a 1st line opiate analgesic as part of post-operative enhanced recovery. programmes following protocol. Patients will not be discharged on oxycodone unless on advice of pain management specialist.
  • M/R Tablets 5mg, 10mg, 20mg, 40mg, 60mg, 80mg 
  • Oxycodone may be initiated in preference to morphine for the management of pain by a specialist GP with an interest in pain or with pain team advice when: Dose escalation with morphine is not possible due to opioid toxicity eg. hallucinations, myoclonic jerks and confusion.
  • For use in palliative care see chapter 21.
21 Oxycodone Longtec®
  • Green  for cancer patients (rest of Wiltshire and Swindon)
  • Amber Amber for cancer patients BCAP
  • M/R Tablets 5mg, 10mg, 20mg, 40mg, 60mg, 80mg Longtec®. Prescribe by brand.
  • For the treatment of moderate to severe pain in patients with cancer pain.
  • Oxycodone may be initiated in preference to morphine for the management of pain by a GP with experience in palliative care or on the advice of the palliative care team or pain team when: Dose escalation with morphine is not possible due to opioid toxicity eg. hallucinations, myoclonic jerks and confusion.
21 Oxycodone Shortec®
  • For cancer patients for break through pain 
  • Tablets 5mg, 10mg, 20mg, Shortec®.
  • Oral solution 5mg/5ml, or concentrate 10mg/ml
  • Prescribe by brand.
  • Oxycodone may be initiated in preference to morphine for the management of pain by a GP with experience in palliative care or on the advice of the palliative care team or pain team. 

 

05.01.03 Oxytetracycline 
  • 250mg tablets
13.06.02 Oxytetracycline 
  • Tablets 250mg
  • 500mg twice a day for 3 months then review (two tablets twice daily)
13.04 Oxytetracycline 3% /Hydrocortisone 1%  Terra-Cortil ®
  • Mild potency steroid
  • Ointment, Hydrocortisone 1%, oxytetracycline 3%, 30g
  • Infected eczema at thin skin sites over the age of 12 years

 

07.01.01 Oxytocin Syntocinon®
  • Injection 5 units in 1ml, 10 units in 1ml
08.01.05 Paclitaxel 
  • Various strengths of concentration
08.01.05 Paclitaxel Abraxane®
  • 100mg infusion
08.01.05 Palbociclib 
  • 75mg, 100mg and 125mg capsules

 

04.02.02 Paliperidone 
  • AWP use only
  • Xeplion® Long Acting Injection (LIA) 50mg, 75mg, 100mg, 150mg once a month after initial loading dose
  • Xeplion is not currently on 3Ts formulary- under review
  • Be aware that there is also a Trevicta® Long Acting Injection (LIA) administered once every three months. Its addition to formulary is under consideration. 
05.03.05 Palivizumab 
  •  50mg vial Injection
  • 100mg vial Injection
  • Note: use in line with JCVI guidance
01.09.04 Pancreatin  Creon®
  • 10,000 unit & 25,000 unit (High Strength) capsules.
  • Please note: 40,000 unit capsules were discontinued in June 2019.
  • It is important to ALWAYS specify capsule strength on any prescription.
15.01.05 Pancuronium 
  • 2mg in 1ml
  • 4mg in 2ml
08.01.05 Panitumumab 
  • 100mg/5ml and 400mg/20ml infusion

 

08.02.04 Panobinostat 
  • 10mg, 15mg and 20mg capsules
07.04.05 Papaverine 
  • Injection 25mg, 80mg.
  • RUH only
  • Non formulary at SFT and GWH
04.07.01 Paracetamol  
  • Tablet 500mg    
  • Dispersible tablet 500mg
  • Oral SuspensionSF 120mg/5ml, 250mg/5ml     
  • Suppository 60mg, 120mg, 240mg, 500mg, 1g
  • Avoid expensive paracetamol capsules, use tablets. If difficulty in taking tablets consider ‘caplets’ before soluble tablets
04.07.01 Paracetamol  
  • Intravenous infusion 1000mg/100ml, 500mg/50ml (Perfalgan)
  • Vigilance is advised when prescribing and administering Intravenous Paracetamol 10mg/mL solution for infusion, to ensure that the correct, weight-adjusted dose is ALWAYS given.
04.07.01 Paracetamol and codeine Co-codamol® 8/500
  • Tablets 8/500     
  • Effervescent tablets 8/500
  • Effervescent analgesics not generally recommended due to cost and high sodium content. Restricted to patients unable to swallow tablets.
  • Low dose weak opioid combinations with paracetamol are not recommended because they offer little additional pain relief compared with regular full dose paracetamol.
04.07.01 Paracetamol and codeine Co-codamol® 30/500
  • Tablets 30/500     
  • Effervescent tablets 30/500
  • Effervescent analgesics not generally recommended due to cost and high sodium content. Restricted to patients unable to swallow tablets.
  • Combination analgesics are not recommended.
04.07.01 Paracetamol and dihydrocodeine Co-dydramol®
  • Previously co-dydramol (dihydrocodeine/paracetamol) was available only in the ratio 1:50 (co-dydramol 10/500 mg). Two additional products are now available with a higher strength of dihydrocodeine (codydramol 20/500 mg and 30/500 mg tablets). It is therefore important that co-dydramol products are prescribed and dispensed by strength to minimise dispensing errors and the risk of accidental opioid overdose.
  • Low dose weak opioid combinations with paracetamol are not recommended because they offer little additional pain relief compared with regular full dose paracetamol.
04.08.02 Paraldehyde 
  • Consultant neurologist recommendation only
09.06.07 Paravit CF 
  • For Cystic Fibrosis patients only
  • Softgel capsules or liquid.
  • Paravit-CF is a ‘Food for Special Medical Purposes’ for the dietary management of patients with cystic fibrosis and is reimbursable on FP10.
    Paravit CF Capsules contain:
    • Vitamin A 1.5 mg (=5,000IU)
    • Vitamin D3 37.5 µg (=1,500IU)
    • Vitamin E 100 µg (=150IU)
    • Vitamin K 5 mg
    Paravit CF capsules provide an alternative vitamin supplementation option for Cystic Fibrosis patients, which offers patients a decreased oral medication load whilst also being a cost-effective option.
    Paravit CF liquid is only available as an option for patients with swallowing difficulties or young children.
04.03.03 Paroxetine 
  • Tablets 10mg, 20mg, 30mg
  • Oral Suspension 10mg/5ml 150ml
  • Paroxetine has a place in therapy for anxiety disorder.  Caution when stopping, higher risk of withdrawal reactions
08.01.05 Pazopanib 
  • 200mg and 400mg tablets
14.04 Pediacel ® 
  • Suspension for injection in pre-filled syringe
  • Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)
08.02.04 Pegaspargase 
  • 3,750mg/5ml injection
08.02.04 Peginterferon Alfa  
  • 90microgram/0.5ml, 135microgram/0.5ml and 180microgram/0.5ml pre-filled syringes
08.02.04 Peginterferon Alfa  
  • 90microgram/0.5ml, 135microgram/0.5ml and 180microgram/0.5ml pre-filled syringes
  • For the treament of leukaemia and lymphoma in accordance with cancer network guidelines
  • For the treatment of Myeloproliferative Neoplasms e.g Essential Thrombocythaemia, Polycythaemia after hydroxycarbamide or anagralide.
08.02.04 Peginterferon Beta-1a 
  • 63microgram/0.5ml, 94microgram/0.5ml and 125microgram/0.5ml pre-filled pens
08.01.05 Pembrolizumab 
  • 100mg/4ml concentration for solution for infusion
  • 50mg powder for concentration for solution for infusion
  • Also available from NHS England Cancer Drugs Fund
08.01.03 Pemetrexed 
10.01.03 Penicillamine 
  •  Amber with Shared Care - Bath, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH)
  •  Red - Swindon DAWN patients
  • 125mg and 250mg tablets
  • Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information
11.03.01 Penicillin 
  • GWH only
  • Non formulary at RUH and Salisbury
  • 500U in 1ml
05.04.08 Pentamidine Isetionate Injection
  • 300mg Powder for Solution for Injection/Infusion
  • Powder for injection (dissolved in water for injection) may be used for nebulisation. Not licensed for primary prevention of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia by inhalation of nebulised solution.
08.01.05 Pentostatin 
  • 10mg infusion

 

01.02 Peppermint Oil 
  • 0.2ml gastro-resistant capsules.
  • Please note: Gastro-resistant capsules are more cost effective than MR capsules.
  • Please prescribe most cost-effective brand of gastro-resistant capsules BY BRAND. Mintec® or Apercap® are cost-effective brands in primary care.
01.02 Peppermint water 
  • Oral solution.

 

01.01.02 Peptac ® Suspension
  • Suspension SF containing sodium alginate 250mg, sodium bicarbonate 133.5mg & calcium carbonate 80mg per 5ml, with equivalent of 6.2 mmol of sodium per 10ml.
  • Please note: Peptac is our first-line option, as it is more cost-effective than Gaviscon Advance.
04.08.01 Perampanel 
  • Tablets 2mg, 4mg, 6mg, 8mg, 10mg, 12mg (Category 2 MHRA)
  • Initiated by a specialist for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older who have failed on treatment with all first and second line agents.
  • Perampanel oral suspension 500mcg/ml is available but is expensive. Use only if no other option is suitable and there are significant swallowing problems.

 

02.05.05.01 Perindopril 
  •   2mg, 4mg, 8mg

 

13.10.04 Permethrin 5%  
  • Topical Cream 30g     
08.01.05 Pertuzumab 
  • 420mg/14ml infusion

 

04.07.02 Pethidine 
  • 50mg/ml and 100mg/2ml
  • Hospital use only: (GWH and RUH) NOT for primary care prescribing.
04.03.02 Phenelzine 
  • Tablets 15mg 
  • Patients should avoid consuming large amounts of tyramine-rich food (such as mature cheddar, yeast extracts, red wine and fermented soya bean products) and sympathomimetics (such as ephedrine, pseudoephedrine and phenylpropanolamine).
  • Patients should be advised to take last dose before 3pm in order to minimise sleep disturbance / insomnia.
  • Refer the patient to the patient information leaflet (PIL) supplied with the product for dietary restrictions or go to https://patient.info/health/depression-leaflet/antidepressants for a full list.
02.08.02 Phenindione 
  •  10mg, 25mg, 50mg (Very costly £538 for 28 tablets June 2019)
  •  Only for patients who are hypersensitive to warfarin.
04.08.01 Phenobarbital 
  • Tablets 15mg, 30mg, 60mg (Category 1 MHRA)
  • For existing patients ONLY - maintain patients on existing brands.
04.08.02 Phenobarbital  
  • 30mg/1ml,60mg/1ml,200mg/1ml
01.07.03 Phenol, Oily 
  •  5% in 5ml injection.
02.05.04 Phenoxybenzamine Hydrochloride Oral,injection
  • Capsule 10mg
  • Injection- note supply problems
05.01.01.01 Phenoxymethylpenicillin Oral
  • Tablets 250mg
  • Oral solution (SF) 125mg/5ml, 250mg/5ml
02.05.04 Phentolamine 
  •  10mg in 1ml injection

 

 

10.01.01 Phenylbutazone 
  • RUH and GWH - Restricted for prescribing by Consultant Rheumatologist for named patients with ankylosing spondylitis.
  • SFT - Restricted for prescribing by Consultant Rheumatologist for named patients with ankylosing spondylitis stabilised on therapy. No new patients.

 

02.07.02 Phenylephrine 
  • 10mg in 1ml
11.05 Phenylephrine 5.4mg and Tropicamide 0.28mg Ophthalmic Insert 
  • RUH and Salisbury only
  • Non formulary at GWH
11.05 Phenylephrine Hydrochloride 
  • Phenylephrine 2.5% and 10% eyedrops
  • GWH only - Phenylephrine 1% injection for consultant/senior ophthalmologist approval
04.08.01 Phenytoin 
  • Capsule 25mg, 50mg, 100mg, 300mg Flynn brand.
  • Prescribe by brand (Category 1 MHRA)
  • Suspension 30mg in 5ml Epanutin brand (15ml of suspension approx. equal to one 100mg phenytoin sodium capsule).
04.08.02 Phenytoin 
  • Intravenous injection 250mg/5ml
03.09.01 Pholcodine Linctus, BP 

Self 

01.06.04 Phosphate  
  • 128ml enema.
09.05.02.01 Phosphate Polyfusor ® 

SFT, GWH, RUH

  • IV infusion 500ml (Polyfusor)
09.05.02.01 Phosphate supplements Phosphate-Sandoz®
  • Green Salisbury and Bath
  • Amber Swindon
  • Effervescent Tablets: 500mg containing the equivalent of 16.1mmol phosphate
02.08.03 Phytomenadione 
  • 10mg/1ml and 2mg/0.2ml solution for injection ampoules

 

09.06.06 Phytomenadione Konakion® MM
  • Injection 10mg in 1 ml 
  • Fat soluble formula (not malabsorption)
09.06.06 Phytomenadione Konakion® MM Paediatric
  • Paediatric
  • 2mg in 0.2ml
  • Fat soluble formula (not malabsorption)
  • Konakion MM Paed 0.2ml ampoules can be given orally for patients on warfarin at risk of bleeding with high INR 
  • See reversal guidance (see General Prescribing Infor Community Pharmacy: Emergency Medicines Supply) in chapter 2.8.2
09.06.06 Phytomenadione 
  •  10mg
01.06.05 Picolax ® Sachet
  • 16.1g sachet containing citric acid anhydrous 10.97 gram, magnesium oxide light 3.5 gram & sodium picosulfate 10 mg.
11.06 Pilocarpine 
  • 2% and 4% drops

 

12.03.05 Pilocarpine Hydrochloride 
  • GWH and SFT only
  • 5mg tablets
  • Useful in refractory sjogrens
13.05.03 Pimecrolimus  
  • Cream 1%: 30g, 60g, 100g
  • Apply only until symptoms resolve, as per BNF, in accordance with NICE
  • Only on prescription by a Clinician experienced in skin disease
  • Short term treatment of mild to moderate atopic eczema (including flares) when topical corticosteroids cannot be used or as advised by a specialist.
06.01.02.03 Pioglitazone 

Green BaNES and Salisbury

Amber Swindon

  • 15mg, 30mg, 45mg
  • Use in accordance with NICE NG28. 
05.01.01.04 Piperacillin and Tazobactam Injection
  • Piperacillin 2g/ tazobactam 250mg
  • Piperacillin 4g/ tazobactam 500mg
  • Piperacillin/Tazobactam 13500mg via surefuser + device over 24hrs
  • Usual duration is 5-14 days.
16.14 Piroxicam 
  • 20mg melts

Swindon only. Third line in children unresponsive to or intolerant of Ibuprofen and Diclofenac.    

Non-formulary in BaNES and Salisbury

05.01.01.05 Pivmecillinam 
  • Tablets 200mg
  • Do NOT use if penicillin allergic.
  • See primary care antibiotic guidance for UTI guidance
05.01.13 Pivmecillinam  
  • Tablets 200mg
  • Use if 1st line nitrofurantoin is unsuitable and eGFR <45ml/min
  • Do NOT use if penicillin allergic

 

08.01.02 Pixantrone 
  • 29mg powder for infusion

 

09.02.02.02 Plasma-lyte 148 

GWH only

RUH/SFT - not on formulary

01.06.05 Plenvu® 
  • Amber - Bath - For use as a second-line bowel cleansing agent, where lower fluid volume is desirable or the taste of MOVIPREP has led to treatment failure.

  • Red - GWH - ONLY for use as a bowel cleansing agent prior to colonoscopy, as part of a 6-month trial, finishing at the end of Jan 2020, at which point formulary status will be reviewed, and may be revoked, unless audit outcome data is favourable.
  •  Red - SFT - ONLY for use as a bowel cleansing agent prior to colonoscopy, as part of a 6-month trial, at which point formulary status will be reviewed, and may be revoked, unless audit outcome data is favourable.
  • Dose 1 (single sachet), providing when reconstituted to 500mL with water Na+ 160.9 mmol, K+ 13.3 mmol & Cl- 47.6 mmol.

  • Dose 2 (sachets A and B), providing when reconstituted to 500mL with water Na+ 297.6 mmol, K+ 16.1 mmol & Cl- 70.9 mmol.

09.01.07 Plerixafor 

RUH only - For use in line with NHS England Policy B04/P/2 January2014 

GWH/SFT - not on formulary

  •  20mg/ml 1.2ml vial

     

 

14.04 Pneumococcal polysaccharide conjugate vaccine (adsorbed) Prevenar 13®
  • Primary Care:  at NHS expense for infants as part of the routine childhood immunisation programme (order free of charge via Immform)
13.07 Podophyllotoxin 
  • Solution 0.5% 3ml
  • Cream 0.15% 5g
  • Genital warts. Apply twice daily, morning and evening (every 12 hours) for 3 consecutive days. Stop for next 4 consecutive days then repeat for three days at weekly intervals up to 4 weeks.
  • This product is currently unavailable (Jan 2020) due to manufacturing and regulatory reasons. Update expected Q2 2020. Do not prescribe and use an alternative option.
13.07 Podophyllum 
  • Podophyllin in benzoin Compound tincture 25% BP Paint
11.03.01 Polihexanide 
  • GWH only
  • Non formulary at RUH and Salisbury
  • 0.02% eye drops
06.01.06 Polycal ® Liquid
  • Bottles 200ml containing Carbohydrate 62g/100ml 
  • Salisbury and Swindon - not on formulary
14.04 Polysaccharide Typhoid Vaccine Typherix®
14.04 Polysaccharide vaccine for injection Typhim Vi®
09.02.01.01 Polystyrene Sulphonate Resins Calcium Resonium®

Amber Salisbury and Bath

Red GWH

  • Powder calcium polystyrene sulphonate. 
  • Note: Calcium resonium can be taken orally mixed in water (not fruit juice or other potassium containing fluids) or rectally.       
09.02.01.01 Polystyrene Sulphonate Resins Resonium A®

GWH only

RUH/SFT - non formulary

  • Sodium polystyrene sulfonate 999.34 mg per 1 gram
  • Oral or rectal administration
  • Resonium A is an ion-exchange resin that is recommended for the treatment of hyperkalaemia associated with anuria or severe oliguria. It is also used to treat hyperkalaemia in patients requiring dialysis and in patients on regular haemodialysis or on prolonged peritoneal dialysis.
13.05.02 Polytar®  
  • Coal tar solution 2.5%, arachis (peanut) oil extract of coal tar 7.5%, tar 7.5%, cade oil 7.5%, light liquid paraffin 35%
  • 150ml bottle
08.02.04 Pomalidomide 
08.01.05 Ponatinib 
  • 15mg, 30mg and 45mg tablets

 

03.05.02 Poractant Alfa Curosurf®
  • Suspension 80mg/ml (Curosurf®)
  • Commissioned by NHS England (for Respiratory Distress Syndrome in neonates). Use product with lowest procurement cost in line with Trust guidelines. Hospital only.  
05.02 Posaconazole 
  • Suspension 200mg/5ml
  • 100mg tablet
  • In accordance with prophylaxis/treatment guidance for neutropenic patients
05.02 Posaconazole 
  • RUH only as per anti-fungal guidance
09.02.01.01 Potassium Chloride Kay-Cee-L®

 

  • 75mg/ml
  • Contains sorbitol: May cause osmotic diarrhoea
    1mmol/mL each of K+ and Cl-
09.02.01.01 Potassium Chloride Sando-K®
  • Effervescent tablets each containing 12mmol potassium  
09.02.02.01 Potassium Chloride 
  • For the administration of IV Potassium infusions available in the Trust, refer to Trust Policy 
  • Pre-mixed infusion solutions should be used when possible.
  • Medical errors involving Sterile Potassium Chloride Concentrate (20mmol/10ml {15%}) can be potentially fatal.
  • The use of Sterile Potassium Chloride Concentrate (20mmol/10ml {15%}) is restricted to use in areas that require potassium-containing fluids not available as pre-mixed solutions.

 

 

13.11.06 Potassium Permanganate Permitabs®
  • Permitabs® solution tablets 400mg
  • 1 tablet to be dissolved in 4 litres of water to provide a 0.01% (1 in 10,000) solution 
  • Notes:   
  • It stains; keep out of contact with clothing, fabrics etc.
  • Do not use a ceramic basin or bath as these will stain.
13.11.04 Povidone-Iodine Betadine® or Videne®
  • Alcoholic solution, povidone-iodine 10% in industrial methylated spirit 95%
  • Antiseptic solution, povidone-iodine 10% in aqueous solution
  • Surgical scrub, aqueous solution, povidone-iodine 7.5%
04.09.01 Pramipexole 
  • Tablets 88 micrograms, 180 micrograms, 350 micrograms, 700 micrograms (generic)
  • Tablets m/r 260 micrograms, 520 micrograms, 1.05mg, 1.57mg, 2.1mg, 2.62mg, 3.15mg
  • Prescribe by brand name for most cost effective prescribing.
  • Pipexus PR is the preferred brand in primary care.

 

02.09 Prasugrel 
  •  5mg, 10mg
  • Initiated by a cardiologist in line with NICE and also for patients who otherwise would be treated with clopidogrel but who are intolerant/allergic to clopidogrel.
  • The treatment period for prasugrel should not exceed 12 months.
  • Prasugrel should not be used in patients at increased risk of bleeding, in patients who are 75 years or older or body weight less than 60kg
  • Prasugrel in combination with aspirin is recommended as an option for preventing blockages in the arteries of people with ACS who are having a PCI only when:
    • immediate PCI is necessary to treat an STEMI or
    • a blood clot has blocked a stent during treatment with clopidogrel or
    • the patient has diabetes mellitus.
02.12 Pravastatin  
  • 10mg, 20mg, 40mg
05.05.03 Praziquantel 
  •  Tablets 500mg.
01.05.02 Prednisolone 
  • 1mg, 5mg & 25mg non enteric- coated tablets ONLY.
  • Please note: Prednisolone soluble tablets have been removed from formulary as they are prohibitively expensive.
01.05.02 Prednisolone 
  • 20mg retention enema.
  • 5mg suppositories.
  • Please note: Prednisolone foam enema has been removed from formulary as it is prohibitively expensive.
06.03.02 Prednisolone 
  • Tablets (non enteric coated) 1mg, 5mg, 25mg, Soluble tablets 5mg Note: Enteric coated tablets of prednisolone are NOT included in the formulary.

  • Please note soluble tablets 5mg and oral solution 1mg/ml are considerably more expensive than plain tablets 5mg.

 

 

 

 

10.01.02.01 Prednisolone  
  • 5mg tablets
  • Do not prescribe EC tablets
  • Plain prednisolone tablets 5mg may be crushed and dispersed in water and administered orally or via NG/PEG tube (off-label).
  • Soluble tablets 5mg are considerably more expensive than both plain tablets 5mg and oral solution 1mg/ml.
11.04.01 Prednisolone 
  • 0.1% and 0.3% ophthalmic drops  NOTE STRENGTHS
  • GWH only - For use in herpes simplex keratitis only
  • These strengths are non formulary at RUH and Salisbury
11.04.01 Prednisolone 
  • 0.5% ophthalmic drops, 1% ophthalmic drops
  • Preservative free available if indicated

 

12.01.01 Prednisolone  
  • Ear drops 0.5%
16.03 Prednisolone 
  • 5mg
  • For emergency treatment of Croup as per BNF-C
04.01.02 Pregabalin 
  • Capsules 25mg, 50mg, 75mg, 100mg, 150mg, 225mg, 200mg, 300mg
  • If the person cannot tolerate SSRIs or SNRIs, consider offering pregabalin.
  • The SPC advises caution when used with opioids due to risk of CNS depression - this increased risk was observed at low doses of pregabalin (≤ 300 mg) and there was a trend for a greater risk at high doses of pregabalin.
04.07.03 Pregabalin 
  • Capsules 25mg, 50mg, 75mg, 100mg, 150mg, 225mg, 200mg, 300mg
  • Pregabalin is also indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults. 
  • The SPC advises caution when used with opioids due to risk of CNS depression - this increased risk was observed at low doses of pregabalin (≤ 300 mg) and there was a trend for a greater risk at high doses of pregabalin.

 

04.08.01 Pregabalin 
  • Capsules 25mg, 50mg, 75mg, 100mg, 150mg, 225mg, 200mg, 300mg (Category 3 MHRA)
  • Oral solution 20mg/ml
  • Schedule 3 CD, exempted from safe custody requirements.
  • The SPC advises caution when used with opioids due to risk of CNS depression - this increased risk was observed at low doses of pregabalin (≤ 300 mg) and there was a trend for a greater risk at high doses of pregabalin.
  • Most cost-effective to prescribe the least number of capsules to form the required dose twice daily instead of three times daily.
  • Oral solution is expensive and only included for people with swallowing difficulties.
  • Pregabalin as an adjunctive treatment of partial seizures with or without secondary generalisation.
  • Pregabalin is also indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults. 

 

15.02 Prilocaine (+ glucose) Prilotekal®
  • GWH only
  • Due to the glucose content Prilotekal is only to be used for spinal anaesthesia. It is not recommended for the use in epidural anaesthesia.
15.02 Prilocaine Hydrochloride injection
  •  Spinal anaesthesia 20mg/ml for injection, 5ml ampoule
15.02 Prilocaine Hydrochloride with Felypressin injection
  •  54mg (3%) with felypressin 0.03 units/ml 1.8ml cartridges